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Abstract

Alexander V. Struck Jannini
DEVELOPMENT OF EXPERIMENTS INVOLVING PHARMACEUTICAL
MANUFACTURING PRINCIPLES
2014
C. Stewart Slater, Ph.D.
Master of Science in Chemical Engineering
Laboratory experiments were developed to incorporate pharmaceutical engineering
concepts into Freshman-level engineering courses. The goal is to increase the interest of
pharmaceutical engineering in students and provide the necessary background for more
advanced courses in the field. The experiments can be used on an individual basis, or to
be grouped into themes for more focused learning objectives. The laboratory
experiments are available at the pharmaceutical knowledge and training website
www.PharmaHUB.org under the Teaching Resources tab.
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Chapter 1
Introduction and Background
Pharmacy itself originates from the ancient art of apothecary. The earliest evidence of
apothecary can be found in ancient Mesopotamia, where medical texts were found on
clay tablets. These texts described symptoms of illnesses, instructions for making “drug"
compounds, and even invocations to gods [1]. This practice can also be seen throughout
all ancient cultures, including: Egyptian, Indian, Chinese, Persian, Greek, and Roman
[2]. This practice was observed in monasteries during the Middle Ages, and taken into
private practice as apothecary shops in the 13th century [1, 2]. Apothecary shops did not
change significantly until the 19th century, when the term pharmacy was used instead of
the traditional apothecary [1].
It was in 1821 when the first United States pharmaceutical board was created in
Philadelphia. The Philadelphia College of Medicine was formed on March 13, which
encompassed not only a school of pharmacy, but a self-policing board of pharmacists to
make sure that frauds and “snake-oil” salesmen were not inflicting damage on the public
through improper pharmaceutical practices in Philadelphia [1]. The educational
institution opened November 9 of the same year. Pharmaceutical education soon spread
throughout America, and the University of Michigan also opened a college of pharmacy
in 1868. What was novel about this program is that the course did not require
pregraduation apprenticeship, which was convention at the time [1, 2].
Pharmacy was again changed in the years of 1890 to 1930. During this time, the
pharmaceutical industry evolved twice; once from small shops to family-name
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companies, and then once again to large-scale manufacturing corporations that are
prevalent today [3]. In this period of time, several aspects of culture and technology
caused these changes in the pharmaceutical industry. Four early instances include;
innovations in the methods of drug preparation using machinery, the growth in popularity
of standardized preparations, changes in therapeutic agents, and the influence of medical
research [4]. This, in addition with the Federal Regulatory Act of 1906, paved the way
for the large-scale manufacturers to dominate the pharmaceutical industry [3].
Since then, the pharmaceutical industry has been steadily growing as one of the most
profitable major manufacturing sectors [3]. This is not to say that the industry has not
had drawbacks. Since the 1950’s pharmaceutical corporations have been faced with
several crises that have harmed their image. Market manipulation, price fixing, dumping,
and scores of unethical medical and business practices have destroyed certain firms [3].
This has not stopped the industry from advancing, however, and the pharmaceutical
sector continues to grow.
The year of 2010 marked one of the highest points of the pharmaceutical industry, where
it had the second largest earnings of all industries [5]. The pharmaceutical industry also
increased its worldwide profit growth of 4.2% to approximately 800 billion USD that
year [6]. This is substantial growth, considering that in the year 2007, the pharmaceutical
industry amassed revenue of 315 billion USD [7]. These economic factors are coupled
with shifting paradigms of the industry, such as a move towards shorter drug
development times and an increased openness to change existing processes, which will
increase the need for chemical engineers with pharmaceutical training [8]. In 2010, 5% of
employed chemical engineers and 14% of all biomedical engineers in the United States
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worked in pharmaceutical and medicinal manufacturing [9, 10]. One engineer reported
that there was an observable increase in chemical engineering emphasis in active
pharmaceutical ingredient process development within Pfizer from the years 1995 to
2010 [11]. From 2004 to 2014, roughly 76 thousand jobs are to be created in the
pharmaceutical and medicine manufacturing sector, while basic chemical manufacturing
jobs are to decrease by roughly 46 thousand in that same time span [12].
As the demand for engineers has increased in the pharmaceutical industry, universities
have found a need to provide engineers with education in the field of pharmaceutical
engineering. Pharmaceutical engineering is defined as the design of pharmaceutical and
diagnostic products and the associated manufacturing processes [13]. Several
universities have incorporated pharmaceutical engineering education into advanced
degree studies. Some examples of universities that have introduced pharmaceutical
engineering programs on the graduate level are Rutgers University, the University of
Michigan, and the New Jersey Institute of Technology. All three of these universities
offer a master’s degree program in pharmaceutical engineering, while Rutgers University
also offers a pharmaceutical engineering option for Ph.D. students in chemical and
biochemical engineering. This pharmaceutical engineering option requires 5 courses
which focus on the different aspects of pharmaceutical engineering [14].
Stevens Institute of Technology offers a master’s degree program in pharmaceutical
manufacturing. The goal of this program is to provide students with a strong background
in Good Manufacturing Practices, project management, and pharmaceutical facilities.
This is considered an interdisciplinary program, administered by the mechanical
engineering department [15]. In addition, Purdue University offers graduate scholarships
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from the Department of Education’s Graduate Assistance in Areas of National Need
program for students to continue research in the field of pharmaceutical engineering. The
graduate student also has the ability to be a part of an international exchange program,
gain industry experience through internship opportunities, and conduct supervised
teaching to prepare them for a career in academia [16].
Due to the expanding interest in pharmaceutical engineering training, the National
Science Foundation funded an Engineering Virtual Organization to facilitate the creation
and sharing of pharmaceutical engineering educational information [17]. The result was
the website pharmaHUB.org. The objective of this website was to facilitate
collaborations with the Engineering Research Center for Structured Organic Particulate
Systems (ERC SOPS) and the National Institute for Pharmaceutical Technology and
Education (NIPTE) [17]. PharmaHUB.org is named based on the middleware that was
used in its creation. This middleware, known as HUBzero, has several features that were
useful for the design of the website; including the ability for online simulation, making it
possible to deliver simulation tools via the web; content management capabilities that
make it possible for online presentations to combine voice and images; communitybuilding capabilities such as content uploading, a question/answer forum, and a user
support area [17, 18].
With this increased interest in pharmaceutical engineering at the graduate level, there has
been some diffusion into undergraduate curricula. A majority of the universities that
have developed undergraduate pharmaceutical engineering programs are found in
Europe. In 2003, the University of Basel, in Switzerland, introduced a bachelor’s
program in pharmaceutical engineering [19]. For the most part, however, colleges and
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universities tend to offer pharmaceutical specializations within traditional bachelor’s
degree programs. This is especially true in the engineering colleges of the United
Kingdom and Scandinavia. In these countries, the pharmaceutical industry is a major
contributor to the country’s economy. For example, 40 percent of all exports from the
Republic of Ireland are pharmaceuticals [20]. In the United States, the University of
Iowa offers a pharmaceutical specialization for undergraduates. This specialization can
be obtained through higher-level electives that focus on different aspects of
pharmaceutical sciences, such as drug delivery systems and basic pharmacology [21].
Stevens Institute of Technology also offers a pharmaceutical manufacturing
concentration for students of mechanical engineering. This specialization is obtained
through courses that incorporate pharmaceutical facility design, validation, and hands-on
projects in the field of pharmaceutical manufacturing [22].
Within these specializations, a majority of emphasis is on upper-level undergraduate
courses, such as creating special topic courses that focus on pharmaceutical sciences. At
the New Jersey Institute of Technology, a class focusing on drug transport and
pharmacokinetics was implemented as a specialty topic course for students wishing to
obtain a specialization in pharmaceutical engineering [23]. The Georgia Institute of
Technology has a course for senior and graduate level students in the field of
pharmaceutical engineering; specifically drug design, development, and delivery [24].
Rutgers University has a Pharmaceutical Engineering Training Program, which allows
both graduates and undergraduates to work on projects based on realistic problems found
in the pharmaceutical industry. These projects deal mainly with product manufacturing
or process research and development [25].

5

Although new upper-level elective courses can be developed to include pharmaceutical
engineering concepts with relative ease, there is a level of difficulty when trying to
incorporate concepts into lower-level undergraduate courses. In particular, the concepts
have to be appropriate for students who are just beginning their undergraduate study. In
addition, these concepts might have to be presented in ways that can be applicable to
different engineering majors. There is also the complexity of adding new courses into an
already saturated curriculum. One approach is to modify pre-existing courses so that they
have a focus in pharmaceutical engineering and at the same time, meet student learning
outcomes. For example, problem sets developed at Rowan University for the use in
lower-level undergraduate courses contain material and energy balances that incorporate
different aspects of pharmaceutical engineering [26, 27]. In addition to using problem
sets, incorporating pharmaceutical concepts into laboratory experiments can be used to
reinforce the course’s existing educational objectives. One of the initial efforts in this
was the development of a first-year laboratory experiment that focused on an
investigation of the controlled release principles of drug delivery methods through the
dissolution of a lozenge [28].
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Chapter 2
Experimental Methods
Experiments that have been developed for the use in a lower-level, laboratory-based
course will be described. Experimental methods as they pertain to the individual
laboratory experiments will be described in the relevant sections. These experiments
were designed to not only introduce pharmaceutical concepts, but also to reinforce basic
engineering educational objectives such as; understand and apply core science and
mathematics principles; work individually and in teams to identify and solve engineering
problems; design and conduct experiments as well as analyze and interpret data [29].
Only the most novel of these works will be described. The experiments to be discussed
are the Tablet Statistical Analysis Lab, the Fluidization of Pharmaceutical Excipients
Lab, the Asthma Drug Delivery Lab, the Degradation of Dissolvable Strips Lab, the
Effervescence Reaction Lab, the Dextromethorphan Crystallization Lab, and the Creation
of Dissolvable Strips Lab. Other experimental write-ups are available on
www.PharmaHUB.org, the resource described previously.
The experiments were designed to meet the safety standards of a typical undergraduate
laboratory and be performed by the students in approximately 2 hours. The cost of these
experiments was also considered so they did not rely on highly specialized equipment
and the operating costs are reasonable. Another point that was considered when
developing these experiments was the ease of the setup.
Two versions of these experiments are available; a student version and an instructor
version, both of which can be found on the website www.PharmaHUB.org in the
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Teaching Materials section. The pharmaceutical and engineering concepts that the
experiment would incorporate are discussed in a brief introduction, which the students
would read before beginning the experiment. The instructor’s version includes a more
detailed procedure, equipment and supplies list, additional pictures of correct setups for
the laboratory experiments, concepts to reinforce, and a solutions section. In order to
obtain access to the instructor versions, faculty members must register to the
PharmaHUB website.
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Chapter 3
Experiments Developed
3.1 Tablet Statistical Analysis Lab
Tablets have a long history in the pharmaceutical industry. The earliest sign of pills
being used can be seen in the 17th and 18th century, when apothecaries were used pill
jars as their necessary equipment [2]. Tablets are often considered the best option for
drug delivery by drug corporations, as they easy and inexpensive to manufacture and are
relatively stable to package, ship, and store. From a patient perspective, tablets are easy
to swallow, have little issues with odor and taste, and are easy to administer [30].
Tablets grew in popularity with the advances in pharmaceutical chemistry. The
progresses in medicine of the 17th to 19th century caused pharmacists and apothecaries to
shift from prescribing whole plants to offering powdered leaves and roots. By the 19th
century, several active pharmaceutical ingredients were being identified from plants and
reproduced via chemical reactions [31]. To mask the often bitter tastes, additives were
added to mask the flavor, which caused the invention of the tablet.
Tablets can be considered one of the products that caused the change in the
pharmaceutical sectors from small shops to large-scale manufacturing corporations. In
the late 19th and early 20th century, pharmaceutical companies gained reputations for their
ability to standardize tablets and used this ability as a selling point. In these terms,
standardization means the process of making a drug or other pharmaceutical product so
that it conforms to a standard, such as a certain amount of active ingredient within a
certain range. Since this laboratory experiment involves statistical analyses on tablets, a
review of standardization practices in the pharmaceutical industry are presented.
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The H.K. Mulford Company was one of the companies that began the practice of
standardization. The H.K. Mulford Company began in 1891 as a small manufacturing
pharmacy, but grew due to its reputation of high quality products [3, 32]. While the
company specialized in lozenges, elixirs, antiseptics, syrups, and other preparations that
were similar to its competitors, what set the Mulford Company apart were its efficient
tableting machines [33, 34]. These patented tableting machines allowed the company to
make tablets in a highly standardized fashion, ensuring that the tablets were relatively
similar to each other [34]. This standardization was found to appeal highly to physicians,
and became one of the selling points of the Mulford Company [3]. Indeed, this early
standardization allowed the Mulford Company to survive the wave of standardization that
would occur in later years.
In the early ages of pharmacy, standards were published in pharmacopeias. The earliest
of these date back to the Medical Edict of 1240 by Frederick II of Sicily, which ordered
that apothecaries prepare remedies always in a similar fashion [35]. Another known act
of drug regulation occurred in 1540, when England enacted the Apothecaries Wares,
Drugs, and Stuffs Act. This act caused inspection and supervision of medicinal
manufacturing of the common medicines of the time [35].
The regulation of drug products via government and laws did not occur in the United
States until the early 20th century. In 1902, the United States government passed a bill
that controlled the production and sales of biologicals after an outbreak of tetanus
occurred in Camden and St. Louis. These outbreaks were thought to be linked to
smallpox vaccines [3]. The act specified that manufacturers of vaccines had to be
licensed in order to sell their products, that the packages be properly labelled and dated,
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and gave the Treasury Department the rite to inspect company policies at any time [36].
This was considered the first act in which pharmaceutical companies had to meet drug
regulation in its modern form [3].
In 1906, another law was passed to regulate the adulteration of foods and drug
manufacturing. After the publication of Upton Sinclair’s The Jungle, in which the
atrocities of the food industry were made public, outcry reached an apex, and the people
demanded better regulation of their goods. From this, the Pure Food and Drug Act was
formed [3]. Through this law, main ingredients had to be identified in foods, drugs,
medicines, and liquors. Chemical examinations were required, and the Department of
Agriculture was given authority over the examinations and regulations of the food and
drug industries [37].
These two acts helped shape the pharmaceutical industry into what it is today. The
regulatory sections of these two acts ensured that pharmaceutical providers had to have
standardized products. This proved to be a feat that was only capable of large-scale
companies, who had the capital to spend on the necessary labs and technicians required
for standardization [3]. The Mulford Corporation provides a great example of this. In
the first few years, the company did not have the equipment needed to test their
diphtheria antitoxins, and so had to use the Laboratory of Hygiene at the University of
Pennsylvania in order to ensure that their antitoxins met specifications [3]. Later, they
managed to obtain their own standardization labs.
Other large-scale manufacturers were hardly affected by the passing of these laws. Parke
Davis, for example, changed very little, as they had been using standardization
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techniques long before legislation [38]. Smith, Kline, and French also had analytical
methods that they used to ensure that they met the standards of the Food and Drug Act.
Indeed, company personnel such as Mahlon Kline were actually in full support of the law
[3]. Wyeth Company was similarly affected, using advanced tableting machines to make
sure they met the standards of the Food and Drug Act [3].
Unfortunately, cataclysmic events once again occurred in 1937 when over 100 people
died of diethylene glycol poisoning in the United States. These victims were poisoned
after taking a sulfanilamide elixir laced with diethylene glycol. These elixirs were
manufactured using diethylene glycol as a solvent, and were sent to the market without
any safety testing. This disaster was one of the catalysts behind the passing of the
Federal Food, Drug, and Cosmetic Act of 1938 [35]. Other factors that caused the
passing of the 1938 Act include Banbar, an ineffective cure for diabetes; Lash-Lure, an
eyelash dye that caused eye injuries; Radithor, a radium containing tonic that caused
painful deaths; and Wilhide Exhaler, a falsified tuberculosis medication [39]. This law
required that drugs be labeled with directions for safe usage, and that approval of all new
drugs be obtained by the Food and Drug Administration (FDA) before being put on the
market. The law also required factory inspections, and gave the FDA several
enforcements tools to ensure compliance [39].
A second tragedy which influenced the development of pharmaceutical regulation
occurred in Western Germany in 1956. At this time, a sedative known as thalidomide
went on sale. Over the next few years, it was linked in over 10,000 birth defects from the
years 1958 to 1960 [35]. Due to this, the United States Government passed the Drug
Amendments Act of 1962. This act, also known as the Kefauver-Harris Amendments,
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allowed the FDA to set good manufacturing practices (GMP’s) and gave the FDA the
authority to enforce these practices. The FDA was also given control over drug
advertising and the marketing of generic drugs [40].
GMP’s are manufacturing requirements that need to be met by corporations. If they are
not met, the product is considered adulterated, which can lead to regulatory actions [41].
GMP’s cover many areas of pharmaceutical manufacturing, including personnel training
and hygiene, building/ facility requirements, packaging, and process control [41, 42].
Several of these GMP’s can be compared to the World Health Organization’s (WHO)
quality assurance measures and the European Medicines Agency’s similar standards,
which call for such things as an acceptable API variances and excipient quality testing
[43, 44].
Since GMP’s deal with acceptable variances and excipient quality testing, statistics play a
vital role in the pharmaceutical industry. This area is of such importance to the industry,
that it has its own journal article, Pharmaceutical Statistics; in which discussions on the
current statistical work done in the pharmaceutical industry is presented. Discussions on
higher-level statistics, such as how to design clinical trials, appropriate sample sizes, and
ethical dilemmas for statisticians are common [45]. The changes in pharmaceutical
statistical practices since the 1980’s have also been an important topic of discussion [46].
In terms of novel approaches to statistics in the pharmaceutical industry is the use of
Bayesian methods, statistical methods and calculations that uses databases of records to
construct probability networks [47]. This has been extensively studied for use in product
development and safety trials [48, 49].
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Engineers who will enter into the pharmaceutical industry should have knowledge of
GMP’s and statistical work [43]. For this reason, engineers should receive a foundation
in GMP’s and statistics if they are to enter into the pharmaceutical industry. The Tablet
Statistical Analysis Lab was designed with this in mind. The objective of this experiment
was to conduct a statistical analysis on the mass of analgesics; in this case, ibuprofen
tablets. From an educational perspective, the intended outcome of the experiment was
that the students would gain experience interpreting data and using some basic statistical
analysis methods. Statistics is an important aspect of the pharmaceutical industry, used
to determine the reliability and accuracy of data taken from drug samples, monitor and
detect the adversities of a process, and assess the capability and reliability of a process
[50].
For this experiment, students take mass measurement of two types of ibuprofen tablets;
Advil® brand and a generic brand. Table 1 shows example raw data of these mass
measurements. Students are given ten samples of each brand, and then take mass
measurements using an analytical scale. The first calculations performed are mean ( ̅ ),
standard deviation ( ), and variance ( ) of both brands. Students then determine if the
mass of the two brands are significantly different from each other through an F-test. The
equation for the F-test, along with the calculations used based on the raw data is shown as
Equation 1.
(
(

)
)
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(1)

For this experiment, the F-critical value was given as 3.18, based on the F-critical value
table found in the Montgomery et al statistics text [51]. Since the experimental F-value is
greater than the critical F-value, the two brands are considered statistically different. A
T-test is then used to compare the two sets of data to a known mass of an ibuprofen tablet
( ), obtained from the Handbook of Pharmaceutical Manufacturing Formulations [52].
The T-test equation, along with a sample calculation of the t-test for the generic brand is
shown in Equation 2.

|

|

|

|

√

(2)

√

The critical t-value, or t-critical, was determined to be 2.262 using a generic t-table in the
Montgomery et al text [51]. Since the experimental t-value was larger than the t-critical
value, it can be concluded that the generic brand is statistically different than the
theoretical value. When the T-test is conducted for the name brand, it was found that the
experimental t-value was smaller than the critical t-value. This leads to the conclusion
that the name brand was not statistically different than the theoretical value. The
calculation for this is shown in Equation 3.
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|

|

|

|

√

(3)

√

Table 1. Raw data of mass measurements for the Tablet Statistical Analysis Lab.
Trial Number Advil® Brand Mass (grams) Generic Brand Mass (grams)
1
0.4784
0.3354
2
0.4837
0.3300
3
0.4715
0.3296
4
0.5019
0.3280
5
0.4840
0.3383
6
0.4842
0.3284
7
0.5050
0.3307
8
0.4930
0.3365
9
0.4804
0.3272
10
0.4845
0.3362
Average
0.4870
0.3320
Std. Dev.
0.010
0.004
Variance
9.72 · 10-5
1.52 · 10-5

From these calculations, students can see that there is a difference between the two
brands. In fact, the data shows that the standard deviation for the generic brand was
lower than the name brand. The reason is that the generic brand did not have a sugar
coating or a polishing coat like the Advil® brand. These coatings are much less regulated
than the active pharmaceutical ingredient (API) content of the tablet, and as such, adds
more variance to the population. The students also see that the generic brand does not
correlate well with the literature value, which is also due to the lack of coatings. As such,
the values may change depending on the generic brand used for this experiment.
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Students also perform an outlier test, taking a portion of their data analysis for a BoxWhisker plot to determine any outliers. Students should not find any outliers in their
experimental data, since the tablets are subjected to the high standards of pharmaceutical
manufacturing [53]. Students also complete an exercise where they are given a table of
mass measurements from a hypothetical batch of tablets, and must determine whether or
not an outlier exists. This data is shown in Table 2.
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Table 2. Example data from the outlier testing problem in the Tablet Statistical Analysis
Lab.
Data
Sorted Data
Provided (Low→High)
0.4850

0.4217

0.5198
0.5048
0.4857

0.4448
0.4465
0.4481

0.4786

0.4662

0.5435
0.4448
0.4668

0.4668
0.4686
0.4786

0.4465

0.4835

0.4835

0.4837

0.4686
0.5211

0.4850
0.4857

0.4863

0.4863

0.4217
0.4481
0.4837

0.5048
0.5101
0.5198

0.5895

0.5211

0.5227
0.4662
0.5101

0.5227
0.5435
0.5895

Quartiles
Q1

0.4665

Q2

0.4844

Q3

0.5150

Once the data has been sorted from highest to lowest, the students calculate the three
quartiles (Q). The first quartile (Q1) is the median of the lower half of the data, while the
third quartile (Q3) is the median of the higher half of the data. The second quartile (Q2) is
the median of the entire data set. Q1 and Q3 are then used to determine the low and high
outlier cut-off points (OL and OH, respectively). The equations for determining OL and
OH are shown in Equations 4 and 5.
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(

)

(

)
(4)

(

)

(

)
(5)

A box-and-whisker plot can then be used to show the outlier (Figure 1).

Figure 1. The Box-and-Whisker plot for the exercise found in the Tablet Statistical
Analysis Lab. One outlier is clearly visible in this plot.

As an introductory experiment, this lab presents important pharmaceutical terminology.
Students learn about the different pharmaceutical substances, such as API and the
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different types of excipients (fillers, binders, glidants, etc.). These technical terms were
reinforced through an exercise where students determine the API and look up the first
three inactive ingredients or excipients; and their functions. In addition, students learn
about batch manufacturing processes and receive an introduction to process flow
diagrams through an exercise. Students are given a manufacturing procedure from the
Handbook of Pharmaceutical Manufacturing Formulations on how to make coated
ibuprofen tablets, read it, and then convert their readings into a flow diagram of this
process [52], shown in Figure 2. The Student and Instructor’s Version of this laboratory
experiment can be found in Appendix A.1 and B.1, respectively.

Figure 2. The solution to the flow diagram exercise found in the Tablet Statistical
Analysis Lab. Above, the powder is corn starch, and mix #1 is ibuprofen and corn starch.

3.2 Fluidization of Pharmaceutical Excipients Lab
Fluidization is defined as a technique or phenomenon where the internal frictional forces
in a bed of solid particles are reduced so that the bed flows like a fluid. Counter forces,
such as drag, also exist in a fluidized bed [54]. The first investigations into fluidization
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began in the late 1940’s with Richard H. Wilhelm and Mooson Kwauk, who investigated
the different phases of fluidization [55]. Fluidization then began a period of extensive
research through the 1950’s and well into the 1970’s, when Kunii and Levenspiel
published their book entitled ‘Fluidization Engineering’ [54]. The book laid out
extensive details on the previous research done; including equations, heuristics, and
graphs of fluidization data [56]. After the 1970’s, fluidization research began to
decrease, only to grow again in the late 90’s. One example is a group of researchers from
Beijing that began an in-depth study on how to fluidize fine particles in 1998 [57].
The pharmaceutical industry has used fluidization technology for several years. Early
investigations of fluidization in the pharmaceutical industry can be seen in a three-part
series of articles by Davies and Gloor [58, 59, 60]. Pharmaceutical manufacturers can
use fluidized beds for granulation, and has been used for this purpose for several decades.
Granulation is defined as a process where small powder particles are gathered and turned
into larger particles [61]. This is done to improve the powder properties for downstream
processing [62]. A two-phase process is usually used for granulation, which includes
spraying, drying, and the addition of a binding liquid [62, 63]. In cases where there are
heat- or moisture-sensitive drugs, granulation can occur with compaction.
In the early days of this unit process, granulation was considered more of an art than a
science. After extensive investigations by a few researchers, models were developed for
granulation phenomenon, and can be seen in several review articles [64, 65]. A highlight
of some of these theoretical developments include: Determining the drop penetration
time based on capillary pressure; determining deformation through a Stokes deformation
number; a multidimensional model that follows distributions in granule size, porosity,

21

and liquid content [66, 67, 68, 69]. From a manufacturing perspective, there have been
several studies on granulation. Controls and scale-up work that has been done has been
compiled by Faure, York, and Rowe [70]. This compilation includes an extensive list of
process parameters that affect wet granulation. Techniques used for controlling the
distribution and shape of granules were also discussed. Some of these techniques include
fuzzy logic, neural networks, and image processing [71, 72, 73].
Fluidization can also be used for coating operations. The appeal of using a fluidized bed
apparatus for coating processes is due to high energy and mass transfer rates that are
available through the system [74]. Coating is often used for taste masking and drug
release control in pharmaceutical products [75]. A patent was filed in 2014 by the New
Jersey Institute of Technology that used fluidized bed coating for drug release control
[76]. Coating can also be used to improve product flowability [77]. One study
investigated the improvement in flow properties of ibuprofen after a thin-coating with a
fluidized bed apparatus [78].
Coating in fluidized beds is mostly used for dry solid particles, powders, or pellets. In
this setup, particles are fluidized by hot air, and then the coating solution is sprayed over
top of the particles. The hot air causes solvents to evaporate, leaving a coating on the
surface of the fluidized particles [79]. In most of the cases in the pharmaceutical
industry, the Wurster process is used. The Wurster process was patented in 1966, and
uses a spray coater that sprays up from the bottom, which allows for higher coating
quality and homogeneity [80, 81]. This process has been shown to be the most useful
equipment setup for small-particle coating [82].
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Fluidized beds are also used for drying. Due to its rapid heat and mass transfer abilities,
large capabilities, and relatively low capital cost, fluidized beds are often utilized for the
drying of wet granules [83, 84, 85]. This type of drying can be done either in batch or
continuous processes. Usually, batch operation is used in small-scale productions and
continuous operation is used in large scale productions. Batch operations may also be
used for heat-sensitive materials [86].
There has been extensive research on drying using fluidized beds. Chandran, Subba Rao,
and Varma published their work on developing a kinetic model for this phenomenon in
1990 [87]. Thomas and Varma investigated several factors on fluidized bed drying,
including temperatures, flow rates of the heating medium, and the mass of solids in the
fluidized bed [88]. Circulating fluidized beds are used for drying, and have been
investigated by Balasubramanian and Srinivasakannan [86]. A model has also been
developed for fluidized bed drying of granular material [89]. Mixtures of solids have
also been investigated for their drying behavior in fluidized bed systems [90].
From the literature review, it is obvious that fluidization is now an important unit
operation in the pharmaceutical industry. The Fluidization of Pharmaceutical Ingredients
Lab was designed so that students would be introduced to the fluidization equipment and
the phenomenon of fluidization. This experiment is based on a polymer coating lab for
freshmen developed by Rowan engineering faculty [91]. The objectives of the lab are to
analyze the fluidization of a pharmaceutical ingredient, such as an excipient, and measure
basic fluid/particle properties. In order to do this, students first determine three
properties; bulk density, particle density, and bed porosity. This is done through a
gravimetric analysis, where the students use a graduated cylinder and water to determine
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the bulk and particle densities, and then calculate the porosity of the substance using
these two parameters. Students compare these to literature values and learn how to use
particulate data bases. The second part of the experiment focuses on fluidization
phenomena. The objective of this part is to determine fluidization regimes and the effect
of process parameters related to fluidization. The setup of the fluidized bed is shown in
Figure 3, in which the excipient is fluidized in air.

Figure 3. The fluidized bed apparatus used in the Fluidization of Excipients Lab.

Students conduct an experiment to measure the bed height as a function of air flow rate.
They notice through this exercise that as bed height starts to increase, fluidization has
also started. Pressure drop readings across the column are also taken during this study.
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Through graphs of these variables, as seen in Figure 4, students observe where the slope
of the lines change, denoting transformation from packed bed to fluidized bed behavior.
In addition, students receive an exercise in using online reference tools. This exercise
asks the students to find an article through library electronic search tools that discusses
fluidized beds in the pharmaceutical manufacturing. The students are to print out the
article of their choosing and discuss it in the next class.
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Figure 4. Sample data from the Fluidization of Pharmaceutical Ingredients Lab. a) Air
flow rate versus bed height is shown. b) Air flow rate versus pressure drop. Studies used
Avicel® Ph200 at 20 °C.

The pharmaceutical objective of this experiment is to show equipment used in
transportation, granulation, coating, and drying of solids [58]. Since the solid particles
act like a fluid, they become much easier to transport through conventional conveying
equipment. Students also see how excipient properties affect the fluidization process.
The students gain this experience through an exercise that has them compare the
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Reynolds Number at minimum fluidization, Remf, of two different substances; Avicel®
(microcrystalline cellulose powder) and kaolin (white clay powder). The main difference
between these two studies is the average particle size (1.4 µm for kaolin and 180 µm for
Avicel®), which is the primary reason the Reynolds Number calculations at minimum
fluidization are different. The Reynolds Number (Re) calculation gives students
experience in units and conversions, requiring them to convert to one system of units and
prove that Re is dimensionless. Students are also introduced to fluid flow in calculations
and conversion of volumetric flow rates to a fluid velocity in the bed. Finally, they use a
design equation to predict what the Remf should be and compare that to their
experimentally determined value [92]. This equation, along with supplemental governing
equations, is shown in Equations 6 through 9.
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)
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Where

is the void fraction at minimum fluidization;

particle;

is the density of the fluid;

is the diameter of the

is the particle density of the solid; and

viscosity of the fluid. In the Avicel® experiment, the design equation predicted a
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is the

Reynolds number of 19.36, while experimental data determined a Reynolds number of
19.10, which is within 1.4% difference. The Student and Instructor’s version of this lab
can be found in Appendix A.2 and B.2, respectively.
3.3 Asthma Drug Delivery Lab
Asthma is one of the most chronic illnesses diagnosed in children. The illness has been
reported throughout most of human history, being recorded in ancient Chinese, Indian,
Egyptian, and Greek writings [93]. Cures from these writings include special teas,
vapors, honey, mustard oil, turmeric, and garlic. Asthma’s current definition wasn’t
established until 1698 by John Floyer, an English physician. Floyer defined asthma as
“laborious respiration with lifting of the shoulders and wheezing” and also understood
that the illness was intermittent and episodic, which requires rescue and controller
therapy [94].
It wasn’t until 1896 that the approach to asthma treatment took on its current form of
acute rescue treatment, controller treatment, and prevention of long-term complications
[95]. Sir Thomas Granger Stewart and George Alexander Gibson noted that
environmental allergens can affect asthma at this time, and offered some advice for
removing offending allergens from the environment [96]. From then on, asthma was
treated pharmacologically. The first treatment prescribed for asthma treatment was
anticholinergic belladonna-related alkaloids [95]. It was Stewart and Gibson who
suggested smoking stramonium, a dried leaf and flower of the plant Datura stramonium,
with tobacco (or preferably pure stramonium) to reduce the symptoms of asthma [96]. In
1914, hypodermic injections of pilocarpine, a drug derived from plants of the genus

28

Pilocarpus, were noted to be effective, and added to the common treatments for asthma
[97].
In 1940, theophylline, a non-anti-cholinergic bronchodilator, was reported for the first
time as a method for treating asthma [98]. This sparked the use of non-anti-cholinergic
bronchodilators for asthma treatments, leading the way to the prescription of ephedrine,
adrenaline, salbutamol, remiterol, and fenoterol [99]. Unfortunately, these drugs did not
go through specific safety regulations, and were unrestrictedly supplied in over-thecounter medications. It was this that caused an epidemic of asthma related deaths in the
United States, Australia, United Kingdom and New Zealand from the 1960’s to 1980’s
[100]. These epidemics lead to the prescribing and careful regulation of asthma
medications.
While cigarettes and injections were used early in asthma treatments, inhalers were used
in the first third of the twentieth century [95]. Atomizers and inhalers can be seen in
early 1900’s and through the 1950’s [93]. In the year 1956, the metering valve was first
invented, and so, the first pressurized meter dose inhaler (pMDI) came into being [101].
A pMDI delivers a dose of pharmaceutical medication that has been suspended through a
chlorofluorocarbon (CFC) [102]. A pMDI consists of three major components: A
reservoir, in which the raw drug is suspended; a metering valve, which delivers a
specified amount of the medication when depressed; and a spray actuator, which delivers
the drug to the body.
The pMDI is arguably the most famous version of an asthma inhaler, with most
respiratory drugs being offered in this form of delivery [102]. The advantages of this
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drug delivery method are that it is efficient when used correctly, they are portable, and
they are relatively easy to use. In most cases, pMDI’s have a deposition efficiency of
6.5% to 24%, which is better than previous methods of drug delivery [103]. However,
there are some drawbacks to this method. The major problem with MDI’s is that if not
used correctly, the drug will deposit itself on the tongue, causing fungal infections in the
mouth [104]. Also, the use of CFC’s has become under fire, since they lead to ozone
depletion. As such, new excipients are used, which cause a decrease in efficiency. These
new propellants also have to be rigorously tested for any possible toxicological effects
[102].
Another form of asthma medication delivery is known as the dry powder inhaler (DPI).
Although DPI’s are not as widely known as pMDI’s, this method of delivery has been
investigated since the 1930’s. The first patent to be given for a powder inhalation method
was awarded in 1940 for the inhalation of aluminum powder [105]. The first
pharmaceutical dry powder inhaler can be seen in a patent from 1949 [106]. These dry
powder inhalers do not use a propellant agent in order to deliver the medication. Rather,
the mechanism of delivery is solely based on the size of the particles and their inhalation
from the device [102, 107].
This lack of needing a propellant is considered a great advantage, since one does not
have to worry about using ozone depleting propellants. Some other advantages for using
a DPI are that it is easy to use and causes less irritation in patients [108]. In addition, the
DPI is just as portable and compact as a pMDI. Thus, several companies have produced
DPI’s for asthmatic therapeutics [93, 102].
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DPI’s are not without their setbacks, however. One of the main problems with DPI’s is
paradoxically caused by their greatest asset; they do not use propellants. As such,
patients who use DPI’s must inhale at a suitable flow rate in order to obtain the correct
dosage of the drug [109]. This is a problem specifically for young children [110]. Some
of the lesser DPI disadvantages include that they are more expensive than MDI’s and also
need to be stored in cool and dry areas [111].
As asthma medications have several different modes of drug delivery, this was thought to
be an opportune moment for introducing differences in drug delivery mechanisms. The
Asthma Drug Delivery Lab compares three different drug delivery systems for asthma
medicines. The first objective of the experiment is to have the students reverse engineer
the three systems; a dry powder inhaler, a metered dose “rescue” inhaler, and a nasal
spray. Secondly, the students determine the quality control measures of the inhalers and
how they deliver a specific dosage each time used.
The dry powder inhaler, an ADVAIR Diskus®, is also known as a diskhaler. The
students compare the production design of the Diskus® with a metered dose “rescue”
inhaler and a nasal spray through a reverse engineering exercise. Only the ADVAIR
Diskus® reverse engineering process is described in this paper, as it was the most
technically complex device. First, the students brainstorm the drug delivery mechanism
of the diskhaler, using the patient insert as the source of information. Most students will
guess that there is some sort of puncture device that allows the medicine to enter the main
chamber of the diskhaler, as it is described in the pamphlet as blisters being punctured
open. Seeing the inner mechanisms gives the student insight into how the inhaler
actually works, using a tearing mechanism to open the blister packets. Since the design
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utilizes blisters, the device ensures that only a certain amount of active pharmaceutical
substance is released for each use, keeping the rest of the powder fresh inside the
individual blisters for subsequent doses, as shown in Figure 5. Students also have to
discuss the ergonomics and aesthetics of each of the products, so that they also
understand the importance of these two factors on product design in drug delivery.

Figure 5. The inner mechanisms of an ADVAIR Diskus®.

The second half of this experiment has the students review the quality control aspect of
the three devices by taking mass measurements of the doses being delivered and
calculating the mean and standard deviation (Table 3). From this data, the students
compare the standard deviations, and what that implies about the function of the devices.
Students observe that the diskhaler has the lowest standard deviation of the three devices,
which is due to the design of the device. Similar results are not obtained with the
metered dose inhaler and the nasal spray because the metered dose inhaler involves a
fluid that easily evaporates and the precision of the nasal spray depends on how well the
apparatus is primed. These product designs enter into the discussion of why the standard
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deviations for those two designs have an order of magnitude difference from that of the
diskhaler. Students are also tasked with looking up typical standard deviations for
therapeutic dosage delivery. The Student and Instructor’s version of this lab can be found
in Appendix A.3 and B.3, respectively.

Table 3. Sample data and results from the Asthma Drug Delivery Lab.
Trial
Number
1
2
3
4
5
6
7
8
9
10

Mass of Diskhaler
Powder(g)
0.0130
0.0130
0.0127
0.0132
0.0126
0.0123
0.0130
0.0129
0.0124
0.0130

Mass of Metered Dose
Inhaler (g)
0.0130
0.0128
0.0088
0.0107
0.0130
0.0140
0.0140
0.0148
0.0120
0.0121

Mass of Nasal Spray
(g)
0.0867
0.0979
0.0989
0.0854
0.1004
0.0983
0.1022
0.1000
0.0991
0.0986

Average
Std. Dev.

0.0128
2.81·10-04

0.0125
1.66·10-03

0.0968
5.48·10-03

3.4 Degradation of Dissolvable Strips Lab
Drug delivery has become a widely popular area of study for chemical engineers. Indeed,
this topic is also of great importance to the pharmaceutical industry as well. From a
pharmaceutical perspective, the purpose of developing novel methods of drug delivery
systems is to improve patient compliance and optimize dosage regiment while not
compromising the therapeutic efficacy [112]. From an economical perspective, drug
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delivery systems also cost less and take about half the time as it does for a pharmaceutical
company to develop as opposed to new drug discovery [113].
Although tablets are the most common form of drug delivery, other methods exist.
Transdermal patches, inserts, and implants are all examples of these other methods.
Implants were first discovered as possible methods for drug delivery in the 1960’s
through the experimentation of Judah Folkman of the National Naval Medical Center.
His experiments found that sealed segments of silicon tubing containing drugs could be
planted within the body as a constant rate drug delivery device [114]. An early form of
insert was offered by the Alza Corporation in the 1970’s, which would deliver glaucoma
medication to the eye through an ocular insert [115]. This insert was found to be more
effective than the commonly prescribed ophthalmic solutions that were available at the
time [116]. Inserts are now becoming popular as modes of contraception. The Alza
Corporation was again early providers of this kind of insert, which was inserted vaginally
to release a contraceptive drug [115]. These rings, and other versions of vaginal inserts,
are still popular forms of contraception.
Another innovation that occurred in the 1970’s was the transdermal skin patch. Once
again, the Alza Corporation was a pioneer in this form of drug delivery, being one of the
first corporations to obtain a patent for transdermal skin patches [117]. This type of
transdermal patch was advertised as a bandage that would administer anti-motion
sickness medication [115]. In the early to middle 1980’s transdermal delivery systems
began to be a popular area of research [118]. Transdermal patches are currently popular
for nicotine delivery for use as smoking cessation aids [119]. More recent research has
investigated transdermal patches for uses in wound and scar treatment [120, 121].
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While the 1970’s drug delivery research was focused on the macroscopic level, the
middle to late 1980’s was the moment when investigations began to focus on the
microscopic level. This is not to say that investigations in the microscopic level did not
occur previously. The earliest patent based on microparticles was dated in 1973 [122].
Microparticles were prioritized during this middle to late 1980’s period [115]. A
revolution of microparticle research occurred in the early 1990’s, when a group of
researchers invented a process for fabricating uniform sized microparticles [123]. This
area of research still continues in this century.
In the late 1970’s, the concept of nano-therapeutics were beginning to form and rise in
interest. Three key technologies developed in the 1980’s stimulated and ensured the
success of the field: Polyethylene glycol drugs and drug carriers; active targeting of the
drug conjugate via cell membrane receptor antibodies; and discovering the enhanced
permeation and retention (EPR) effect. The conjugation of polyethylene glycol was the
first of these technological jumps, and was first reported by researchers at Rutgers
University in the 1960’s [124]. It was effectively used to deliver cancer fighting proteins
[115]. In 1975, the first example of drug conjugate targeting was published [125]. This
research led to another cancer fighting breakthrough, in which drug conjugates were
actively targeted by ligands which were imperative for liver cancer treatment [115, 126].
The EPR effect was the last of the developments to be discovered. This discovery was
made in 1984 by Hiroshi Maeda of Kumamoto University after carrying out animal
studies with a novel drug conjugate [115]. Further investigation lead to a publication on
the effect, and helped shape the research done in nanoparticles to this day [127].
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Surface-controlled drug release has been a clinically successful area of research since the
1960’s, and can be one of, or a combination of, macroscopic, microscopic, and
nanoscopic technologies [115]. One of the first successful investigations into surface
controlled drug delivery began with the polysaccharide heparin, which was used to coat
surfaces of polymers to prevent coagulation of blood on polymers. This area of research
was heavily investigated since the 1960’s [128]. More recent investigations look at using
drug eluting stents, which have been investigated by Johnson & Johnson and Boston
Scientific [129]. There have also been insights into surface coatings for enhanced drug
delivery for mucosal tissues. Gastric retention formulations have been one of the key
areas of study for mucoadhesive systems [130].
While the drug delivery development of the past century might seem impressive,
scientists and engineers conclude that development has been quite poor for this time
period. One worker of SmithKline Beecham Pharmaceuticals stated in 1999 that the
developments of the century would score no more than a 2 or 3 on a 1-10 scale [131].
There is speculation, however, that development will increase in this current century.
More emphasis will be placed on creating “smart tablets” that can be used for both
immediate and controlled release [131]. These smart tablets are to be more beneficial to
patients by maximizing drug efficacy by using a smarter drug delivery selection system.
With this in mind, regulatory requirements are also hypothesized to change [131]. With
this in mind, it is imperative that those seeking employment in the pharmaceutical
industry be well-versed in the drug delivery process.
Drug delivery education is not always a difficult concept to incorporate into engineering
curriculums. One of the benefits of this area is that it contains aspects of important
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engineering topics. Drug delivery itself relies heavily on transport phenomenon, a staple
in the chemical engineering curriculum [118]. Others have already made significant
progress integrating drug delivery into engineering education. Farrell and Hesketh of
Rowan University developed an introduction to drug delivery for chemical engineers in
2002 [28]. A drug delivery experiment was also developed that could be used for the
Freshman Engineering Clinic class offered at Rowan University by Farrell and Vernengo
[132]. At the National University of Singapore, a group of educators used a design
project to discuss controlled-release drug delivery devices [133]. Simon, Kanneganti,
and Kim of the New Jersey Institute of Technology introduced a laboratory on drug
transport and pharmacokinetics, as mentioned previously [23]. As also mentioned in a
previous section, the Georgia Institute of Technology offers an interdisciplinary course
on drug design, development, and delivery [24]. The Georgia Institute of Technology
developed a laboratory module around the same time focusing on skin diffusion, an
important aspect of transdermal drug delivery [134].
Following this trend, the Degradation of Dissolvable Strips Lab is an investigation into
the drug delivery aspects of dissolvable strips. In this experiment, students are tasked
with investigating the dissolution rate of ingredients in dissolvable strips. Strip films
have become an area of interest in the past few years as an alternative to conventional
tablets and capsules, especially for patients suffering from dysphagia [135]. Some
examples of consumer products formulated into orally administered strips include breath
fresheners, energy supplements, and analgesics for flu and sinus symptoms [136]. In this
lab, students work with Sheets™ brand energy strips, containing caffeine and blue food
dye. Blue food dye in the product is used to model the release of a pharmaceutical

37

ingredient. The students are to investigate the effect of temperature on the dissolution
rate by placing one strip in water kept at room temperature (~ 22 °C), and placing another
in water at body temperature (~ 37 °C). To simulate the mouth, a shallow petri dish is
filled with 25 mL of water, in which a strip is placed; absorbance measurements are taken
at regular intervals, generating graphs as seen in Figure 6. The absorbance values are
related to the concentration of the ingredients released by using a standardization curved
developed at the beginning of the experiment.
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Figure 6. Sample data from the Dissolvable Strip Lab, using one strip film for each.

The experiment introduces the students to spectrophotometry, and the principles related
to the methodology used to measure solution concentration. This is done by having the
students apply the Beer-Lambert law to determine the molar absorptivity coefficient of
the blue food dye at both temperatures at the time of 80 minutes, which is considered a
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point where the strip has fully dissolved in the water. The equation and a sample
calculation are shown in Equation 10.

(

)(

)

(10)

Where A is the absorbance (unitless), ℓ is the measurement cell width, and c is the molar
concentration of the sample. The students should notice that the coefficients are identical
between the two cases (ε22 and ε37 are 1.401· 106 M-1 cm-1), which determines that for the
ranges used in this experiment, the temperature does not significantly affect the molar
absorptivity coefficient. The students are then charged with determining how the BeerLambert law and molar absorptivity coefficients can be applied in other engineering
applications. Some of the common answers will be waste water treatment, product
synthesis, and algae growth.
The pharmaceutical relevance of this experiment is that students are introduced to a novel
drug delivery system. The students also see how the strip film quickly dissolves in water,
indicating that the polymer used in the strips breaks down when it comes in contact with
water. The concept of higher temperatures affecting the dissolution rate of the strip is
also reinforced through an example involving rate laws. In this example, the students use
absorbance readings and determine the rate law coefficient, k, for both experimental
conditions. Upon calculating, the students see that the rate coefficient is higher for the
body temperature experimental run than the room temperature study.
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Some additional parts of this experiment have been developed based on advanced
instrumentation and the available time. If a broader range spectrophotometer is available,
absorbance data can be taken for caffeine at a wavelength of 273 nm. An agitated system
can also be used to examine the convective effects on dissolution rate of the strip. The
Student and Instructor’s version of this lab can be found in Appendix A.4 and B.4,
respectively.
3.5 Effervescence Reaction Lab
An effervescence reaction is one in which an organic acid and a carbonate substance
which will release carbon dioxide upon reaction with the organic acid [137].
Effervescent reactions can be seen in several different areas of chemical research.
Recently, investigations have been made in using effervescent reactions for the extraction
of solids. The effervescence reactions help to improve the extraction yield, with absolute
recoveries in the range of 61 to 85 % [138]. Another study also looked at using
effervescent reactions and nanoparticles to increase the extraction yields in dispersive
liquid-liquid microextraction [139].
Effervescence reactions are also important in the food industries, specifically the
champagne and sparkling wine industry. Carbon dioxide plays an important role in the
champagne and sparkling wine; as it affects the frequency of bubbles, the growth rate of
bubbles, the oral feelings, and the aromatic perception [140]. Carbonation is also an
important aspect in beer, seltzers, and sodas. In beer production, carbonation helps to
release aroma compounds, improving the smell of beers [141]. This process is also used
highly in coffee production [142].
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Effervescence itself has been used for over 250 years in the pharmaceutical industry
[143]. The most famous pharmaceutical product that makes use of effervescence is AlkaSeltzer®. Alka-Seltzer® was developed in 1930’s as a cure for a hangover [144]. Since
then, the tablets have been used as cures for heartburn, headaches, seasickness, and
flu/cold-like symptoms. Due to the success of Alka-Seltzer®, other manufacturers began
to produce their own form of effervescent tablets. This has led to several patents being
awarded for the production of effervescent tablets, including a novel process for making
tablets in 1978, granules in 1986, and a modification of the effervescent compositions in
1987 [137, 145, 146].
Currently, effervescent tablets are still an area of research. Ranitidine, an API often used
for ulcers, acid reflux, and Zollinger-Ellison syndrome, is currently being investigated for
possible inclusion in effervescent tablets [147]. Prochlorperazine maleate, an API for
nausea treatment, is also investigated for use in effervescent tablets for improved patient
compliance [148]. In the field of prostate cancer research, the API flutamide was
incorporated into effervescent tablets in order to increase its bioavailability with
considerable success [149]. The effervescent powders themselves are also an area of
study. Effervescent powders are currently being investigated for their use in respiratory
drug delivery to incorporate an active release mechanism, increasing the release
efficiency [150].
Since effervescence is an interesting and innovative area of the pharmaceutical industry,
it was decided that an experiment should be developed to introduce this type of reaction.
This experiment, the Effervescence Reaction Lab, evaluates the effect of tablet
manufacturing process on the rate of this effervescence reaction. Students compare the
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effervescent reaction of a whole tablet of Alka-Seltzer® to the initial raw ingredients.
These are allowed to react with water, while students take residual mass measurements as
time progresses. Students must determine why the whole tablet reacts faster. Upon a
review of the manufacturing procedure, it is determined that there is a milling step to
reduce the active ingredient particle size. Therefore, with greater surface area and a more
uniform composition, the reaction proceeds faster than the un-milled raw materials.
By having students measure the amount of mass that left the system, they determine the
amount of carbon dioxide (CO2) gas produced via the effervescence reaction. Using
stoichiometry, the students also determine the amount of CO2 they should have
theoretically generated during the reaction. The stoichiometric equation is shown in
Equation 14.
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Using these two values, the students determine the percent difference between their
theoretical and experimentally observed values, as shown in Figure 7. They see that the
longer the reaction continues the difference between theoretical values and experimental
values starts to decrease. Students use this information in an exercise to obtain an
equilibrium constant for the effervescent reaction. The Student and Instructor’s version
of this lab can be found in Appendix A.5 and B.5, respectively.
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Figure 7. The differences from stoichiometry between the tablet and the pure
components, students see that as the time increases, the percent error decreases.

3.6 Dextromethorphan Crystallization Laboratory
Crystallization is an important aspect of several different industries. In chemical
engineering, crystallization is an important process for solid-liquid separation, and is
often incorporated into separation texts [151, 152, 153]. Crystallization is a process in
which solid particles are formed from a homogenous mixture. In crystallization, a
mixture is concentrated, usually to saturation, and is then cooled until the solute
concentration becomes greater than the solubility of the mixture at that temperature. This
causes the solute to form crystals and precipitate out of solution [153]. Crystallization is
often employed as a separation process for two reasons. Crystallization has a large
separation factor, and as such, creates crystals of high purities; crystallization also
produces crystals of uniform sizes and shapes [152]. The latter characteristic is a highly
regarded aspect for the pharmaceutical and food industry.
In crystallization theory, there are four important parameters of the crystal; saturation,
purity, nucleation rate, and single crystal growth rate. Saturation is the maximum
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concentration of a solute which is thermodynamically stable [151]. In several cases,
however, a solution can contain more solute than the saturation limit. In this case, the
system is considered supersaturated, and is often metastable, meaning that the solution,
while unstable, can remain unaltered for long periods of time [151]. Purity is the relative
purity of crystals created, which is important if several different substances can be
formed from one reaction. Factors such as crystal size and shape can affect the purity of
the solids precipitating out [154].
Nucleation rate concerns the rate of crystal production, and occurs in four specific
mechanisms; homogeneous, heterogeneous, secondary, and attritive [151]. Homogeneous
nucleation is the formation of crystals due to supersaturation only, while heterogeneous
results from the presence of other insoluble materials. Secondary nucleation is somewhat
of a catch-all, and includes nucleation caused by the contact between different crystals.
Attrition is the breakup of existing crystals that then grow into larger crystalline
structures [151]. Single crystal growth defines the rate at which existing crystals grow in
size. Factors such as agitation of the system, crystal size, and geometry of crystal all
affect single crystal growth [151].
The solubility of a solute, and its dependence on temperature, is an important aspect of
the designing of crystallization equipment. To visualize this dependence, solubility
curves are often employed. Solubility curves, or solubility diagrams, can also be used
with Miers diagrams, which graph the metastable, stable, and unstable regions of
solutions [152]. Through these diagrams, calculation of yields for crystallizers can be
easily completed. Particle sizes and nucleation rates can be determined theoretically
[153].

44

Crystallization, as stated before, is an important unit operation in the pharmaceutical
industry. API’s often are synthesized and purified using crystallization processes [155].
The areas of crystallization; including theory, empirical formulas, appendices of data, and
scale-up considerations have been well documented [156, 157, 158]. Crystallization is
also an important aspect of pharmaceutical research and development, with numerous
papers being published on novel approaches in this field.
Crystallization is being investigated for possible uses in changing crystal characteristics.
For example, acetaminophen can have its thermodynamic stability and other properties
change by adding other molecules before the crystallization process [159]. Indeed,
cocrystallization is often used to change the properties of one or two molecules so that
they may be optimized for use in a pharmaceutical product [160]. This has recently been
investigated to increase the solubility of nitrofurantoin, an API used in treating urinary
tract infections [161]. The melting point of a crystal can be changed in this manner as
well. Researchers found that using cocrystals of hexamethylenebisacetamide A, an
anticancer drug, helped increase the solubility and melting point of the API [162].
Compressibility and flowability can also be improved by using cocrystals, as was
discussed in an article on carbamazepine cocrystals published in 2007 [163].
One of the unit operations that have been researched for crystal engineering and
cocrystallization is supercritical fluid processes. Several studies have been completed
that focus on supercritical fluids and their use in crystal engineering. Researchers have
found that using supercritical fluids not only reduces solvent waste, but also reduces the
necessary volumes for API crystal formation [164]. Others have found that using
supercritical fluid crystallization can also be used to change particle size to alter the
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particle dispersion of the final product [165]. Feasibility studies are included, such as an
investigation into the feasibility of creating indomethacin-saccharin cocrystals to use in
anti-inflammatory medications via supercritical fluid technology [166]. Another study
found that cocrystals of indomethacin, theophylline, caffeine, sulfamethazine, aspirin,
and carbamazepine could all be produced viably using supercritical CO2 [167].
In addition to using supercritical fluids, others are looking at developing other methods,
such as high-throughput crystallization technologies. These technologies combine design
of experiments, experimental protocols, and data analysis, and consist of both hardware
and software components [168]. This technology can be used to determine a selection for
specific salts. For example, a study used several salt forms of the antibacterial
sulfathiozole to determine the use of high-throughput systems. The results of this found
that the high-throughput machine rapidly identified 10 salt forms and could characterize
them based on melting point ranges [169]. Another study found that high-throughput was
effective in determining which cocrystals of caffeine-oxalic acid and theophylline-oxalic
acid had proper solubilities and solid/solution stability properties [170]. Others have
looked at including Raman microscopy in the high-throughput process to gain even more
information, such as equilibrium of cocrystal formation and polymorphic transformation
[171].
While crystallization is a relevant topic in pharmaceutical manufacturing, many engineers
in the industry find that the unit operation is de-emphasized in most engineering
curriculums. Most newly employed engineers learn what they do about crystallization
from on the job training [155]. The Dextromethorphan Crystallization Lab is designed
specifically to provide background in crystallization for undergraduates. Objectives for
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this experiment are to develop a solubility curve for dextromethorphan hydrobromide
(DXM), and to also learn the underlying theory of crystallization, such as the thermal
energy transfer that occurs in the crystallization process. Students are tasked with
determining the temperature at which saturation occurs for several concentrations of
DXM in water. Students complete this by heating up solutions of DXM and water and
recording the point of recrystallization. The experiment involves the students taking a
specific mass of DXM and adding it to 5 mL of water in a test tube. DXM is known for
being an insoluble molecule in water [172]. As such, students will observe that the
particles simply sink to the bottom of the test tube. To obtain solubility data, the students
are to heat this mixture in a hot water bath, kept at around 90 °C, which can be seen in
Figure 8.

Figure 8. The hot water bath setup used for the Dextromethorphan Crystallization Lab.
Two thermocouples are used to regulate the temperature of the hot water bath and the
water in the test sample.
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The mixture is heated until the students see all the crystals dissolve in the water. Using a
thermocouple, the students will record the point at which crystals start to reform in the
test tube. A sample of what this looks like can be seen in Figure 9. This is considered the
temperature of saturation for that concentration. This is done for several concentrations,
including one which is chosen by the students. A sample solubility curve that would
have been produced can be seen in Figure 10.

Figure 9. The DXM and water solution once recrystallization has begun. Notice the
white substance at the bottom of the tube.
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Figure 10. An example of a solubility curve developed for the Dextromethorphan
Crystallization Lab.

By recording the saturation temperatures, students are given the task of creating a
solubility curve for DXM in water. The random concentration that the students chose is
used for two purposes; to allow students to determine the reliability of their solubility
curve; and to gain experience using interpolation. Interpolation is an important tool for
engineers, as it can be used to determine new values that lay inside existing data points.
Students are to determine the saturation temperature that corresponds to their chosen
concentration. Calculating the percent difference from their interpolated value to that
which they found experimentally will determine how well their solubility curve can
predict the point of saturation for a given temperature. For example, for a random
concentration of 150 grams per liter, the temperature was determined via interpolation to
be 53 °C. This is 0.95% different than the 52.5 °C temperature found via
experimentation. A sample of this interpolation is shown in Equations 15 and 16.
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Interpolation is also reinforced through exercises. In these exercises, a solubility curve
adapted from Dalman is given to the students [173]. Students are given a scenario in
which they need to determine a temperature for a solution in which a specific mass of
crystals will precipitate out. The interpolation necessary for this solution is shown in
Figure 11. Another exercise is also given that uses interpolation; this time using the
DXM solubility curve that the students generated. This exercise has them determine a
saturation concentration at a certain temperature. The interpolation necessary in this
exercise is shown in Figure 12.
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Figure 11. The interpolation used for the citric acid exercise. Here, the dark line is the
solubility curve, and the lighter line is the interpolation steps to determine the
temperature.
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Figure 12. The interpolation necessary for the DXM exercise. Once again, the dark line
represents the solubility curve (provided by sample data), while the lighter line represents
the interpolation steps.

This was used as part of an exercise that introduced some topics that would be in a
principles of chemical processes course. This problem was developed from an example
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problem found in the Felder and Rousseau text [174]. In this problem, a simplified
crystallization process is described using a cooler/crystallizer, a filter, and a dryer. A box
diagram of this process is shown in Figure 13. The interpolation shown in Figure 12 is
used to determine the solids produced in the crystallizer. Once this is done, the mass of
liquid that leaves with the filter cake can be determined, given that the filter is 100%
effective at removing crystals and that the cake is 80% crystals by mass. The mass %
equation is used for this calculation, which can be seen in Equation 17. Lastly, the yield
is determined by finding the mass of crystals removed via the process and comparing it to
the mass of crystals in the starting solution. The mass of crystals and yield were
calculated using Equations 18 and 19, respectively.

Figure 13. The box diagram for the industrial crystallization exercise given in the
Dextromethorphan Crystallization Lab.
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The solubility curves are the focus of this experiment, as they are a useful tool for
engineers when designing crystallization equipment [152, 153]. Another focus of this
experiment is to discuss a separate aspect of crystallization; thermal energy transfer. The
flow of heat is an important concept for crystallization theory, since heat will need to be
transferred to or from the solution in the process. And with this flow of heat there is also
the transfer of energy. For transferring energy, a scenario is given to students in which
they determine the energy required to heat the water bath used in the experiment, and also
a theoretical 200 gallon tank of water. The equation they use, and a sample calculation
for the 200 gallon tank of water, is shown Equation 20.

(
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(20)

Where Q is the energy in the form of heat added to the system, m is the mass of the water,
is the specific heat of water, and ΔT is the temperature change for the water. This
introduces the students to the differences in values from lab-bench to industrial scale. In
terms of heat transfer, two exercises are given. The first example has students determine
the thermal diffusivity ( ) of a substance. The thermal diffusivity of a substance is the
ratio of a substance’s ability to conduct thermal energy in relation to its ability to store
thermal energy [175]. Students are tasked with calculating the thermal diffusivity for
aluminum and water. They are also tasked with determining the temperature dependence
of the thermal diffusivity of aluminum by calculating this ratio for several temperatures.
The theoretical equation and a sample calculation for the thermal diffusivity of water at
25 °C are shown in Equation 21.
⁄
⁄

Where

is the thermal conductivity,

⁄

is the density, and

(21)

is the specific heat of the

substance. The calculation for aluminum at the same temperature yields an α value of
9.77 · 10-5

, showing that water has a higher thermal diffusivity, and thus a higher

conduction to storage of thermal energy ratio than aluminum at this temperature. When
comparing α values for aluminum at different temperatures, students see that the thermal
diffusivity decreases with increasing temperature. The sample values can be seen in
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Table 4. This reinforces the notion that pure metals show a decrease in thermal
conductivity and thermal diffusivity with increasing temperature [175].

Table 4. Sample thermal diffusivity values of aluminum at varying temperatures. As
shown, thermal diffusivity values decrease as temperature increases.
Temperature (K) α (m2/s)
200
1.09 · 10-4
400
9.43 · 10-5
800
7.34 · 10-5

The second exercise has the students model the rate of heat transfer for a test tube.
Students are to model the flow of heat from the center of the water in the test tube to the
top of the water in the test tube (Figure 14). In this exercise, a simplistic model is given
to the students in which three assumptions are made: That heat flows at a steady state;
that all the sides, except for the open end of the tube are perfectly insulated; that free
convection on the top surface of the water is negligible. While these assumptions are
simplistic, they are necessary to provide appropriate content for lower level
undergraduates.
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Figure 14. A representation of the one-dimensional, steady-state conduction model for
the test tube in the Dextromethorphan Crystallization Lab.

With these assumptions, a heat flow equation that models heat flow in one direction can
be used (Equation 22).

(22)

With

being the heat transfer rate,

place (

),

substance, and
(

the length at which the heat transfer is taking

the surface area of the heat transfer,

the thermal conductivity of the

the difference in temperature from the end point to the start point

). This exercise has the students use different values for ; one assuming the

substance is pure water, and the other via an approximation for salt solutions (Equation
23) [176].
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With

being the thermal conductivity,

solution, and

being the concentration of the salt in the

being the temperature of the system. In both instances, the students use

their test tube #1 data to determine the heat flow. The percent difference between the two
heat transfer rates is then calculated. Since the solution is dilute, percent difference will
be minimal between the two. The Student and Instructor’s version of this lab can be
found in Appendix A.6 and B.6, respectively.
3.7 Creation of Dissolvable Strips Laboratory
In the field of drug delivery, there has been a focus on finding different sites of
administration for therapeutics. While the oral route remains the most popular, it does
have its drawbacks. These include hepatic first pass metabolism or first pass effect, and
degradation of the drug in the gastrointestinal tract [177]. In addition, tablets are known
to be problematic for patients that suffer from dysphagia, the medical term for difficulty
swallowing [135]. As a consequence, researchers have investigated transmucosal drug
delivery methods. One of the promising subsets of these methods is oral transmucosal
drug delivery. Oral transmucosal drug delivery systems deliver the drug through the
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buccal region of the mouth. The buccal region is the area of the mouth that corresponds
to the inner cheeks. The rough texture of the buccal mucosa (mucous membrane) makes
it suitable for drug delivery [178]. Buccal drug delivery offers three advantages; direct
entry into systematic circulation, ease of administration, and the ability to terminate
delivery when required [179].
This buccal region is becoming especially popular for pediatrics and pediatric
medications. Oral transmucosal delivery has been investigated for pediatric medications
in order to increase patient compliance in this subset [180, 181]. There has been a new
focus on pediatrics in the pharmaceutical industry, especially in Europe. The European
Union began a tighter regulation of pediatric medicines beginning in 2007, after the
concern of unlicensed and off-label medicines for pediatric use reached an apex [182].
Since then, there have been several studies on the challenges faced by the pharmaceutical
industry to provide effective products for child patients [181, 183, 184]. Investigations
from this have led to several systems that have been developed for oral transmucosal drug
delivery; including liquids, solids, semisolids, and even sprays [177].
Of all the delivery systems that have been developed, one of the most recent is orally
dissolving thin films, or strips [185]. Thin films, or buccal patches, improve patient
compliance in those with difficulty swallowing due to their small size and thickness
[186]. Thin films have an area similar to a postage stamp and a thickness between 50 and
200 millimeters [135, 187]. In addition, thin films are usually designed so that they
dissolve without the patient needing to administer water [187]. Fast dissolving films
were first developed for the confection and oral care markets, used as breath strips and/or
delivering vitamins and personal care products [188]. It was only in the past few years
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that thin films have been used to deliver API’s found in several over the counter
products; including dextromethorphan HBr, found in cold medications; simethicone, an
anti-foaming agent found in anti-gas medications; and benzocaine, an anesthetic used in
oral pain relief [189]. This delivery method is currently being investigated for
prescription drugs [187].
While thin films do have great advantages, there are some drawbacks to the delivery
method. For example, due to the instability of the films, specifically their hygroscopic
nature, they need to be packaged and stored in dry areas [188]. To combat degradation,
film products are often stored individually in flexible plastics that act as moisture barriers
[189]. This can lead to some additional costs in manufacturing, but there are methods to
reduce these costs. A recent invention has been developed to form a pharmaceutical
product directly onto packaging surfaces, reducing wasted material and the associated
costs [190]. In addition, dosage uniformity can be a technical challenge for these films
[188, 191]. The last setback for thin films is that high dosages cannot be incorporated
into them [135, 188]. These limitations of thin films also put constraints on the drugs that
can be incorporated into them. API’s and drug formulations that can be delivered via this
method must meet certain criteria: They must have a dosage lower than 20 mg; they
must be of a small to moderate molecular weight; they must have good stability in water
and saliva; they must be able to diffuse and partition into the epithelium of the upper
gastrointestinal tract; they must be able to permeate oral mucosal tissue. When used for
pediatric medicine, it is also beneficial to use a drug with no bitter tastes [188]. Of
course, this last criterion is not as important, as it is possible to use excipients to mask
bitter tastes.
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These setbacks have not stifled investigations of this method. One of the earliest research
investigations into thin films was in using patches of miconazole nitrate, an anti-fungal
agent. Researchers found that the patches were able to deliver a potent dosage over a
longer period of time than the commonly used gel delivery method [192]. Another early
study looked at optimizing mucoadhesive patches that contained cetylpyridinium
chloride, a common antiseptic used to kill bacteria in the mouth [193]. Immunization
was also investigated early in thin film research. The idea that vaccination could be
conducted without needles provided advantages in both cost and safety. Animal research
studies have been conducted to show that immunization via mucosal thin films is
achievable [194]. Contraception is also an area of study for dissolvable strips. Jain, Jain,
Gupta, and Kharya investigated polyvinylpyrrolidone (PVP) films for the buccal
administration of the contraceptive drug progesterone [195].
Others have explored using other types of plastics for making dissolvable strips, such as
hydroxypropylmethylcellulose and pullulan, and their qualities when made into thin films
dissolvable strips [196, 197]. Maltodextrins, a polymer that is formulated from natural
sugars is also under investigation as a possible polymer for making dissolvable strips.
Maltodextrins have several characteristics that make them good candidates for thin film;
such as solubility in water, an inherent sweetness, and favorable hygrscopicity [198].
One research team investigated the effect dextrose equivalents have on the physical
characteristics of the maltodextrin films [199]. Another study used nicotine to further test
the sweetness of the maltodextrin films, since nicotine is known for having a bitter taste
[198]. Lastly, some researchers have investigated loading thin films with nanoparticles.
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This has been studied for enhancing the dissolution rate of poorly water soluble drugs
[200].
Dissolvable strips are also being considered for use in cancer therapies. In this case,
dissolvable strips are loaded with antiemetic drugs to cancer patients, to reduce the
effects of nausea and vomiting that can occur when they are given potent opioid
analgesics [201]. The use of thin films in this type of therapy is regarded for reducing the
time it takes for the drug to take effect. This was first seen in 2009, when a group of
researchers published their work on using disintegrating films containing
prochlorperazine and found the films to deliver the drug in rats within 2 minutes [202].
This was soon followed by a study that focused on using thin films loaded with
dexamethasone for reducing nausea in chemotherapy patients [203]. This latter work was
soon tested in a clinical trial, which produced favorable results. This led the researchers
to conclude that these oral thin films are effective at reducing nausea and vomiting in
chemotherapy patients [204].
With the advances in thin film research, and with several dissolvable strip products on the
market, the need for engineers to have an understanding of this drug delivery technique,
from its manufacture to end use is important. The Creation of Dissolvable Strips Lab is
designed to introduce students to the manufacturing and quality testing of dissolvable
strips. In this lab, students are introduced to the different ingredients that make up
dissolvable strips; these being polymers, plasticizers, sweeteners, and other flavoring
agents [135]. The students are then tasked with creating these thin films and conducting
quality control measurements on their final products.
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To create these films, students are given a “recipe” for making these strips which was
developed based on literature [135, 188]. This includes the polymer
carboxymethylcellulose (CMC), the plasticizer glycerol, citric acid for saliva stimulation,
sucrose as a sweetening agent, and sodium lauryl sulfate as a surfactant. Included for
flavor and color were peppermint oil and blue food dye, respectively. All of these items
are added to water kept just below the boiling point (approximately 80 to 90 °C) and at a
vigorous stir. Since this process is open to the atmosphere, air bubbles do form in
solution. To remove these, students create an apparatus involving two Buchner flasks
and some tubing. The mixture is placed in this apparatus, seen in Figure 15, and allowed
to sit under vacuum for approximately 30 minutes.

Figure 15. The vacuum apparatus used for removing air bubbles from the thin film
mixture.

Once this is complete, the students place their mixture in a petri dish and also a special
casting tray developed for this lab (Figure 16). Students pour 400 mL of their thin film
solution into the cast using a graduated cylinder, while students determine the amount
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added to the petri dish using a bench scale. The thin films solutions are allowed to sit for
1 to 4 days, allowing the solution to dry and form dissolvable strips.

Figure 16. The casting tray used to create dissolvable strips. The surface is a Teflon®
baking sheet, and the guides are aluminum strips. The guides are reinforced using
silicone caulk.

Once the films are dried, students perform different analyses on their strips. Using the
dried solution in the cast, students cut 4 samples with dimension of 1 in. by 1.5 in. These
samples are then used for quality analysis. The tests used in this section of the lab were
chosen from literature based on their ease of setup and lack of specialty or expensive
equipment [135, 188]. The three tests chosen were thickness measurements, folding
endurance, and surface pH. Thickness measurements are taken using a caliper and
measuring the thickness of each side of the samples. The folding endurance is calculated
by folding a strip in half repeatedly until the strip breaks in two. Surface pH is found by
placing one drop of water unto the surface of a sample. Litmus paper is then placed on
the watered surface to collect the pH of the sample. The mean and range is calculated for
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each of these quality tests. Students are then asked to comment on their findings; such as
if the surface pH was acceptable for human ingestion, how the folding endurance
compares to a commercial brand strip, and what dangers there are for large variances in
strip thickness. Quality measurements can be seen in Figure 17. Sample data can be seen
in Table 5.

Figure 17. Sample quality measurements for the Creation of Dissolvable Strips Lab. a)
Creation of sample strips for quality testing. b) Measuring the thickness using a caliper.
c) Pinching the strip sample before conducting a folding endurance test, ensuring a good
fold.

Table 5. Sample data for the Creation of Dissolvable Strips Lab quality analysis section.
Sample
1
2
3
4
Average

Thickness
(mm)
0.08
0.10
0.12
0.07
0.09

Folds
endured
32
28
39
23
30.5
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Surface
pH
5.0
5.5
5.5
6.0
5.5

Using the petri dish sample, students conduct a moisture content analysis. By weighing
the sample before and after drying, and assuming the mass that evaporated was strictly
water, students can determine the mass of water that left the sample. The moisture
content equation, and a sample calculation, is shown in Equation 24. In this equation,
is the final mass of the sample and

is the initial mass of the sample. Using this,

students can also determine the amount of energy that was needed to evaporate the water.
This calculation is seen in Equation 25, with
sample,

being the energy required to dry the

being the mass of the water vaporized, and

being the latent heat of

vaporization for water. Lastly, students determine where this energy came from. Since
the sample was allowed to sit in an open area, the energy was transferred from natural
convection in the air. In addition, students might cite solar energy if they left their
sample in a sunny area of the lab.
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The manufacturing aspects of thin films are also discussed throughout the lab. Students
are first given an introduction to the two processes that are usually used in industry to
produce dissolvable strips; solvent-casting and hot melt extrusion [187]. Students are
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given a comparison of the two processes, including the unit operations used and when it
is preferred to use one process over the other. To reinforce this, students are given a
scenario in which the specifications of a thin film product are given and are tasked with
determining which unit operation would best suit their product. Students also research
different API’s that are placed in thin films, and what kinds of treatments they are used
in. Students are then tasked with determining what kind of thin film polymer,
hydrophilic or hydrophobic, would be best to use for these API’s. The Student and
Instructor’s version of this lab can be found in Appendix A.7 and B.7, respectively.
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Chapter 4
Assessment

Initial assessment efforts show that the experiments convey both desired pharmaceutical
concepts and core engineering objectives. Preliminary assessment of the laboratory
experiments was completed and assessment of broader pharmaceutical engineering
educational activities in underway. Some of the results relevant to the experiments
developed will be shown. Other results from course development, problem sets, and
laboratory activities are planned for later. Representative results using the Tablet
Statistical Analysis Lab are provided, which involved three student groups. The students
were individually given a pre-lab test to measure their knowledge of several
pharmaceutical and statistical aspects that were covered in the laboratory experiment.
Multiple choice questions included several pharmaceutical concepts such as definition of
an API and function of excipients, along with questions about appropriate use of F- and
T-tests. A representative question about excipients would be “The substance used in a
tablet to take up space in a pharmaceutical product is…” and a representative question
about the F-test would be: “The purpose of an F-test is to …”. The correct answer to the
excipient question and the F-test question is “filler” and “to compare two sets of data to
one another”, respectively. After the experiment was completed, a post-lab test was
performed and the average of the correct responses of the students is shown in Figure 18.
This indicates that the students have a better understanding of pharmaceutical concepts
and the purpose of statistical tests after conducting the experiment. The test can be seen
in Appendix C.

67

Percent of Correct Responses

100
80
60

Pre-Lab

40
Post-Lab
20
0
API Definition

Excipient
Function

F-test Use

T-test Use

Figure 18. Pre-lab and post-lab concept test results for the assessment of the Tablet
Statistical Analysis Lab.

Students were given a post-lab survey to determine if the experiment helped to advance
the broader educational objectives of increasing pharmaceutical interest and experimental
methods. The survey asked the students to agree or disagree with a statement about their
experience with the laboratory using a Likert scale (1 being a strong disagreement and 5
being a strong agreement with the statement). The statements used in the survey relate to
the student’s interest in pharmaceutical engineering (I wish to pursue more studies in the
field of pharmaceutical engineering), the pharmaceutical aspect of the laboratory (The
experiment introduced a concept of pharmaceutical engineering), the utility of the
statistical tests (I can apply the statistical principles I learned in this lab to other
engineering problems), and the educational objectives of the experiment (I had to
appropriately use laboratory equipment (scales, etc.) for data collection). The survey in
its entirety can be found in Appendix C. The average responses showed that most
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students gave a response of 4 for all categories of statements (Figure 19). We have also
solicited input from current employers about the industrial relevance of the experiments.
Representative feedback from one of our pharmaceutical professionals indicates, “These
experiments are valuable in exposing engineering students to principles of
pharmaceutical engineering.” Raw assessment data can be found in Appendix D.
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Figure 19. Post-lab student survey results from the Tablet Statistical Analysis Lab.
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Chapter 5
Future Work

With the current laboratory experiments, it is possible that a course could be adapted to
include these experiments for a semester. With this, a more thorough assessment plan
should be implemented. While some assessment has been shown, this was only for a
small population and for one laboratory experiment. The goal would be to gain a
population of a whole class (approximately 24 students) and receive input for more
experiments. The implementation would be similar to the assessment shown previously,
where students are given a pre- and post-lab quiz and a post-lab survey. These will be
developed to target specific goals of the intended laboratory experiments.
In addition, more experiments should be developed. This will not only give more options
to faculty as far as which experiments they will have the students conduct for one
semester, but may also rise to a second semester of experiments. Experiments could also
be developed for other classes, such as a thermodynamics or mass transfer course. These
experiments would be more complex than the experiments shown in this work, and would
be more targeted to the specific field of engineering.
For future laboratory experiments on the freshman level, emphasis will be placed on
taking existing experiments and expanding on those concepts. An example would be an
expansion of the Tablet Statistical Analysis and the Creation of Dissolvable Strips Labs.
For the Tablet Statistical Analysis Lab, an expansion would be on using different tablets
or other forms of drug delivery. With these different forms of drug delivery, different
statistical analysis techniques could be used. Using analysis of variance, control charts,
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and design of experiment techniques, students could gain an in-depth assessment of
statistics and experimental design. Emphasis could also be put on Bayesian
methodology.
The Creation of Dissolvable Strips Lab could be expanded to using advanced
mathematical equations to model certain parameters of the thin film. For example,
students may use advanced heat transfer equations to determine drying times for different
polymer matrices. This could be used for the students to design different dryers. In
addition, a semester long project could be developed specifically with dissolvable strips.
The semester long project would investigate starting volumes versus final volumes using
a fixed volume cast. The students could then develop a mathematical model to determine
the final volume of a thin film when it is cast in a certain initial volume. In addition,
design of experiments could be implemented to investigate this. Students would start
with a simple 22 factorial model and move to more rigorous models, such as a 23
factorials.
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Chapter 6
Conclusions

The experiments developed can be easily integrated into Freshman-level engineering
courses. These experiments illustrate basic engineering and science principles, while
acquainting students with fundamentals of pharmaceutical engineering. The experiments
convey concepts in pharmaceutical fundamentals, drug manufacture, drug
formulation/delivery, and pharmacokinetics/pharmacodynamics. Experiments developed
to date include: Tablet Statistical Analysis Lab; Asthma Drug Delivery Lab; Antacid
Comparison Lab; Effervescence Reaction Lab; Fluidization of Pharmaceutical
Substances Lab; Degradation of Dissolvable Strips Lab; Bandage Comparison Lab;
Dextromethorphan Crystallization Lab; and Creation of Dissolvable Strips Lab. The
experiments can be used individually to meet specific educational objectives, such as
applying statistical methods to manufacturing quality control, or grouped into a theme for
more in-depth learning. The experiments have multiple parts that allow faculty to add
more complexity or accomplish other learning objectives. These experiments can peak
student interest in pharmaceutical engineering and provide background needed for
advanced courses or laboratories. Complete laboratory procedures, both students and
instructor versions, are available through the pharmaceutical knowledge and training
website, www.PharmaHUB.org.
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Appendix A
Student Versions of Laboratory Experiments
A.1 Tablet Statistical Analysis Lab
Tablet Statistical Analysis Lab
Developed by: Alex Jannini, David Krause, Heather Malino and Kevin Sweeney,
Rowan University, Department of Chemical Engineering
Edited by: C. Stewart Slater and Mariano Savelski, Rowan University,
Department of Chemical Engineering
Date of Experiment:
OBJECTIVES



Students will perform a basic statistical analysis applied to an over-thecounter drug
Students will learn about pharmaceutical engineering, including key terms
and concepts

INTRODUCTION
In the pharmaceutical industry, drugs are manufactured, produced, and marketed
for therapeutic use. The industry has been one of the highest earning industries
of the last decade, with 791 billion dollars in worldwide sales in 2010. The
majority of these sales were in North American companies, totaling 335 billion
dollars1.
A pharmaceutical product is not just one specific chemical, but many chemicals
combined together to make a final product. Tablets, which the students will be
working with in this lab, are composed of a few chemicals mixed together and
then compressed. The therapeutic ingredient is known as the active
pharmaceutical ingredient (API). The API is what causes the desired effect of
the drug. The rest of the ingredients that remain inert are known as the
excipients.
Excipients can have different functions, which is why there are sub-categories of
excipients found in pharmaceuticals. For example, a filler is a type of excipient
used to make up the volume of a medicine so that it can be taken in the form of a
pill. In some cases, excipients known as binders are used to act as glue and
make sure the ingredients stick together. Lubricants and glidants are used in
combination since they reduce wall friction and interparticle friction, respectively.
This prevents the tablet from clumping and sticking to equipment. Excipients
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may also be flavors or colors, which will mask any unpleasant tastes that the
other ingredients have and improve the appearance of the product.
In any engineering field, statistical analysis is an important tool. In the
pharmaceutical industry, statistics can be used in various ways. For example,
statisticians use statistics to create trials for experimental drugs. A chemical
engineer might use statistics in order to figure out a new process that creates
more product for less. In these cases, statistics play an important role in
analyzing data in order to come to a conclusion.
In this lab, the students will be looking at two different over the counter
medications that contain the API ibuprofen, a known pain reliever and fever
reducer. The rest of the inactive ingredients in the tablets are binders, fillers, or
any other kind of excipient. This lab will consist of a statistical analysis on the
difference in mass between the ibuprofen tablets, and also the difference in the
mass of a generic brand and the trademarked brand Advil®. An introduction to
creating a flow diagram will also be incorporated into this experiment.
MATERIALS NEEDED






Container of Advil® tablets (minimum of 10 tablets)
Container of generic ibuprofen tablets (minimum of 10 tablets)
Weigh boat
Tweezers
Bench scale (accurate up to 1/1,000 g).

SAFETY CONSIDERATIONS
Always wear laboratory safety glasses when working in the lab.
PROCEDURE
1. Make sure that the bench scale is turned on, and that the scale is set to
measure weight in grams.
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2. Take the Advil package and note where they list the active and inactive
ingredients. Record all of the ingredients that are listed as non-active
ingredients.

Figure 1. Where to find the active and inactive ingredients

3. Place the weigh boat on the bench scale. Record the weight, and then
tare the instrument. The bench scale should now read 0 grams.
4. Open the box of Advil®, and with tweezers, place one tablet in the weigh
boat. You may use the table provided below, but you should also record
your findings in your lab notebook.
5. Once the mass has been recorded, tare the scale again.
6. Repeat the two previous steps until you have weighed ten Advil tablets.
Empty your weigh boat, place it back on the bench scale, and tare the
instrument. You should now have the Advil® portion of the data table filled
out.
7. Now, look at your generic brand. Record all the non-active ingredients.
8. Open the container, and using the tweezers, place one tablet in the weigh
boat. Once again, tare the instrument after recording the mass.
9. Repeat until you have collected ten measurements of the generic brand.
You should now have the generic brand portion of the data table filled out.
10. Once all measurements have been completed, dispose of the measured
tablets and the weigh boats. Return the containers to their respective
boxes.
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Table 1. Empty table for recording the mass of the tablets

Trial Number Name Brand Mass (grams) Generic Brand Mass (grams)
1
2
3
4
5
6
7
8
9
10

Figure 2. Proper technique for weighing tablets

STATISTICAL ANALYSIS
You will need your calculator to do the following calculations. You must show all
work to receive credit.
1. First, take the average of each set of data. Use the equation below, with i
being the trial number (given in the data table), n being the total number of
trials (10), and x being the mass recorded for the specific trial number.
Record this in your lab notebook and include in your results.
∑
(1)
̅
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2. Standard deviation is defined as the variation from the average. In other
words, it is the average of the difference between each value obtained and
the average value obtained. So, in this case, it would be important to
know the standard deviation of the mass of the tablets for the trademarked
brand and also the generic brand. To calculate the standard deviation,
use the equation below, with i once again being the trial number, n being
the total number of trials, and x being the mass recorded.
∑
√

(|

̅| )

(2)

3. Now, we will look for any outliers in our data. An outlier can be defined as
a data point significantly different than the mean of the data. In other
words, an outlier is a datum point that significantly distant from other
points. To do this, find the median data point in both sets of data. To find
the median, list the data in order from lowest value to highest value, and
find the point that resides in the middle. If you have an even number of
data points, the median is found by averaging the two middle data points.
From now on, this median (the median of the entire data set) is known as
overall median. From here, find the first and third quartiles. These
values are found by splitting the list of data in half. In this case, we now
have two sets of five data points; one with the lower data points, and the
other with the higher data points. The first quartile can be found by
taking the median of the lower data points. The third quartile is the
median of the higher data points. Lastly, we state that the overall median
is the second quartile. Using the equations below, calculate if any of
your data points are outliers.

(

)

(3)

Where, OL is the low-value outlier cutoff, Q1 is the first quartile, and Q3 is
the third quartile.

(

)

(4)

Where, OH is the high-value outlier cutoff, Q3 is the third quartile, and Q1 is
the first quartile.
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Are any weights you measured above OH or below OL? If so, they are
outliers. Arrange your findings in a box-and-whisker plot as described in
the diagram below.

Figure 3: A typical box-and-whisker plot.

RESULTS
Be sure to record all findings for this lab. Answer any questions that might
have been asked in the procedure section of the lab.
QUESTIONS
1. During the statistical analysis section, you were asked to find the standard
deviation of the trademarked and the generic brand. Explain what this
value tells you. Compare the two standard deviations you calculated, and
determine what this means.
2. Now, you will determine whether or not these two brands are different
from each other. To do this, you will use a statistical analysis technique
known as an F-test. An F-test is used to compare two samples. This test
can become difficult if the samples are not done in a similar manner. In
this case, the number of measurements taken in each sample is similar,
so this makes the F-test much simpler. To conduct an F-test, do the
following:
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a. Find the variance of the two samples. The variance of a sample is
defined as the average of the squared difference of the means. An
equation of what this would look like is shown below:

(5)
∑(

̅)
(6)

Another way of looking at the variance is it’s relation to the standard
deviation of a sample. The relation of the variance of a sample to
the standard deviation of a sample is shown below:
(7)
If you compare the equation of variance to the equation of standard
deviation, you can see how this is true. Use the relation between
standard deviation and variance to find a value of variance for the
two samples.
b. Now, find the F-value for your experiment. To find your F-value,
use the following equation:
(8)

For this equation, the variance in the numerator “s1” has to be the
larger of the two variances.
c. Now, compare this value to a critical value. This is known as the Fcritical value. The F-critical value is dependent on the number of
measurements taken in each sample, and the percent confidence
that is desired. The percent confidence is another way of saying
how accurate one wishes to be in their experiments. The higher
the percent confidence, the more certain one is in their
experiments. In this case, you will use a standard percent
confidence of 95%. So, you will need an F-critical value which
corresponds to a 95% percent confidence, a variance based on 10
measurements in the numerator, and a variance based on 10
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measurements in the denominator. Usually, these would be looked
up in tables, as seen in appendix A Figure 1. However, below you
will find an critical F value for your calculations3:

If the F value you calculated in part b of this problem is larger than
the critical value given, then the two samples are significantly
different. If the F value you calculated in part c of this problem is
smaller than the critical value given, then the two samples are not
significantly different. State whether or not there is significant
difference between the two samples .
3. Research suggests that one ibuprofen tablet should have a mass of 480
mg.2 Do you think there is significant difference between the values you
obtained and this literature value for a typical formulation? To answer this,
you will use another statistical test known as the t-test. There are several
different types of t-tests used in statistics. In this case, you will be using a
one-sample t-test, which compares a single mean to a fixed value. So for
this test, the fixed value will be the 480 mg. You will conduct a t-test on
both samples. In order to conduct this analysis, do the following:
a. For a t-test, you will need to find a t-value. The t-value for an
experiment relates the average, standard deviation, and number of
measurements to a given value. Using the symbols found
previously in this experiment, the equation for the t-value is as
follows:

|

|
√

(9)

In this case, μo will be the mass found in research (480 mg).
b. You will now compare this value to a critical value. This is known
as the critical t-value. Like the F-critical value, the critical t-value is
dependent on the percent confidence that is desired and the
number of measurements taken in the sample. Again, you will use
a percent confidence of 95%. The critical t-value you will be using
is given below3:
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Just like with the F-test, if the critical t-value is higher than the value
obtained earlier, then there is no difference between your sample
and the value from literature. If the t-value calculated earlier is
higher than the critical t-value, then there is a significant difference
between the sample and the value obtained from literature. State
whether or not there is significant difference between the value
obtained from experiments and the value obtained from literature.
c. Repeat this process for whichever sample you did not already
conduct the analysis on.
4. It has been estimated that the world production of ibuprofen is in the
vicinity of 15,000 tons per year.4 It has also been estimated that the
average price for one ibuprofen tablet is roughly 0.12 USD. 5 Using this
information, calculate the total price of ibuprofen production for a year.
5. Remember that you listed the inactive ingredients from each of the
brands. Research the first three ingredients from both brands and state
what type of excipient you believe them to be (i.e. filler, preservative,
lubricant, etc.).
6. It is your first day on the job working for Pfizer and you are told to do an
experiment on the Advil production line. A new tablet press has been
installed and your boss wants to know if it is producing tablets with
consistent weight. To start your experiment, you pull a sample of 20
tablets off of the line and weigh them. The data is arranged in a table
below. Your boss tells you that each pill must be 90% to 110% of the
mean tablet size, which is 0.485 g. Do any pills in your sample fall outside
of these bounds? Furthermore, did you find any outliers in your sample?
What does this say about the consistency of the new pill press?
Table 2: Experimental data from production line

Advil Sample - 20 Tablet weights (g)
0.4850
0.5198
0.5048
0.4857
0.4786

0.5435
0.4448
0.4668
0.4465
0.4835
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0.4686
0.5211
0.4863
0.4217
0.4481

0.4837
0.5895
0.5227
0.4662
0.5101

7. You will now have an introduction to creating process flow diagrams.
These diagrams are an important part of engineering, as they are used in
most plants. A process flow diagram indicates the major equipment used
in a process. In this case, a box with a label will be acceptable as a piece
of equipment. An example is shown below:
A heater heats water from 10°C to 50°C:
HEATER
If you have more than one stream entering or exiting a process, multiple
lines can be drawn. For example, if a mixer blends water and titanium
dioxide to make a slurry the process flow diagram would look like:
TiO2

Mixer

Slurry

Water
a. Make a process flow diagram for the creation of the ibuprofen
tablets as described by the steps below:
i. Mix the powder (maize starch) for 15 minutes at high speed.
Add 10.67 g of cold water and check weight (theoretical
weight, 58.00g). If required adjust with hot water. Record
the quantity of extra water added.
ii. Mix this binding solution with Mixture 1 (Ibuprofen and maize
starch).
iii. Collect and spread the granules onto the trays, one third the
thickness of the tray.
iv. Load the trolley into the oven and dry the granules in the
trays and change the position of the trays for uniform drying.
v. Mix stearic acid and corn starch separately and add to the
granules before sending them to a compressor. Compress
into 330-mg tablets, using 10-mm convex punches at 4 to 9
kPa.
vi. Put the tablets into the coating and rolling pan.
b. Make another process flow diagram that shows the coating of the
ibuprofen tablets as described by the steps below:
i. Make sugar coating:
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1. Heat 72.0 g of item 6 (purified water) in mixer to
boiling.
2. Dissolve 168.0g of item 4 (sucrose) and then cool to
25°C.
3. Filter the syrup through a 180-µm stainless steel
sieve.
4. Dispense item 5 (titanium dioxide) into the sugar
syrup from the previous step and homogenize.
5. Check for evenness of the dispersion.
ii. Apply Sugar Coating to tablets in coating pan by rolling
tablets and slowly adding the sugar solution over 30
minutes.
iii. Make gloss solution
1. Melt items 1 - 3 (bee’s wax, polyethylene glycol,
carnauba wax) in a steam-heated vessel by gentle
heating to 70°C or in a stainless steel container on a
hotplate heater.
2. Mix thoroughly.
3. Pass the mixture through a homogenizer.
4. Store the polishing emulsion in a closed container at
room temperature.
iv. Apply gloss solution to tablets in coating pan by rolling
tablets. Once the desired polish appears, stop rolling the
pan.
v. Dry the tablets in the pan at 30°C for 30 minutes. Final
tablet weight should be 480 mg.

REFERENCES
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A.2 Fluidization of Pharmaceutical Excipients Lab
Fluidization of Pharmaceutical Substances
Developed by: Alex Jannini, David Krause, Heather Malino and Kevin Sweeney,
Rowan University, Department of Chemical Engineering
Edited by: C. Stewart Slater and Mariano Savelski, Rowan University,
Department of Chemical Engineering
Date of Experiment:
OBJECTIVES




Students will fluidize a pharmaceutical excipient, and learn about the
variables affecting fluid-particle transport
Students will construct and interpret fluidization graphs using experimental
data
Students will gain experience using the online literary search engines

INTRODUCTION
A fluidized bed occurs when solid
particulate matter is put under specific
conditions that allow it to behave as a
fluid. This is usually performed in some
sort of vessel and achieved through the
use of a pressurized fluid, such as air.
Some of the properties that the
particulate matter has in its fluidized
state include the ability to be transported
in a manner that is similar to other fluids.
This phenomenon is called fluidization.
Fluidization and fluidized beds are used
in several different industries for several
different purposes.

Solid
Particles

Gas

In fluidization, there are many different
variables that need to be considered. If
one was to design a fluidized bed,
Figure 1: Simple schematic of a
equipment parameters such as the
fluidized bed
pressure of the incoming fluid, the flow
rate of the incoming fluid, and the temperature of the system would need to be
part of the design process. In addition, the material that is to be fluidized will also
need to be investigated. Material properties such as particle size, density, and
porosity (also known as the void fraction, or the fraction of empty space in a
packed vessel) are important when designing a fluidized bed.
As the solids are fluidized, they behave as common fluids. As such, flow
variables can be investigated with the moving particles. One such variable is
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called pressure drop. Pressure drop is the difference in pressure between two
points along the path of fluid movement in the process. Pressure drop is caused
by frictional forces, resistances to the flow, as the fluid flows through the vessel.
In the pharmaceutical industry, fluidized beds have many different applications.
Initially, fluidized beds were mainly used for the drying and coating of solids 1.
Granulation, the act of forming or crystallizing substances into grains or granules
in fluidized beds, was later investigated for pharmaceutical purposes.1
Fluidization can also be used for the transportation of solids, as the fluidized
solids can be transported via pipes rather than conveyer belts or in discrete
amounts1.
In this experiment, you will be investigating four different variables of a fluidized
bed; air flowrate, air pressure, pressure drop, and bed height. You will then use
the data you collected to perform some fluidized bed calculations. By the end of
this experiment, you should have a better understanding on how fluidization
occurs, and why it is an important aspect of pharmaceutical manufacturing.
MATERIALS NEEDED
PART I
 250 mL plastic graduated cylinder
 1000 mL plastic graduated cylinder
 Bench scale capable of reading at least 1 kg
 Avicel® PH 200
 Kaolin powder
 DI water
 Stirrer
PARTS II & III
 Fluidized bed filled with Avicel® PH 200
 Ruler

SAFETY CONSIDERATIONS
Laboratory goggles must be worn at all times when in the laboratory. Laboratory
gloves and a dust mask must be worn if handling pharmaceutical powders.
Obtain and read the MSDS on Avicel® PH 200 and kaolin.
PROCEDURE
PART I – DETERMINING BULK AND PARTICLE DENSITIES
1. Begin by placing the empty 250 mL graduated cylinder on the bench
scale. Tare the instrument.
2. Place approximately 50 to 60 grams worth of one of the powders into the
graduated cylinder. If you are a little over or under, that is fine, as long as
the powder does not surpass a measureable level on the graduated
cylinder. You may have to use a scoop or a beaker to do this.
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3. Record both the mass of the powder you added to the cylinder, and how
much volume it takes up. Use these values to calculate the bulk density
by dividing the mass added by the volume it takes up. Set aside this
graduated cylinder.
4. Now, fill the 1000 mL graduated cylinder with DI water to around the 700
to 800 mL mark. Again, this does not need to be precise. Record the
volume of water you added.
5. Place the graduated cylinder filled with water on the bench scale, and
once again tare the instrument.
6. Slowly, add the powder from the small graduated cylinder into the large
one. You may need to stir the solution at intervals of the pouring process
so that all the particles are suspended. Remember that you do not want
to surpass the readable levels of the graduated cylinder.
7. Once the particles have been poured in, stir the mixture thoroughly, but
carefully. You do not want to lose any of the water. Once stirred, place
back on the scale bench and record the mass of the powder you added to
the water. Also, record the new volume of the water and powder mixture.
8. Now, find the particle density. The particle density is the mass of the
powder added to the water and the volume taken up by the particles. You
can determine the volume taken up by the particles by subtracting the
volume of water from the volume of the mixture.
9. Do this for the other powder. Make sure that you clean and dry the
graduated cylinders thoroughly, and use new cylinders before starting to
work with the new powder. You may use the following table to record your
findings, but you should copy this table into your lab notebook.
Table1. Empty table for recording data during the fluidization lab.

Measurement
Mass of substance (g)
Volume of substance (mL)
Bulk density (g/cm3)
Volume of water (mL)
Volume of mixture (mL)
Volume of particles (mL)
Mass of substance (g)
Particle density (g/cm3)

Kaolin

Avicel PH 200

PART II – THE FLUIDIZED BED
1. The first step in running these experiments is to become acquainted with
the equipment. First, briefly look over the equipment and the station in
front of you. Note where your pressurized air is coming from.
2. After investigating your system, measure the inner diameter of the
fluidized bed. You will need this for calculations later.
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Figure 2. Laboratory scale fluidized bed.

PART III – SUBSTANCE INVESTIGATIONS
1. After becoming familiarized with your equipment, you may begin testing.
Begin by measuring the height of the fixed bed.
2. Set the incoming air at a pressure of 60 pounds per square inch (psi).
Make sure that the flowmeter is closed, but the air valve is open (make
sure you know which is which!).
3. With the inlet air pressure at 60 psi, open the
flowmeter and
slowly raise the flow
rate of the incoming
air to 5 gallons per
minute (gpm). At
this reading, take a
pressure drop
measurement and a
bed height
measurement.
4. Once the
Figures 3 and 4. From left to right; the inlet air
measurements have
valve and the flow meter used in the fluidized bed
been recorded,
setup.
increase the air flow
rate by 5 gpm. Again,
measure the pressure drop and the bed height.
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5. Repeat this until you reach 30 gpm. Now, increase the intervals to 10
gpm. If you notice plug flow, bubbling, or channeling in the fluidized bed,
record the flow rate and pressure drop, but make a note of the
phenomenon that occurred. Also, it might be necessary to check on the
air pressure periodically during the experiment. You should make sure
this is done before taking any measurements.
6. Once you have taken the pressure drop and bed height at the maximum
flow rate of air, bring the flow rate back down to zero.
7. Complete the same steps as above, but now using an air pressure of 100
psi. You may use the tables below to record your data, but you should
also copy your data into your lab notebook.

Figure 5. Plug flow occurring in
the fluidized bed.
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Table 2. Empty data table for recording pressure drop at an air pressure of 60 psi and bed
expansion in the fluidization lab

Air Pressure of 60 psi
Flow Meter Reading
(gpm)
0
5
10
15
20
25
30
40
50
60
70
80
90
100

Pressure Drop (in H2O)

Bed Expansion
(inches)

Table 3. Empty data table for recording pressure drop at an air pressure of 60 psi and bed
expansion in the fluidization lab

Air Pressure of 100 psi
Flow Meter Reading
(gpm)
0
5
10
15
20
25
30
40
50
60
70
80
90
100

Pressure Drop (in H2O)

RESULTS
Record all results in your lab notebook.
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Bed Expansion
(inches)

QUESTIONS
1. Based on your results, what was the point of minimum fluidization (the
point where fluidization was first noticed) for both of the data sets? What
does this tell you about air pressure when it comes to minimum
fluidization? Does this mean that air pressure is a negligible variable
when it comes to fluidization? Why or why not?
2. You will make a graph of the air flow rate versus the bed height (this
means that the air flow rate is on the x-axis and the bed height is on the yaxis) for both of the air pressures. Using the graph, determine when the
bed goes from behaving as a packed bed to a fluidized bed.
3. Prepare a fluidization graph. A fluidization graph is obtained by plotting
the air flow rate versus the pressure drop. When you make these graphs,
there will be a change in the slope at a certain point. This point is known
as the point of minimum fluidization. At this point, the bed of solids
changes from behaving like a packed bed to behaving like a fluidized bed.
Label where you believe this point is on the graphs you made. Also label
what sections of the graph model the packed bed behavior and fluidized
bed behavior.
4. For this experiment, we have delved into some of the properties of fluid
mechanics, a branch of science that deals with the properties of fluids and
some of the phenomenon that occurs when they are placed under certain
conditions. One of the first variables you will learn in fluid mechanics is
known as the Reynolds Number, a dimensionless quantity that is used to
determine a flow regime. Today you will determine the Reynolds number
of the system at minimum fluidization. To do this, you will use the
following formula:
(1)
a. The Reynolds Number is considered a dimensionless quantity.
This means that there are no units attached. Prove this with the
following information:
= Average diameter of the particle (m)
= Velocity of minimum fluidization (m/s)
= Density of the gas (kg/m3)
= Dynamic viscosity of the gas (Pa*s)
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b. Find the Reynolds number for the minimum fluidization point for
both of your experimental runs. To help you in the calculation of this
number, use the following values2,3,4:
(

)
⁄
⁄

In addition, determine which of the fluidization regimes the fluidized
bed was in at minimum fluidization based on the figure below.

Figure 6. A few fluid regimes of fluidized beds.
Adapted from Perry’s Chemical Engineering
5
Handbook.

5. The following fluidization data was collected using kaolin powder with the
same apparatus (same dimensions) at an air pressure of 60 psi:
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Table 4. Fluidization data using kaolin powder at an air pressure of 60 psi

GPM Bed Height (in.) ΔP (psi)
0
5.00
0.0
5
5.00
0.5
10
5.00
1.8
15
5.50
1.8
20
5.75
2.4
25
5.75
2.4
30
6.00
2.5
40
6.00
2.8
50
6.50
3.2
60
6.50
3.6
70
6.50
3.8
80
6.75
4.1
90
6.75
4.2
100
6.50
4.6

a. Create a flow rate versus bed height graph and a flow rate versus
pressure drop graph.
b. Determine if there is a point of minimum fluidization using the
graphs.
c. If you could determine a point of minimum fluidization, determine
the Reynolds number at that point. If not, find the Reynolds
number at the same point you used for Question 4. Use an
average particle diameter of 1.4 µm for this problem.6
6. Now, we will go over another important tool for engineers; design
equations. Design equations are used by engineers to determine
information about a process without having to do extensive
experimentation. These equations are usually based on data obtained by
research. For example, the following equation can be used to determine
the Reynolds number at minimum fluidization7:
√(

)

Where Ar (Archimedes Number), C1, C2, are shown below:
(
)
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(2)

(3)

(

)

(4)
(5)

Where:
= Average diameter of the particle (m)
= Density of the gas (kg/m3)
= Particle density of the excipient (kg/m3)
= Acceleration due to gravity (9.81 m/s2)
= Dynamic viscosity of the gas (Pa*s)
In order to use the equations above, you will need to determine the
porosity at minimum fluidization (εmf). This can be a difficult characteristic
to determine, which is why many researchers have come up with different
constants to approximate the porosity.8 However, we have enough
information to determine εmf, so we will solve for C1 and C2.
To determine εmf, we first need to know the normal porosity, ε. This can
be determined by using the bulk density (ρb) and the particle density (ρs):
(6)
We also have to determine the total volume (Vtot). For this, use the bed
height at the 0 gpm air flowrate, and multiply by the cross-sectional area of
the bed. Now, we can determine the void volume (Vv) using the following
equation:
(7)
Now, to determine the volume occupied by the particles (Vp):
(8)
From here, we now need to use the point of minimum fluidization to
determine the volume (Vmf). This can be done by using the bed height at
the point of minimum fluidization and the cross-sectional area. Using Vmf,
you can determine the void volume at minimum fluidization (Vvmf):
(9)
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Finally, determine εmf:
(10)

a) Determine εmf for the Avicel® trial at the air pressure of 60 psi.
b) Determine the Remf using Equation (2) for the same conditions as part
a).
c) Calculate the percent difference between your answer for part b) and
the answer you obtained in Question 4.
|

|

(

)

(11)

d) You should notice a considerable (>10%) difference in part c). This is
because you are using superficial velocity, as opposed to interstitial
velocity. Superficial velocity is defined as the theoretical flow through
the bed based on the flow rate of the liquid divided by the cross
sectional area of the tube. Interstitial velocity takes into account how
the flow is affected by the volume occupied by particles. Interstitial
velocity is the flow velocity post a particle, and is the “correct” velocity
to use in the Remf equation. To determine the interstitial velocity (vi):
(12)
Where:
= volumetric flow rate at minimum fluidization (m3)
= cross sectional area (m2)
= porosity at minimum fluidization (dimensionless)

Determine vi, calculate a new Re as in Question 4, and then compare
as in part c).
7. It is important to learn how to use the online library tools that you have
available. These online tools have thousands of scientific papers and
articles in databases that you have free access to. Using one of the
scientific online resources (i.e. Science Direct, SciFinder, etc.) available,
you and your lab partners will find an article online about pharmaceutical
manufacturing practices. Try to find an article that also discusses either
fluidization or fluidized beds. Print out the article, and as a group, be
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prepared to discuss the article in class. NOTE: It is all right if you do not
understand all of the technical details of the paper, but you should have a
good understanding of the overall concept being discussed.
In addition, use the MSDS’s that you obtained as part of your pre-lab and
any other literature to compare the bulk densities that you found in part I of
the experiment.
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A.3 Asthma Drug Delivery Lab
Asthma Drug Delivery Laboratory Experiment
Developed by: Alex Jannini, David Krause, Heather Malino and Kevin Sweeney,
Rowan University, Department of Chemical Engineering
Edited by: C. Stewart Slater and Mariano Savelski, Rowan University,
Department of Chemical Engineering
Date of Experiment:
OBJECTIVES
 Students will learn about
intrusive laboratory
experiments
 Students will gain experience
in reverse engineering
strategies and project designs
 Students will conduct a basic
quality control analysis
operation
Figure 1: Diagram of the dry powder inhaler

INTRODUCTION
ADVAIR® is a dry powder inhaler prescribed to patients with asthma and chronic
obstructive pulmonary disease that uses two active pharmaceutical
ingredients. Fluticasone propionate, one of the two, is a corticosteroid, which is
used to reduce the inflammation of the lungs. Salmeterol xinofoate, the second,
is a bronchodilator, which relaxes the muscles in the airways to help improve
breathing.1
ADVAIR® is not only used as an option for people with asthma, but also can be
used as a maintenance treatment for chronic obstructive pulmonary disease.¹
Chronic obstructive pulmonary disease (COPD) is a disease that makes it difficult
to breathe. It also takes the form of chronic bronchitis, causing a long-term
cough with mucus, and emphysema, which destroys the lungs over time. Most
sufferers of COPD have a combination of the two symptoms.² Asthma occurs
when the airways of the lungs tighten and narrow, which leads to wheezing,
shortness of breath, coughing, and a tightening in the chest.³
ADVAIR® comes in three varieties: ADVAIR DISKUS® 100/50; ADVAIR DISKUS®
250/50; ADVAIR DISKUS® 500/50. The three varieties of ADVAIR® have
different amounts of fluticasone propionate in the powder. For example, in an
ADVAIR DISKUS® 100/50, there will be 100 μg (micrograms) of fluticasone
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propionate and 50 μg of salmeterol. The 250/50 prescription of ADVAIR® is used
for COPD treatment.¹
In this lab, the teams will be examining an ADVAIR DISKUS®, and conduct an
invasive reverse engineering experiment on the diskus. They will then compare
the dry powder inhaler to two other types of inhaled medication transport
systems; a nasal spray and a traditional metered dose inhaler. The goal is to see
the difference in the transport process that each system uses, and to also see if
there is any way to improve the design of the diskus. A quality control study on
the packaging of powder in the ADVAIR DISKUS® is also provided. This will
include an average and a standard deviation of the powder packages.
MATERIALS NEEDED
● ADVAIR DISKUS®
● Small flathead screwdriver
● Analytical scale (able to read at least 1/10,000g)
● Albuterol metered dose inhaler (or suitable substitute)
● Fluticasone propionate nasal spray (or suitable substitute)
● Narrow-headed spatula
● KimWipes
● Weigh boats
SAFETY CONSIDERATIONS
All students should know that laboratory
gloves and eyewear must be worn at all
times to protect from sharp edges and
medicines.
PROCEDURE
PART I - REVERSE ENGINEERING
1. Open up the diskus box and
remove the information packets.
Make general observations on the
diagrams and information included.
2. Remove the inhaler from the
tinfoil package. Based on its outside
appearance, how do you think it
works? Sketch the diskus.
3. With the flathead screwdriver,
proceed to remove the outer shell of
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Figure 2: Removal of outer shell

Figure 3: Proper removal of mouthpiece

the inhaler. Be careful to not break or shatter any plastic.
4. Insert the screwdriver under the mouthpiece and use it as a lever to
dislodge the mouthpiece.
5. Along the outside
circumference of the diskus you
will notice several slots and tabs
that hold each half of the inhaler
together. One by one, carefully
depress each tab and pry the
inhaler open.
6. This should expose the
inside of the inhaler. Make
observations on its appearance Figure 4: Proper depression of the tabs
and the gears. Sketch the
inside of the diskus.
7. Pull the lever down and reset it a few
times. Discard the powder inside the
blisters. Note how the gears move. Based
on this, do you have any other ideas as to
how the inhaler works?
8. Remove the foil strip. It will be stuck
at one part after the foil has been split in
half. Cut this section away to fully remove
the rest of the foil strip.
9. The large white plastic mold that the
foil fits into can be removed. Look for white
tabs interlocking with the purple exterior
shell by the mouthpiece. Push these tabs
in to remove the white mold.
10. At this point, the gears should be
fully exposed. Move the lever up and
down. Was your hypothesis as to how the
diskus worked correct? If not, what is
Figure 5: Inside the Diskus
actually happening?
11. Set the diskus aside and look at the aerosol inhaler and nasal
spray. Compare and contrast these methods of asthma drug delivery to
the diskus. (i.e. size, complexity, ergonomics, visual appeal, etc.)
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Figure 6: Operating the open Diskus

Figure 7: Removal of the inner plastic layer

PART II - QUALITY CONTROL/MEASUREMENT
You may wish to place your findings in the table found in the RESULTS section
of this experiment, but you should also record them in your laboratory notebook.
ADVAIR® Quality Control
1. Take the foil strip that was previously removed over to a weighing
station that has a precise analytical scale.
2. Place a weigh boat on the scale and tare the instrument.
3. Remove the boat and pull back the foil strip exposing the powdered
drug in one blister. Carefully empty its contents into the weigh boat using
a spatula to scrape off any remaining powder.
4. Place the boat back on the scale and record the result. Tare the
scale once again so the powder does not have to constantly be thrown out
in between measurements. Repeat this nine more times so that the
weights of ten blister packs have been recorded.
5. After all measurements have been taken, dispose of the boat and
powder in the trash.
6. Reassemble the diskus and place it back in the box along with
included pamphlets.
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Figure 8: Proper removal of medicine from blister pack

Metered Dose Inhaler Quality Control (See Figure 9 for proper techniques for this
section)
1. First, take a weight boat, and place it on the analytical scale.
2. Now, take a KimWipe and fold it until you have a small rectangle that will
fit over the end of the metered dose inhaler. Place this folded KimWipe in
the weigh boat, and then zero the analytical scale.
3. Take the metered dose inhaler, and shake well. Remove the KimWipe
from the weigh boat, and place on the end of the inhaler where the
propellant will exit.
4. With the KimWipe on the end of the inhaler, press down on the canister
section of the inhaler, allowing the propellant to exit the inhaler and the
KimWipe to capture it.
5. Quickly place the Kimwipe back on the weigh boat and take a mass
measurement. (This may be difficult as the excipient, which acts as a
propellant, will evaporate.) Take the measurement once the scale stays
on the same value for at least a second.
6. Dispose of the KimWipe. Repeat steps 2 to 5 with fresh KimWipes until
you have ten mass measurements.
Nasal Spray Quality Control (See Figure 9 for proper techniques for this section)
1. Once again, take a weight boat, and place it on the analytical scale.
2. Now, take a KimWipe and fold it. Place this folded KimWipe in the weigh
boat so that it covers the bottom and most of the sides of the weigh boat.
Once this is done, place the weigh boat back on the scale, and then zero
the instrument.
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3. Take another KimWipe or a paper towel and fold several times. Take the
nasal spray and shake. Prime the device by spraying it a few times into
this second wipe.
4. With the spray primed, take the weigh boat off the scale, and place on a
slightly downward angle. Spray the propellant into the weigh boat once.
5. Place the weigh boat back on the scale and take a mass measurement.
6. Dispose of the KimWipe. Repeat steps 2 to 5 until you have ten mass
measurements. (Step 3 may not need to be repeated every time, but once
every 2 to 3 measurements.)

Figure 9: Different examples of the correct technique for metered dose inhaler (MDI) and
nasal spray quality control measurements. a) The folding of the KimWipe before taking a
mass sample of the MDI. b) The MDI cartridge being pushed down so that the medicine
will be ejected into the KimWipe, and a mass measurement taken. c) The lining of a
KimWipe on the bottom of a weigh boat far nasal spray mass measurements. d) Priming
the nasal spray apparatus before taking a mass measurement. e) Taking a mass
measurement using the nasal spray.

RESULTS
Make sure that the students record all results in a lab notebook, and that all
members of the teams receive the data. These results can be placed in the table
below and turned in along with solutions to the questions below. Questions were
also asked throughout the procedure, and should be answered as well.
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Table 1. Empty data table for collecting data in the Asthma Drug Delivery laboratory
experiment

Diskhaler Trial Mass (g) MDI Trial Mass (g) Nasal Spray Trial Mass (g)
1
1
1
2
2
2
3
3
3
4
4
4
5
5
5
6
6
6
7
7
7
8
8
8
9
9
9
10
10
10
Average
Std. Dev.
QUESTIONS
1. Compare and contrast the different styles of drug delivery that you
examined in part I. Which of these systems did you think had the most
appeal? Which do you think will work the best?
2. When comparing the MDI and the nasal spray, which of the two has a
higher standard deviation? Compare all three standard deviations.
Determine the highest and the lowest standard deviation. Explain what
these results imply about the quality control measures of the three
devices.
3. What were some sources of error in part II? How do you think you could
fix some of these problems?
4. Based on the average weight of the blisters, what percentage of the
powder are active pharmaceutical ingredients (API’s) and what
percentage is inactive? Assume that the amount of active ingredient from
each sample is equal to the amount stated in the prescription dosage.
The formula for finding the percentage of inactive ingredients is as
follows:
(1)
∑
(
)

123

From this, find the percentage of active ingredients.
5. Do you think that the assumption made for problem 4 was a valid
assumption to make? Why or why not?
6. The Advair dry powder inhaler, as described in the introduction section,
contains two active ingredients, fluticasone propionate and salmeterol
powder. There is one other ingredient listed on the label, lactose.
a. What is lactose? Where else is lactose commonly found?
b. Why would lactose be used in the inhaler? What type of excipient
should it be considered?
c. What are some negatives of using lactose?
Be sure to site all references.

7. All metered dose inhalers (MDIs) need a propellant. A propellant makes
up almost 99% of the dose of an inhaler. The propellant must have
specific properties. Some of these include the boiling point, solubility of
the API, toxicity and others. The API is suspended in the propellant and
when the medication is dispensed the propellant creates an aerosol cloud,
that the medication can be inhaled by the patient.4
a. What is a CFC?
b. Why are CFCs no longer used as propellants in inhalers?
c. What type of propellant is used in the Ventolin inhaler? Which type
of propellant did it replace?
d. Compare the two propellants. Why do you think they replaced the
propellant?
Be sure to cite all references.
REFERENCES
1. GlaxoSmithKline. “Highlights and Full Prescribing Information for ADVAIR
DISKUS.” January 2011. http://us.gsk.com/products/assets/us_advair.pdf
2. United States National Library of Medicine. "Chronic Obstructive
Pulmonary Disease." May
2011. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001153/
3. United States National Library of Medicine. “Asthma.” July
2012. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001196/
4. Noakes, T. Medical aerosol propellants. The Journal of Fluorine
Chemistry. Vol. 118, pp. 35-45. 2002.
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A.4 Degradation of Dissolvable Strips Lab
Degradation of Dissolvable Strips
Developed by: Alex Jannini, David Krause, Heather Malino and Kevin Sweeney,
Rowan University, Department of Chemical Engineering
Edited by: C. Stewart Slater and Mariano Savelski, Rowan University,
Department of Chemical Engineering
Date of Experiment:
OBJECTIVES


Students will learn about mass transfer and degradation rates of drug
delivery films
 Students will learn how to properly operate a spectrophotometer
 Students will determine the effect of temperature on this process
INTRODUCTION
In 2000, the pharmaceutical company Pfizer
introduced a new over-the-counter product for
the treatment of bad breath. This product
came in a novel form that was not seen before;
a small, orally dissolvable strip. This product
revolutionized the industry, generating roughly
250 million dollars in sales. By 2002, many
other brands of dissolvable strips were also on
the shelves.1 In 2011, the energy supplement
industry also saw the potential profits of
sheets. One company, known as Sheets,
introduced a caffeine based strip which they
claim has zero calories, zero sugar, and has
Figure 1. The energy strips you
will be using in class.
the same caffeine as one cup of coffee, shown
in Figure 1. The brand also states that
negative side effects, such as a “crash,” are not common when taking the
product. Although the company has faced controversy, especially with the
endorsement of LeBron James, Sheets continues to make energy supplement
strips.2
While the use of dissolvable strips is a relatively new delivery method, it has
become a popular method of drug delivery. In fact, many other fields of over-thecounter pharmaceutical products have introduced dissolvable strip products.
Dissolvable strips that contain medicines for flu and sinus infection symptoms
can now be found in most pharmacies.3
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With dissolvable strips, the delivery vehicle is a thin, flexible sheet of polymer.
The active pharmaceutical ingredient (API) is incorporated into this polymer to
form the final product. Depending on the nature of the medicine, the API can be
incorporated in one of two ways; either through liquid dissolution or solid
suspension in the polymer. The size and thickness of these strips is dependent
on the dosage of API that needs to be delivered.3
In this experiment, you will investigate the dissolution and degradation rate of a
dissolvable strip that contains menthol. You will be using a spectrophotometer to
take absorbance readings. These absorbance readings will then be used to find
the amount of menthol that was released from the strips. You will also be
comparing these rates for two different temperatures; ambient, otherwise known
as room (roughly 20°C), and body (37°C).
MATERIALS NEEDED











2 Sheets™ brand Mint Boost dissolvable strips
2 petri dishes
2 timers
Incubator or oven capable of reaching and maintaining 37°C
Pair of tweezers
Deionized water
500 µL to 5000 µL pipette
Spectrophotometer capable of measuring absorbance at 630 nm
Cuvettes
Thermometer/thermocouple

SAFETY CONDITIONS
Laboratory gloves and eyewear must be worn at all times inside the lab. Be sure
to keep water away from the spectrophotometer.
PROCEDURE
1. Start by turning on the spectrophotometer and setting it to take
absorbance readings at 630 nm.
2. While the spectrophotometer warms up, place 2.5 mL of deionized water
into each of the petri dishes.
3. Place one of the petri dishes into the oven/incubator that is set at 37°C.
4. Allow 20 minutes to pass so that the water may reach 37°C and the
spectrophotometer may warm up.
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5. After the 20 minutes
have passed, fill a
cuvette with
deionized water and
zero the
spectrophotometer.
6. Now that the
spectrophotometer
has been zeroed, use
the tweezers to place
a strip into one of the
petri dishes. Once
the strip has been
Figures 2 and 3. From left to right, the proper (l) and
improper (r) way to take a sample.
placed in the petri
dish, cover and start
the timer.
7. Place the other strip in the other petri dish using the tweezers. Once
placed, close the petri dish and start a secondary timer. NOTE: It is a
good idea to stagger the starting times so that you do not find yourself
rushing to take two measurements. It may also be a good idea if you are
working in teams to split the team so that one section of the group is in
charge of one specific temperature study.
8. After five minutes have elapsed, take a sample of your water into a
cuvette. Make sure that this sample is relatively far from the dissolvable
strip so that you do not accidentally pick up any large portions of the
dissolvable strip, as in Figures 2 and 3.
9. Take an absorbance reading then return the sample to the corresponding
petri dish.
10. Take absorbance readings every five minutes for the first thirty minutes.
After that, take absorbance readings every ten minutes until you have
reached 90 minutes. You may use Table 1, but you should also record
your results in your laboratory notebook.
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Table 1. Empty data table to record absorbance at 630 nm data for the dissolvable strips
laboratory.

Time (min)
0
5
10
15
20
25
30
40
50
60
70
80
90

Absorbance readings at 630 nm
Body Temperature
Room Temperature (20°C)
(37°C)
0
0

11. Once you have taken all the necessary measurements, make sure to turn
off the spectrophotometer and the incubator/oven.
12. Dispose of all equipment used in this lab, and make sure that any water
spills were cleaned up before exiting the laboratory.
RESULTS
Be sure to record all the data you collected in this experiment into your laboratory
notebook. If you split into two groups to complete this experiment, be sure that
you share the data sets.
DATA ANALYSIS
To analyze the data, the best method is to create a graph of the time versus
absorbance reading. In this case, the x-axis will be the time axis and the y-axis
will be the absorbance axis. Create one of these graphs using Excel or another
program and turn it in along with the rest of your laboratory report.
QUESTIONS
1. Now, you will take your absorbance readings and figure out the
concentration of menthol in your solutions. You will do this using the
following graph, which correlates absorbance at 630 nm to concentration
in mg/mL. Once you have the concentrations, create another graph of
concentration versus time for both temperature sets. In addition, fill in
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Table 2. Make a copy of this table and turn in along with the rest of the
deliverables for this experiment.

Absorbance at 630 nm

Blue 1 Standards Curve
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
0.0E+00

y = 1767.505155x

2.0E-04

4.0E-04

6.0E-04

8.0E-04

1.0E-03

1.2E-03

Concentration (mg/mL)

Table 2. Empty data table for recording concentrations in the dissolvable strips laboratory.

Time (min)
0
5
10
15
20
25
30
40
50
60
70
80
90

Concentration (mg/mL)
Room Temperature
Body Temperature
(20°C)
(37°C)
0
0

2. Now that you have found the concentration of the solution over time, you
will need to use concentration and absorbance readings to determine the
molar absorptivity of the blue food dye. The molar absorptivity, or the
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molar absorption coefficient, is defined as how strongly a substance
absorbs light at a particular wavelength4. This coefficient is seen in the
Beer-Lambert Law, an important law that governs the absorbance of light.
This law is shown below:
(1)

With:
(

)
(
( )

)

a) Use one of the higher time points (70 to 90 minutes) of both the
room temperature and body temperature experimental runs to
determine the molar absorption coefficients of both runs. Use the
following constants to help you in this calculation.

b) Based on the values, do you think that the temperature affects the
molar absorption coefficient?

3. Determine how well the molar absorption coefficients can determine the
concentration of the solution based on absorbance readings. Use the
molar coefficients you previously found and determine the concentration
that the solution should be at based on the Beer-Lambert Law. Use a time
point between 30 and 50 minutes in both cases. Determine how different
these two numbers are by using percent difference. The equation for
percent difference is shown below. In this case, the “E” terms are the
molar concentrations. It should be noted that percent difference is a
dimensionless number. Make sure you do all the necessary unit
conversions before calculating the percent difference.
|
|
(2)
(

)

4. It is known that the molar absorptivity coefficient of the blue food dye used
in these sheets is 1.3x106 M-1cm-1.5
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a) How different is the molar absorptivity coefficient that you found
using your experimental data from this known value? Use
experimental error to determine this difference. The equation for
percent error is shown below.

|

|

(3)

Here, the “E” term is the molar absorptivity coefficient obtained
through the experimental data, while the “A” term is the molar
absorptivity coefficient given to you above. It should be noted that
when using this equation, the two terms need to be in the same
units. It should be noted that percent error is also a dimensionless
number.
b) Now, use the same time point that you used in Question 6 and
determine the concentration based on the given molar absorptivity
coefficient. Again, compare using percent error. Do this for both
experimental runs. Here, the “E” term will be the concentration that
you obtained during experimentation, while the “A” term will be the
concentration that you obtained using the given molar absorptivity
coefficient.
5. The Beer-Lambert Law is one of the most important laws used in
spectroscopy (the interactions between light and matter). How could you
use this law in an engineering aspect?
6. Now, we will discuss a rate law. A rate law, or rate equation, is an
equation that governs the rate of a process as a function of a variable,
such as time. These laws are used by engineers to determine the design
of a chemical process. Rate laws applied to this experiment relate
absorbance with time. For example, an important variable of a rate law,
the rate coefficient/constant (k), can be determined using absorbance
data. This can be done using the following equation:
(
(

)
)
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(4)

Where:
t
Time
A Absorbance at time t
A0 Absorbance at t=0
A∞ Absorbance at t=∞
k
Rate coefficient
a) Determine the rate coefficient from your absorbance data. To do this,
you will need to determine A∞ based on your data. Use a point earlier
in your experiment, and determine a rate coefficient for both sets of
data.
b) Based on these results, does temperature affect the dissolution rate?
Use the rate constant values you obtained to verify your answer.
REFERENCES
1. InnovateUs, Inc. “What are Breath Strips?”
http://www.innovateus.net/health/what-are-breath-strips.
2. Donaldson James, Susan. “Sheets Give Caffeine Jolt, Potential for
Abuse.” ABC News. 10 June, 2011. http://abcnews.go.com/Health/lebronjames-shills-sheets-caffeine-strips-badidea/story?id=13805037#.UeWj2m1nA6e.
3. Particle Sciences Drug Development Services. “Dissolving Films.” 2010.
Volume 3.
4. Biology Online. Molar Extinction Coefficient. Biology Online.org. 22 June
2008. Accessed 11 September 2013. http://www.biologyonline.org/dictionary/Molar_extinction_coefficient.
5. Reeves, J. Beer’s Law. Laboratory for science majors at The University
of North Carolina Wilmington. Accessed 12 September 2013.
http://uncw.edu/chem/Courses/Reeves/OnLineLabs/scienceMajors/BeersL
aw_PH.pdf
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A.5 Effervescence Reaction Lab
Effervescence Laboratory Experiment
Developed by: Alex Jannini, David Krause, Heather Malino and Kevin Sweeney,
Rowan University, Department of Chemical Engineering
Edited by: C. Stewart Slater and Mariano Savelski, Rowan University,
Department of Chemical Engineering
Date of Experiment:

OBJECTIVES




Students will perform a basic mass balance on an effervescence reaction
in pharmacology
Students will conduct theoretical stoichiometric calculations and compare
to experimental results
Students will learn about the equilibrium constants and other fundamental
aspects of reactions

INTRODUCTION
Alka-Seltzer® is an effervescent
antacid (NaCO3, KCO3 plus
anhydrous citric acid) containing
acetylsalicylic acid (aspirin), which is
an analgesic, antipyretic, and antiinflammatory drug. Simply put, AlkaSeltzer® relieves upset stomach,
Figure 1. Standard original strength packet
provides pain relief, breaks fevers,
and reduces inflammation.
The effervescence allows for a faster rate of drug
dissolution into a liquid medium (water in this
case) by increasing the surface area of the drug
exposed to solution and by “bubbling” the mixture,
causing a stirring effect. The effervescence
reaction is:
C6H8O7(aq) +
NaHCO3(aq) → H2O(l) +
CO2(g) + Na3C6H5O7(aq)

(1)
Figure 2. Weighing the tablets
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In this lab you will determine how much CO2 is generated and released to the
atmosphere by taking the initial and final weights of an Alka-Seltzer® solution.
This is an introduction to mass balances, an important concept for engineers.
This experimental value will then be compared to the theoretical amount of CO2
mass generated, found through stoichiometry.
MATERIALS NEEDED







2 Alka-Seltzer® tablets (1 packet)
Analytical scale (+/- 0.0001 g)
Weigh boat
Graduated cylinder
200 mL plastic beaker
Timer

PROCEDURE
1. Make sure safety glasses and examination
gloves are on before entering the lab.
2. Remove both Alka-Seltzer® tablets from the
packet. If the tablets are broken, be careful to
not lose any pieces. How do you think a
Figure 3. Creating the
broken tablet will affect the rate of the tablets solution
dissolving?
3. Place a weigh boat on the scale. Tare the instrument so it calibrates to
zero with the added weight of the boat.
4. Weigh the Alka-Seltzer® tablets and record in your notebook.
5. Alka-Seltzer® is supposed to be dissolved in 4 oz. (118.3 mL) of water
according to the manufacturer’s directions. Using deionized water,
measure out this volume of water with a graduated cylinder and add it to
the beaker.
6. Weigh the beaker plus the added water and record it in your notebook.
This weight plus the weight of the Alka-Seltzer® tablets is your initial
weight.
7. Drop both tablets into the beaker.
8. For the first five minutes, take a weight every 60 seconds. After five
minutes have passed, measure the weight every five minutes until an hour
has elapsed. Tap the bubbles off of the sides of the beaker as they form.
9. Dispose of the solution down the sink.
PART II
10. Fill the beaker back up with the same amount of deionized water and
weigh the water and the beaker.
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11. On a weigh boat, measure out 2.0 g citric acid and 3.832 g sodium
bicarbonate.
12. Drop the powder into the beaker and record weights at the same time
intervals as Part I.
13. Dispose of the solution down the sink and clean up the lab area.
QUESTIONS
1. Fill in the tables:

1. You should notice that the initial weights of the two solutions are different.
a. What may cause this?
b. To fix this, take the difference between the two sets, find the
difference between the two initial points. This difference will need
to be subtracted from the solution with the higher weights. Find the
new weights and record them in the table below.
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Adjusted

Weight Time

Initial:

0m
1m
2m
3m
4m
5m
10 m
15 m
20 m
25 m
30 m
35 m
40 m
45 m
50 m
55 m

Final:

60 m

c. Please graph the revised data set along with the other set that was
not changed.
2. Determine the experimental amount of CO2 generated and released to the
atmosphere by subtracting the initial weight from the final weight.
3. Balance the reaction given in the beginning of the laboratory.
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4. According to the manufacturer’s website, each tablet contains 1000 mg of
citric acid and 1916 mg of sodium bicarbonate. Determine the moles of
each reactant.
5. Determine which reactant is the limiting reactant. What is the percent
excess? Why do you think there is extra added?
6. Using the effervescence reaction given in the beginning of the lab,
determine the moles produced of CO2 gas.
7. How many milligrams of CO2 were made in both reactions?
8. What is the theoretical final weight of each solution? Use the weight of the
beaker and water measured in the lab.
9. Determine your percent error at each point with the given equation:
(
(

(

))

)

(3)

10. What were some sources of error in this lab?
11. Was there if a difference in the way the pure components dissolved versus
the tablets? Why do you think they behaved the same/differently? It is
known that Alka-Seltzer tablets use a milling process to reduce the size of
their powder.1 Do you think that the use of milling the powders when
forming the tablets adds into the difference in behavior?
12. What is a different way that this experiment can be designed so that the
gas released could be directly measured?
13. In reaction engineering, it is important to understand the mathematics
behind chemical reactions. One of the important concepts is the reaction
rate of a chemical reaction. This reaction rate determines how many
moles of a reactant are being converted to a product over a period of time.
The rate of reaction is commonly symbolized by rA. The basic equation of
the rA is:
[ ]
(4)
Where k is the rate constant and CA is the concentration of the limiting
reactant in a chemical reaction. This is also known as a rate law. A rate
law can be linear or nonlinear in regards to the concentration. In most
cases, rate laws are zero-order (x=0), first-order (x=1), or second-order
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(x=2). Now, you will determine the rate constant and order of the rate law
for a sub-reaction that takes place in the effervescent reaction.

This sub-reaction is the formation of bicarbonate to carbon dioxide:
(5)
In this reaction, the limiting reactant is the bicarbonate ion. To determine
the concentration of the bicarbonate ion (
), we can use the following
equation.
(6)
We can assume that all the sodium bicarbonate breaks down to sodium
ions and bicarbonate ions, giving us the initial moles of bicarbonate ions.
a. Using the data you collected, determine the moles of CO2
generated at each time point, and use that to determine the
concentration of bicarbonate ions at each time point. Once this is
done, make graphs of the following:
vs. time, ln(
) vs.
time, and 1/
vs. time. Determine which one is a linear
relationship, and print out that graph. Do this for both sets of data.
b. The rate constant can be found by determining the slope of the
linear relationship. Find the k for both sets of data.
c. Now, determine the order of both sets of data. As a reminder; a
zero-order reaction will be linear for concentration vs. time; a firstorder reaction will be linear for ln(concentration vs. time; a secondorder reaction will be linear for 1/concentration vs. time.
d. Do the orders match for the tablet and raw ingredients? What
about the k values?
REFERENCES
1. H. Phykitt, "Analgesic Composition and Method of Making the Same".
United States of America Patent 8,580,853, 13 June 2011.
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A.6 Dextromethorphan Crystallization Lab
Dextromethorphan Crystallization Laboratory
Developed by: Alex Jannini, David Krause, Heather Malino and Matthew Van
der Wielen, Rowan University, Department of Chemical Engineering
Edited by: C. Stewart Slater and Mariano J. Savelski, Rowan University,
Department of Chemical Engineering
Date of Experiment:
OBJECTIVES
 Students will develop a solubility curve for dextromethorphan.
 Students will gain an understanding of the techniques of crystallization
and how it is used in the pharmaceutical industry.
 Students will learn the fundamentals of energy balances and heat transfer.
INTRODUCTION
A crystal is defined as a solid material whose atoms, molecules, or ions are
arranged in an ordered pattern in three dimensions. Crystallization is the
process by which solid crystals precipitate out of a solution. After the
precipitation occurs, there will be a solid phase and a liquid phase in the solution.
Then, the solution will be filtered to separate the two phases. Sometimes the
solid phase is the desirable phase while other times the liquid phase is desired.
Crystallization is a commonly used method of separating solid-liquid solutions in
industry. Crystallization has been utilized in many different processes for
decades. For example, many commodity chemicals like xylene and inorganic
salts such as sodium chloride are formed using crystallization1.
In more recent years, crystallization is used in the pharmaceutical industry. The
most common reason for using crystallization in the pharmaceutical industry is to
obtain a high purity active pharmaceutical ingredient (API). In the case of vitamin
C purification, crystals are formed in either an aqueous or alcohol based media
and then filtered out of solution2.
One of the tools used in designing crystallization processes is the solubility
curve. A solubility curve can be used to determine the saturated concentration of
a solution of solids in a liquid. An example solubility curve is shown on the next
page. The solubility curve is usually based on the concentration of solid in the
solution and the temperature of the solution. In most cases, solubility curves are
made with a solute in a solvent. In this lab, you will be making a solubility curve
for the salt form of dextromethorphan in water.
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Solubility (g/100mL water)
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Figure 1. A sample solubility curve for several different salts. Adapted from the Halifax
3
Regional School Board.

Dextromethorphan (DXM) is the active pharmaceutical ingredient (API) in several
cough syrups. Dextromethorphan is a strong antitussive agent. 4 It is often found
as a monohydrated hydrobromated salt. This means that one molecule of HBr is
attached to the dextromethorphan crystal. It belongs to the morphine group of
alkaloids. A typical amount of dextromethorphan in one dose of cough medicine
is approximately 15 mg.
SAFETY AND CONSIDERATIONS
Safety googles must be worn at all times in the lab. Gloves should also be worn
during this experiment. When working with the powder, a dust mask should be
worn. The chemical is of USP grade.
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MATERIALS NEEDED















Dextromethorphan HBr (one lab that contains 6 groups of students will
need approximately 30 grams)
Citric Acid, Anhydrous (one lab that contain 6 groups of students will need
approximately 180 grams)
Analytical scale (capable of reading 10-3 grams)
Weigh boats
14 test tubes
Test tube rack
1 large (approximately 800 mL or higher) beaker
Heat/stir plate
Stir bar
2 thermocouples with rod attachments
Large graduated cylinder (1000 mL)
5mL micropipette
Sharpie® or marking pencil
Ring stand with test tube clamp

PROCEDURE
PART 1: DXM
For time limitations, divide the lab up so that half the team completes steps 1-2
while the other half of the group completes step 3-6.
1. Using the marking pencil or Sharpie®, number 7 test tubes and place them
into a test tube rack.
2. Using the analytical scale, measure the dextromethorphan and prepare
the test tubes as indicated below:
Test tube # Milligrams (mg) of DXM
1
200
2
400
3
600
4
800
5
1000
6
1200
7
450-750
Tube #7 is a choice. You may choose any value (other than 600 mg) to
place in this vial. Make sure to record this number.
3. Note the maximum volume of the large beaker. You will need to fill the
beaker ¾ of the way full. Use the large graduated cylinder in order to
precisely measure the amount of water you add to the beaker. Record the
volume of water that you added to the beaker.
4. The beaker that you filled with water will be used as a hot water bath.
Place the water bath on the hot/stir plate, and place a stir bar in the
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beaker. Place the heat control setting somewhere in the middle, and set
the stir setting to the lowest possible setting.
5. Place one of the thermocouple rods in
the water. The water bath needs to stay
within 80 to 90 °C, which is the
temperature suitable for dissolving all
the DXM. This will require supervision
and maintenance.
6. Now, setup the test tube clamp on the
ring stand so that the clamp is just
above the beaker.
7. Once you have measured out the
masses of DXM necessary, use the
micropipette and place 5 mL of water in
each of the test tubes.
8. Now, secure test tube #1 in the tube
clamp, and place the second
thermocouple rod in the tube. Lower the
clamp so that the test tube is as
Figure 2. Proper setup of a test
submerged as possible in the water
tube in the hot water bath.
bath.
9. Stir the test tube with the rod of the
thermocouple. Keep stirring the
solution until you see the DXM
completely dissolve in the water.
Loosen the clamp and remove
the tube. Use a test tube holder
if the tube is too hot.
10. Now hold the thermocouple in the
solution. You may also need to
wipe off the tube if there is
excess condensation on the tube.
Hold the test tube up to the light
and examine the solution for the
first signs of crystallization.
Record the temperature
immediately as crystallization
begins in the data table.
Figure 4. The
Figure 3. The
11. Repeat steps 8 through 10 for
DXM and water
DXM and water
the other test tubes. Record all
solution once
solution
once
data. You may use the table
crystallization has
completely
below, but you should also
begun. Notice the
dissolved.
record all results in your lab
white substance
notebook.
at the bottom of
the tube.
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RESULTS
You may use the table below to record your data. However, it is encouraged to
also write your results down in your lab notebook.
Test Tube
Number
1
2
3
4
5
6
7

Temperature of
Recrystallization (°C)

DATA ANALYSIS
For this section, you will be using Microsoft
Excel. Once you have completed the lab and
collected all the data, open up a new Excel file
and place the data in a spreadsheet. Now, the
concentration that we have right now is in
mg/5mL. Change this to g/L. Remember that
there are 1000 mg per g and 1000 mL per L.
Figure 5. A screenshot of
the graph you will need in
Excel.

Once this is done, we need to create a solubility
curve. To do this, we will be using the chart
wizard. In excel, go to the insert tab and chose to
insert a scatter graph. Look specifically for the “scatter with smooth lines and
markers” option. Create a scatterplot that has temperature on the X-axis and
concentration on the Y-axis for the first six points of the data collected. In
addition, please use the following data points when creating your graph of the
DXM data:

Table 1. Additional points for the solubility curve for DXM. Obtained from DrugBank and INCHEM.

Concentration (g/L) Temperature (°C)
0.00851
0
0.0747
20
15.0
25
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5,6

Once this is done, change the chart layout so that you have titles for the x- and yaxis. This should be the first option in the chart layout section. Once you have
titles for the axes, label them accordingly. Label the chart with your group
number or the last names of your group members, and then delete the “Series 1”
label.
Once you have a chart, you will need to edit the x-axis. To do this, click on the
values on the x-axis. You should see these values boxed. Once done, right
click, and click on the “Format Axis” option. You should now see the Axis Option
menu. In this menu, look for “Major tick mark type.” In the dropdown menu,
select the inside option. Once this is done, print out your graph. Do the same
thing for the citric acid data. Make sure to print out that graph as well. You will
need these later.

Figure 6. A screenshot of the “Major tick mark” option.

QUESTIONS
1. Now that we have a graph, we can check the accuracy of it. We will do
this by using the random point that you collected during the procedure.
a. We will check the accuracy of the graph through a process known
as interpolation. In interpolation, you determine a new data point
that lies within data that has already been collected. To do this,
you will need a ruler. First, determine the concentration of your
unknown in grams/L. Once you know that value, locate it on your
chart. If your concentration lies within two tick marks, you will need
to use the ruler. First, determine the length between the two tick
marks. Next, solve the following equation:
(

)
(

(1)
)
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Once you have found the length between the concentration and the
lower tick, mark that on your graph. Once that is done, draw a
straight line from this point to the line generated. Then, draw a
straight line down to the x-axis. Now, you will have to determine
the temperature this corresponds to. Here, you will have to do the
same thing that you did previously. Determine the length between
the tick marks on the x-axis, and then determine the length
between the lower tick mark and the line you drew down. Using the
equation below, determine the temperature:
(

)

(

)

(2)

b. Now that we have the temperature obtained from interpolation, we
will determine the percent error between the temperature obtained
through part a. and the temperature obtained experimentally. Use
the following equation:
|
|
(3)

What does this tell you about the possible shape of the solubility
curve?

2. Energy is required to heat the water bath to 90°C. The most basic
equation that models the energy required to heat the water from room
temperature to 90°C is:
(4)
Where “Q” is the energy required in J/g, “m” is the mass of water and “Cp”
is the specific heat capacity of water.
a. Using the specific heat as 4.18 J/(g * °C) and the density of water
as 1.00 g/mL, determine the amount of energy required to heat the
water to 90°C. You may assume that the water was at room
temperature (20 °C) before heating.
b. If a tank in an industrial process needs to heat 200 gallons of water
to 90°C, how much energy would be needed?
3. Whenever there is a flow of heat from one source to another, there is an
exchange of energy. This flow of energy is studied in the field of heat
transfer. We will now discuss one of the basic conventions of heat
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transfer; conduction. Conduction can be defined as the transfer of energy
from more energetic particles to less energetic particles due to their
interactions.7 One important term in conduction is the thermal diffusivity of
a substance. The thermal diffusivity (represented from now on by the
variable, α) measures the ability of a material to conduct thermal energy in
relation to its ability to store thermal energy.7 To find α, we can use the
following equation:
(5)
With:
[
[

]

]
[

]

a. The term α is considered a dimensionless constant. With the units
provided, prove that this is so.
b. Determine the thermal diffusivity of water at 25 °C and aluminum at
25 °C. Which is higher? What does this tell you about the two
substances in regards to the conduction and storage of thermal
energy? To do this, you will need to use the following table:
Table 2. Thermophysical properties for water and aluminum at varying temperatures.
7,8
Adapted from Incropera et al and Thermal Fluids Central.

Temperature
(K)
290
300

Water
[
0.598
0.613

]

[

]

0.999
0.997

Aluminum
[
4.184
4.179

]

[
235
237

]

[
2708
2702

]

[

]

0.868
0.903

Obviously, you will need to use interpolation in order to obtain the
correct data points. Use a similar method as used in Question 1.
c. Now, determine the thermal diffusivity for aluminum at 200 and 400
K. Use the following data below. What does this tell you about the
thermal diffusivity of aluminum in regards to temperature? Do you
think this is true for all temperature ranges? Try with 400 and 800.
Does this provide more insight into the thermal diffusivity of
aluminum with respect to temperature?
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Table 3. Thermophysical data for aluminum at varying temperatures. Adapted from
7,8
Incropera et al and Thermal Fluids Central.

Temperature (K)

[

⁄

]
[

200
400
800

2719
2681
2591

⁄

]

237
240
218

4. In simple heat transfer, we can model the flow of heat using onedimensional, steady-state conduction. What this means is that we model
the flow of energy as though it were in one direction at an unvarying rate.
This allows us to model the flow of heat over a certain distance. We will
do this for the case of the test tubes we used in this experiment.
First, we must show how to properly model this flow of heat. Picture the
test tubes used in this. We will say that in the direct middle of the water
will be the starting point. Then, we will say that top of the water level
(where water meets air) is the ending point. So with these start and end
points, we will be modeling the flow of heat from the middle of the test
tube water level to the top of the test tube water level.

Figure 7. A representation of the one-dimensional, steady-state conduction
model for the test tube.
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In order to model this, we need to make two assumptions: 1) that the heat
flows at a steady-state (does not fluctuate over time) and 2) that all the
sides except for the end point are perfectly insulated. (NOTE: The other
assumption that is made in order to use this model is that the surface
temperature of the water is the same as the air temperature. If this
assumption is not made, the flow of heat from the surface via natural
convection, or the natural flow of air on the surface of the water, needs to
be taken into account. This makes the model much more difficult; and as
such, is eliminated from the model.)
With these assumptions made, we can use the following equation to
model the flow of heat from the starting point to the end point. To do this,
we can use the following equation to solve for the heat flow7:
(6)
With:

[ ]
[ ]
[ ]
[

]

[ ]
Now, we will also say that half the volume of the water added to the test
tube is in this specific space used for the model (2.5 mL). Assuming that
the water is a perfect cylinder, and that the test tube has an inner diameter
of 0.55 in, you find all the information necessary to model this flow of heat.
a. First, we will model this as though it were pure water. Take the
temperature of recrystallization you found for test tube #1 in your
DXM experiments, and state that this is To. T1 will be the
temperature of the air (20 °C). Determine the heat transfer rate if
the thermal conductivity of water is at a weighted average of 0.58
W/m*K.
b. Now, we are going to find the thermal conductivity (k) for a mixture
of the salts used in this experiment. To do this, we will use a
thermal conductivity approximation for salt solutions. This is shown
below9:

Where:
(
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(

)

)

⁄

⁄

⁄

Make sure to use these units when using the calculation. Again,
use data obtained from test tube #1 for this. For the temperature,
determine the average between the air and the temperature of
crystallization. Determine the k value for DXM using this equation,
then find qx using the equation from part a.
c. Determine the percent difference between parts a and b. Is there a
considerable difference? Which do you think is more accurate?
Keep in mind that the thermal conductivity approximation you were
given was developed using sea salt.
d. In order to calculate this, we made two assumptions about the heat
flow. Can these assumptions be made for our experiment? Why or
why not?
5. Citric acid is often used as a flavoring agent in pharmaceuticals. The
saturation point for citric acid in water is provided. This is another way of
showing the solubility of a substance, but with different units. Instead of
concentration in mass solute per volume solution, we give the
concentration in mass solute per mass solution.
85

Weight % Citric Acid
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Temperature (°C)
Figure 8. The saturated weight percent of citric acid in water with
10
respect to temperature. Adapted from Dalman.

a. Now, we have discussed solubility curves in great detail. In the
introduction of this experiment, we discussed how a solubility curve
tells you the point where a solution of solid crystals will completely
dissolve into a solvent. Using the graph above, describe what
would happen if you picked a point above the solubility curve
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(example, 60 wt% and 10 °C) and what would happen if you picked
below the solubility curve (example, 50 wt% and 60°C).
b. During the production of the new pharmaceutical tablet, 75 kg of
citric acid is placed in a mixer with 100 kg water at 40 °C. The
operators on duty notice that not all of the powder is dissolving into
the water. Using the solubility curve, explain why this occurs. If we
needed to fully dissolve the citric acid in the water, what would you
recommend doing?
c. In another operation that uses citric acid, 78 pounds of citric acid is
dissolved in 60 pounds of water and is heated to 80 °C. The
solution needs to be cooled so that 18 pounds of crystals can be
collected. To what temperature should this solution be cooled to?
6.

In the previous question, you were given a scenario in which a solution of
crystals and solvent were cooled past the solubility point. Indeed, this is
what is commonly done in industry in order to separate crystals from
liquids. Usually, the solution is sent to a cooler, a type of machine that
drops the temperature of the solution. This allows crystals and saturated
solution to form. This mixture is sent to a filter, which physically separates
the liquid from the solid. Then, the solid (known as “cake”) is sent to a
dryer, so that more liquid can be removed from the crystals. An example
of this can be seen below:

Figure 9. A simplified version of the setup used to separate crystals from
11
solution. Adapted from Felder and Rousseau.
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a. 100 kg of a solution with a concentration of 150 grams of DXM per
liter of water is sent through this process. The temperature of the
solution is initially 75 °C, and is cooled down to 45 °C. Using your
DXM data, determine the mass of crystals that would precipitate
out. Assume that the solution has the same density as water.
b. Now, say this cooled solution is sent to a filter. The filter is
considered 100% effective at removing the crystals. If the
composition of the cake is 80% crystal by mass, calculate the mass
of saturated solution that has been separated with the crystals.
c. If the dryer only allows the water to evaporate, what is the overall
mass of crystals that was collected? If compared to the original
amount of crystals in solution, what is the overall yield of this
process?
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A.7 Creation of Dissolvable Strips Lab
Creation of Dissolvable Strips
Developed by: Alex Jannini, David Krause, Heather Malino, and Matthew van
der Wielen, Rowan University, Department of Chemical Engineering
Edited by: C. Stewart Slater and Mariano J. Savelski, Rowan University,
Department of Chemical Engineering
Date of Experiment:
OBJECTIVES




Students will learn about the commonly used processes for industrial thin
film production
Students will learn and use basic quality control testing methods
Students will gain insight into energy requirements for drying thin films

INTRODUCTION
Dissolvable strips have become an important mechanism for drug delivery.
Orginially created as candy, dissolvable strips fill a niche role, providing rapidrelease drug delivery. Due to the drug being dissolved directly into the blood
stream through the tounge, it bypasses the metabolism of the body, which can
cause drugs to lose some of their bioavaliability (the amount of drug that will
circulate through the body). Other advantages of using thin films include not
having to take the drug with water, no risk of choking, and reduced dose size
because the drug is more bioavailable sublingually (tissues under the tounge). 1
The ingredients of a dissolvable strip will vary, depending on the desired drug
release rate, the sensitivity of the drug, and several other factors. However, all
strips will contain the following ingredients; an active pharmaceutical ingredient
(API), polymers, placticzers, and sweetners/flavoring.2 A polymer is often
determined based on its reactions with water. The more hydrophilic (attraction to
water) the polymer is, the faster the film will dissolve and release the API. The
plasticzer helps improve flexibilty and prevent brittleness in the strip, while the
sweetners and flavorings help to improve palatability and increases patient
compliance.
On an industrial level, dissolvable strips are primarily made with either a solventcasting film system or a film extrustion system. Solvent-casting systems are the
most common process, as they do not require heat, which could damage an API,
and are relatively inexpensive to construct. A typical setup for a solvent-casting
system can be seen on the next page.3 The drawbacks to solvent-casting
techniques can include variances in film thickness and non-uniform drying.
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Figure 1. A diagram of a solvent-casting system as adapted from Particle Sciences.

Alternatively, hot melt extrusion
is also used to create strips.
The advantages to extrusion
are a simpler design and the
lack of water needed to run the
process, but the materials used
in the dissolvable strip must be
heat resistant and be able to
flow as a dry powder. A sample
of both of these systems can be
seen in Figures 1 and 2.

3

Figure 2. Screw-forced extrusion of dry feedstock
3
as adapted from Particle Sciences.

In this lab, you will be creating your own dissolvable strips. This procedure is
based on the solvent casting method described above. Through this lab, you will
have a better understanding of the way that dissolvable strips are created, and
some of the engineering principles behind the process.
SAFETY CONSIDERATIONS
Make sure to wear safety goggles at all time. Laboratory safety gloves should
also be worn.
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MATERIALS NEEDED

























1000 mL beaker
Hot plate and mixer
Magnetic stir bar
CMC (carboxymethylcellulose)
Pectin
Xanthan gum
Sodium lauryl sulfate
Citric acid (anhydrous)
Glycerol
Sucrose
Blue Food Dye (Blue #40)
3 drops of Peppermint oil
Dropper




Deionized water
3 mL syringe
2 Buchner (vacuum) flasks
Funnel
Fine mesh screen
Vacuum tubing
Vacuum source
Spatula
Petri Dish
Teflon-lined sheet/plate
apparatus with thickness
guiding bars
Analytical scale
Tubing and stopper

PROCEDURE
CMC Method
Table 1: CMC preparation

Species
CMC
Glycerol
Peppermint oil
Citric acid
Sodium lauryl
sulfate
Sucrose
Water
TOTAL

Weight (g)
7.7
2.6
0.5
1.0

Weight %
1.6
0.6
0.1
0.2

1.0

0.2

1.5
500
514.3

0.3
97
100

1. Weigh out the appropriate amounts of all powdered ingredients.
2. Add the required amount of deionized water to the large beaker.
Reminder: density of water = 1 g/mL.
3. Place the beaker on the hot plate and add the stir bar. Set the heat to the
lowest setting and set the stir to a low-medium rate (4 out of 10).
4. Add the CMC to the water at a very slow rate, dusting the powder over the
surface of the water and waiting for it to be absorbed. Once most of it is
mixed in, the solution will become very viscous and trap air bubbles.
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Once the viscosity increases, you will need to increase the stirring
intensity. Do this slowly.
5. Add the glycerol to the solution with the 3 mL
syringe. You will need approximately 2 mL of
glycerol to correspond to the weight shown in
Table 1.
6. Add the remaining components to the solution
similarly to how the CMC was added. At this
point, the solution should be extremely
viscous and appear opaque white.
7. Add three drops of peppermint oil to the
solution.
8. Add one drop of blue food dye. The mixture
Figure 3. Funnel and
should now be a light blue color.
screen setup for pouring
into flask.
9. Transfer the solution into the vacuum flask
with the mesh and funnel, pouring through
the mesh, to catch any large clumps of
solidified product and the stir bar. Discard
the solidified product.
10. We will now make a vacuum filtration
system. The purpose of this is to deaerate the mixture. This minimizes the
bubbles in the solution. Hook the
vacuum flask up to a tube and place a
rubber stopper in the top of the flask.
Then, connect the tube to the other
vacuum flask. Next, place a stopper
with an attachment into the top of the
Figure 4: The setup that should
other flask and connect this to the
be used when using the
vacuum.
vacuum source. See Figure 4 for the
appropriate setup. This second beaker
will stop any foam from entering the vacuum.
11. Turn on the vacuum and wait approximately 30 minutes for the gas to
leave the solution. The solution should slowly turn clear and may get
frothy. The froth will subside.
12. Turn off the vacuum and disconnect the tubing from the vacuum source.
Then, remove the beaker with solution from the setup.
13. Carefully pour some of the solution into a 500 mL graduated cylinder.
This will make it easier to transfer the solution to the Teflon sheet or petri
dish.
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14. Take a petri dish and weigh it. Record this weight.
15. Prepare a sample of the film in the petri dish by adding 10 mL to the dish.
Do this by using a small graduated cylinder (10 to 25 mL). If any bubbles
remain on top of the solution, be sure to draw solution from under the
surface.
16. Weigh the wet petri dish and record this weight.
17. Pour out 400 mL of the remaining solution onto the sheet using the 500
mL graduated cylinder.
18. Allow 1-2 days for the samples to dry. The batch should appear much
thinner and have a glossy finish on its surface. Take a final weight of the
petri dish sample and record its weight.
QUALITY ANALYSIS
How uniform is your batch? In industry, this is done
by sampling a batch and testing it in several ways to
ensure that specifications are met. Several samples
are taken and their results are averaged. Quality
analysis is critical to the success of a company, so
that deviations can be caught and fixed before they
become a costly problem.
Sample Creation
1. Carefully peel the strip out of the mold with a
spatula.
2. Take a ruler and measure 4 samples with
dimensions of 1” x 1.5”. Try to find room for
samples from each of the four corners so that
the samples are representative of the entire
batch.
3. Using a scalpel carefully cut out the four
samples.

Figure 5. Strips being cut

Thickness Measurements
1. Using a caliper, take each sample and place it
in the jaws of the caliper.
2. Adjust the jaws so that the sample fits snugly
between them. Do not over tighten the caliper
so that the sample tears. The sample should
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Figure 6. How to use the
calipers to determine
thickness

be pinched, but also be able to slide out from between the jaws when a
small force is applied to it.
3. Record your results and repeat for all samples.
Folding endurance
1. Take a sample and fold it in half along the 1.5” face (At the 0.75” mark).
Pinch the folding point with your fingers so that a distinct crease is formed.
2. Unfold the strip and flip it over. Carefully fold the strip in the opposite
direction, along the same crease and pinch. This has now been 2 folds.
3. Repeat steps 1 and 2, counting the number of folds that you perform.
4. Record the final number of folds, and repeat for the rest of the samples.
Surface pH
1. Using one of the halves from each sample, use a
pipette to drop a small quantity of DI water on
the strip.
2. Place a broad-range litmus paper strip in the
drop.
3. Compare the color of the strip to the package to
determine the pH of the sample.
4. Record your results and repeat for the rest of the
samples. Again, you only need to measure the
pH from one half of each sample.
Figure 7. Ensure a good
Analysis
fold by pinching the
strip

1. Average the results from each test.
2. Find the range of results for all tests. Was there significant variance in the
data you collected?
3. Do you think that the average pH of the samples would be dangerous to
ingest? What about the highest/lowest pH sample?
4. The average number of folds it takes to break a Sheets® brand strip was
found to be in the range of 15-20 folds. Does your average fall in this
range? If not, why do you think it didn’t?
5. What could be a dangerous consequence from a lot of variance in the
thickness of each sample? Would you sell the strips you made to
pharmacies?
Moisture Content Analysis
In this section, you will use the initial and final weights of the petri dish sample,
as well as an introductory energy balance, to find the energy required to dry the
sample and the amount of water remaining in the sample.
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1. Find the change in mass of the sample. Assume that the mass that
evaporated was 100% water.
2. Find the moisture content with the following equation:
[

(

)]

Where,
= final weight of the sample
= initial weight of the sample
3. You will now calculate the amount of energy required to evaporate all of
the water that was lost. This energy was transferred into the sample from
its surroundings, so the balance of energy transferred appears as such:

Where,
= energy required to dry the sample
= mass of water vaporized, (
)
= Latent heat of vaporization for water, 2260 kJ/kg
Make sure to watch your units!
4. Where do you think this energy came from?

QUESTIONS
1. For the following APIs, research the drug’s therapeutic value and
determine if a hydrophilic or hydrophobic polymer matrix would be best
suited for drug delivery:
a) Salbutamol
b) Zolpidem tartrate
c) Ondansetron
d) Fentanyl citrate
2. Your boss approaches you with a new design project. The
pharmaceutical company you work for has recently signed a contract with
a client, requiring that you produce 800,000 dissolvable strips/year of a
new API designed to treat the common cold. The API, referred to as DK12, is potent in very small doses, but degrades rapidly when it hits
stomach acid. Therefore, a dissolvable strip is the perfect method for
introducing the drug into the body. The film must be fast-dissolving.
a) Before any equipment can be decided upon, you must create the
formulation. The required ingredients are:
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 DK-12 (10% w/w)
 Water soluble polymer (40-50% w/w)
 Plasticizers (0-20% w/w)
 Sweetening agent (3-6% w/w)
 Saliva stimulating agent (2-6% w/w)
 Colors and flavors (1-10% w/w)
Find a suitable chemical for each of these components and compile
a list for your boss.
b) Now that you’ve selected the ingredients for the strip film, you have
to select whether you are going to use a hot-melt extruder or a
solvent casting system. The material dissolves easily in water and
polar solvents, and is not friable (does not degrade from heat). It
must be noted that since DK-12 is new, it is very expensive, and
therefore it is important to minimize wasted API. Explain your
reasoning.

REFERENCES
1. K. Mandeep, A. C. Rana and S. Nimrata, "Fast Dissolving Films: An
Innovative Drug Delivery System," International Journal of Pharmaceutical
Research & Allied Sciences, vol. 2, no. 1, pp. 14-24, 2013.
2. T. Kalra, M. Madhra, K. Gandhi, A. Dahiya and Khushboo, "Fast dissolving
film: A review," International Journal of Research in Pharmaceutical
Sciences, vol. 3, no. 4, pp. 542-551, 2012.
3. Particle Sciences, "Dissolving Films," Particle Sciences, vol. 3, 2010.

160

Appendix B
Instructor’s Versions of Laboratory Experiments
B.1 Tablet Statistical Analysis Lab
Tablet Statistical Analysis Lab – Instructor’s Version
Developed by: Alex Jannini, David Krause, Heather Malino and Kevin Sweeney,
Rowan University, Department of Chemical Engineering
Edited by: C. Stewart Slater and Mariano Savelski, Rowan University,
Department of Chemical Engineering
Date of Experiment:
OBJECTIVES


Students will perform a basic statistical analysis applied to an over-thecounter drug
 Students will learn about pharmaceutical engineering, including key terms
and concepts
INTRODUCTION
In the pharmaceutical industry, drugs are manufactured, produced, and marketed
for therapeutic use. The industry has been one of the highest earning industries
of the last decade, with 791 billion dollars in worldwide sales in 2010. The
majority of these sales were in North American companies, totaling 335 billion
dollars1.
A pharmaceutical product is not just one specific chemical, but many chemicals
combined together to make a final product. Tablets, which the students will be
working with in this lab, are composed of a few chemicals mixed together and
then compressed. The therapeutic ingredient is known as the active
pharmaceutical ingredient (API). The API is what causes the desired effect of
the drug. The rest of the ingredients that remain inert are known as the
excipients.
Excipients can have different functions, which is why there are sub-categories of
excipients found in pharmaceuticals. For example, a filler is a type of excipient
used to make up the volume of a medicine so that it can be taken in the form of a
pill. In some cases, excipients known as binders are used to act as glue and
make sure the ingredients stick together. Lubricants and glidants are used in
combination since they reduce wall friction and interparticle friction, respectively.
This prevents the tablet from clumping and sticking to equipment. Excipients
may also be flavors or colors, which will mask any unpleasant tastes that the
other ingredients have and improve the appearance of the product.
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In any engineering field, statistical analysis is an important tool. In the
pharmaceutical industry, statistics can be used in various ways. For example,
statisticians use statistics to create trials for experimental drugs. A chemical
engineer might use statistics in order to figure out a new process that creates
more product for less. In these cases, statistics play an important role in
analyzing data in order to come to a conclusion.
In this lab, the students will be looking at two different over the counter
medications that contain the API ibuprofen, a known pain reliever and fever
reducer. The rest of the inactive ingredients in the tablets are binders, fillers, or
any other kind of excipient. This lab will consist of a statistical analysis on the
difference in mass between the ibuprofen tablets, and also the difference in the
mass of a generic brand and the trademarked brand Advil®. An introduction to
creating a flow diagram will also be incorporated into this experiment.
MATERIALS NEEDED
 Container of Advil® tablets (minimum of 10 tablets)
 Container of generic ibuprofen tablets (minimum of 10 tablets)
 Weigh boat
 Tweezers
 Bench scale (accurate up to 1/1,000 g).
SAFETY CONSIDERATIONS
Always wear laboratory safety glasses when working in the lab.
PROCEDURE
1. Make sure that the bench scale is turned on, and that the scale is set to
measure weight in grams.
2. Take the Advil package and note where they list the active and inactive
ingredients. Record all of the ingredients that are listed as non-active
ingredients.
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Figure 1. Where to find the active and inactive ingredients

3. Place the weigh boat on the bench scale. Record the weight, and then
tare the instrument. The bench scale should now read 0 grams.
4. Open the box of Advil®, and with tweezers, place one tablet in the weigh
boat. You may use the table provided below, but you should also record
your findings in your lab notebook.
5. Once the mass has been recorded, tare the scale again.
6. Repeat the two previous steps until you have weighed ten Advil tablets.
Empty your weigh boat, place it back on the bench scale, and tare the
instrument. You should now have the Advil® portion of the data table filled
out.
7. Now, look at your generic brand. Record all the non-active ingredients.
8. Open the container, and using the tweezers, place one tablet in the weigh
boat. Once again, tare the instrument after recording the mass.
9. Repeat until you have collected ten measurements of the generic brand.
You should now have the generic brand portion of the data table filled out.
10. Once all measurements have been completed, dispose of the measured
tablets and the weigh boats. Return the containers to their respective
boxes.
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Table 1. Empty table for recording the mass of the tablets

Trial Number Name Brand Mass (grams) Generic Brand Mass (grams)
1
2
3
4
5
6
7
8
9
10

Figure 2. Proper technique for weighing tablets

STATISTICAL ANALYSIS
You will need your calculator to do the following calculations. You must show all
work to receive credit.
1. First, take the average of each set of data. Use the equation below, with i
being the trial number (given in the data table), n being the total number of
trials (10), and x being the mass recorded for the specific trial number.
Record this in your lab notebook and include in your results.
∑
(1)
̅
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2. Standard deviation is defined as the variation from the average. In other
words, it is the average of the difference between each value obtained and
the average value obtained. So, in this case, it would be important to
know the standard deviation of the mass of the tablets for the trademarked
brand and also the generic brand. To calculate the standard deviation,
use the equation below, with i once again being the trial number, n being
the total number of trials, and x being the mass recorded.
∑
√

(|

̅| )

(2)

3. Now, we will look for any outliers in our data. An outlier can be defined as
a data point significantly different than the mean of the data. In other
words, an outlier is a datum point that significantly distant from other
points. To do this, find the median data point in both sets of data. To find
the median, list the data in order from lowest value to highest value, and
find the point that resides in the middle. If you have an even number of
data points, the median is found by averaging the two middle data points.
From now on, this median (the median of the entire data set) is known as
overall median. From here, find the first and third quartiles. These
values are found by splitting the list of data in half. In this case, we now
have two sets of five data points; one with the lower data points, and the
other with the higher data points. The first quartile can be found by
taking the median of the lower data points. The third quartile is the
median of the higher data points. Lastly, we state that the overall median
is the second quartile. Using the equations below, calculate if any of
your data points are outliers.

(

)

(3)

Where, OL is the low-value outlier cutoff, Q1 is the first quartile, and Q3 is the third
quartile.

(
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)

(4)

Where, OH is the high-value outlier cutoff, Q3 is the third quartile, and Q1 is the
first quartile.
Are any weights you measured above OH or below OL? If so, they are outliers.
Arrange your findings in a box-and-whisker plot as described in the diagram
below.

Figure 3: A typical box-and-whisker plot.

RESULTS
Be sure to record all findings for this lab. Answer any questions that might
have been asked in the procedure section of the lab.
QUESTIONS
1. During the statistical analysis section, you were asked to find the standard
deviation of the trademarked and the generic brand. Explain what this
value tells you. Compare the two standard deviations you calculated, and
determine what this means.
2. Now, you will determine whether or not these two brands are different
from each other. To do this, you will use a statistical analysis technique
known as an F-test. An F-test is used to compare two samples. This test
can become difficult if the samples are not done in a similar manner. In
this case, the number of measurements taken in each sample is similar,
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so this makes the F-test much simpler. To conduct an F-test, do the
following:
a. Find the variance of the two samples. The variance of a sample is
defined as the average of the squared difference of the means. An
equation of what this would look like is shown below:

(5)

∑(

̅)
(6)

Another way of looking at the variance is it’s relation to the standard deviation of
a sample. The relation of the variance of a sample to the standard deviation of a
sample is shown below:
(7)
If you compare the equation of variance to the equation of standard deviation,
you can see how this is true. Use the relation between standard deviation and
variance to find a value of variance for the two samples.
b. Now, find the F-value for your experiment. To find your F-value,
use the following equation:
(8)

For this equation, the variance in the numerator “s1” has to be the larger of the
two variances.
c. Now, compare this value to a critical value. This is known as the Fcritical value. The F-critical value is dependent on the number of
measurements taken in each sample, and the percent confidence
that is desired. The percent confidence is another way of saying
how accurate one wishes to be in their experiments. The higher
the percent confidence, the more certain one is in their
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experiments. In this case, you will use a standard percent
confidence of 95%. So, you will need an F-critical value which
corresponds to a 95% percent confidence, a variance based on 10
measurements in the numerator, and a variance based on 10
measurements in the denominator. Usually, these would be looked
up in tables, as seen in appendix A Figure 1. However, below you
will find an critical F value for your calculations3:

If the F value you calculated in part b of this problem is larger than the critical
value given, then the two samples are significantly different. If the F value you
calculated in part c of this problem is smaller than the critical value given, then
the two samples are not significantly different. State whether or not there is
significant difference between the two samples .
3. Research suggests that one ibuprofen tablet should have a mass of 480
mg.2 Do you think there is significant difference between the values you
obtained and this literature value for a typical formulation? To answer this,
you will use another statistical test known as the t-test. There are several
different types of t-tests used in statistics. In this case, you will be using a
one-sample t-test, which compares a single mean to a fixed value. So for
this test, the fixed value will be the 480 mg. You will conduct a t-test on
both samples. In order to conduct this analysis, do the following:
a. For a t-test, you will need to find a t-value. The t-value for an
experiment relates the average, standard deviation, and number of
measurements to a given value. Using the symbols found
previously in this experiment, the equation for the t-value is as
follows:

|

|
√

(9)

In this case, μo will be the mass found in research (480 mg).
b. You will now compare this value to a critical value. This is known
as the critical t-value. Like the F-critical value, the critical t-value is
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dependent on the percent confidence that is desired and the
number of measurements taken in the sample. Again, you will use
a percent confidence of 95%. For an example of a t-Table, see
Appendix A Figure 2. The critical t-value you will be using is given
below3:

Just like with the F-test, if the critical t-value is higher than the value obtained
earlier, then there is no difference between your sample and the value from
literature. If the t-value calculated earlier is higher than the critical t-value, then
there is a significant difference between the sample and the value obtained from
literature. State whether or not there is significant difference between the value
obtained from experiments and the value obtained from literature.
c. Repeat this process for whichever sample you did not already
conduct the analysis on.
4. It has been estimated that the world production of ibuprofen is in the
vicinity of 15,000 tons per year.4 It has also been estimated that the
average price for one ibuprofen tablet is roughly 0.12 USD.5 Using this
information, calculate the total price of ibuprofen production for a year.
5. Remember that you listed the inactive ingredients from each of the
brands. Research the first three ingredients from both brands and state
what type of excipient you believe them to be (i.e. filler, preservative,
lubricant, etc.).
6. It is your first day on the job working for Pfizer and you are told to do an
experiment on the Advil production line. A new tablet press has been
installed and your boss wants to know if it is producing tablets with
consistent weight. To start your experiment, you pull a sample of 20
tablets off of the line and weigh them. The data is arranged in a table
below. Your boss tells you that each pill must be 90% to 110% of the
mean tablet size, which is 0.485 g. Do any pills in your sample fall outside
of these bounds? Furthermore, did you find any outliers in your sample?
What does this say about the consistency of the new pill press?
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Table 2: Experimental data from production line

Advil Sample - 20 Tablet weights (g)
0.4850
0.5198
0.5048
0.4857
0.4786

0.5435
0.4448
0.4668
0.4465
0.4835

0.4686
0.5211
0.4863
0.4217
0.4481

0.4837
0.5895
0.5227
0.4662
0.5101

7. You will now have an introduction to creating process flow diagrams.
These diagrams are an important part of engineering, as they are used in
most plants. A process flow diagram indicates the major equipment used
in a process. In this case, a box with a label will be acceptable as a piece
of equipment. An example is shown below:

A heater heats water from 10°C to 50°C:
HEATER

If you have more than one stream entering or exiting a process, multiple lines
can be drawn. For example, if a mixer blends water and titanium dioxide to make
a slurry the process flow diagram would look like:
TiO2

Mixer

Slurry

Water
a. Make a process flow diagram for the creation of the ibuprofen
tablets as described by the steps below:
i. Mix the powder (maize starch) for 15 minutes at high speed.
Add 10.67 g of cold water and check weight (theoretical
weight, 58.00g). If required adjust with hot water. Record
the quantity of extra water added.
ii. Mix this binding solution with Mixture 1 (Ibuprofen and maize
starch).
iii. Collect and spread the granules onto the trays, one third the
thickness of the tray.
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iv. Load the trolley into the oven and dry the granules in the
trays and change the position of the trays for uniform drying.
v. Mix stearic acid and corn starch separately and add to the
granules before sending them to a compressor. Compress
into 330-mg tablets, using 10-mm convex punches at 4 to 9
kPa.
vi. Put the tablets into the coating and rolling pan.
b. Make another process flow diagram that shows the coating of the
ibuprofen tablets as described by the steps below:
i. Make sugar coating:
1. Heat 72.0 g of item 6 (purified water) in mixer to
boiling.
2. Dissolve 168.0g of item 4 (sucrose) and then cool to
25°C.
3. Filter the syrup through a 180-µm stainless steel
sieve.
4. Dispense item 5 (titanium dioxide) into the sugar
syrup from the previous step and homogenize.
5. Check for evenness of the dispersion.
ii. Apply Sugar Coating to tablets in coating pan by rolling
tablets and slowly adding the sugar solution over 30
minutes.
iii. Make gloss solution
1. Melt items 1 - 3 (bee’s wax, polyethylene glycol,
carnauba wax) in a steam-heated vessel by gentle
heating to 70°C or in a stainless steel container on a
hotplate heater.
2. Mix thoroughly.
3. Pass the mixture through a homogenizer.
4. Store the polishing emulsion in a closed container at
room temperature.
iv. Apply gloss solution to tablets in coating pan by rolling
tablets. Once the desired polish appears, stop rolling the
pan.
v. Dry the tablets in the pan at 30°C for 30 minutes. Final
tablet weight should be 480 mg.
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ANSWER KEY
PROCEDURE
2. Take the Advil package and note where they list the active and inactive
ingredients. Record all of the ingredients that are listed as non-active
ingredients Ans: On the container of a bottle of Advil purchased
November 2012, the inactive ingredients listed were acetylated
monoglycerides, colloidal silicon dioxide, corn starch, croscarmellose
sodium, methylparaben, microcrystalline cellulose, pharmaceutical glaze,
pharmaceutical ink, povidone, pregelatinized starch, propylparaben,
sodium benzoate, sodium lauryl sulfate, stearic acid, sucrose, synthetic
iron oxide, titanium dioxide, and white wax.
7. Now, look at your generic brand. Record all the non-active ingredients.
Ans: This answer will vary depending on the generic brand that was purchased
for this experiment. For a bottle of CVS Pharmacy® brand ibuprofen tablets
purchased November 2012, the non-active ingredients are carnauba wax, corn
starch, and fumed silica gel, hypromellose, lactose, magnesium stearate,
microcrystalline cellulose, polydextrose, polyethylene glycol, red iron oxide,
sodium starch glycolate, stearic acid, and titanium oxide.
STATISTICAL ANALYSIS
These calculations were done using the following table of data.
Table 3. Sample data used for the answer key section of this guide.

Trial
Number
1
2
3
4
5
6
7
8
9
10

Name Brand Mass
(grams)
0.4784
0.4837
0.4715
0.5019
0.4840
0.4842
0.5050
0.4930
0.4804
0.4845

Generic Brand Mass
(grams)
0.3354
0.3300
0.3296
0.3280
0.3383
0.3284
0.3307
0.3365
0.3272
0.3362

1. First, take the average of each set of data. Record this in your lab
notebook and include in your results.
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Ans: The average for the Advil data was found to be 0.487g. The average for
the generic brand was found to be 0.332g.
2. Standard deviation is defined as the variation from the average. In other
words, it is the average of the difference between each value obtained and
the average value obtained. So, in this case, it would be important to
know the standard deviation of the mass of the tablets for the trademarked
brand and also the generic brand.
Ans: The standard deviation for the Advil data was found to be 0.010g. The
standard deviation of the generic brand was found to be 0.004g.
3. Are any weights you measured above OH or below OL? If so, they are
outliers. Arrange your findings in a box-and-whisker plot as described in
the diagram below. (Omitted from solutions, see above for diagram.)
Ans: FOR THE ADVIL® BRAND:
(

)

;

;

(

)

Since the minimum value in this data set is 0.4715 g, a low-value outlier does not
exist.

(

)

Again, all data points are less than this number, so a high-value outlier does not
exist. A Box-and-Whisker plot of this is shown below.

®

Figure 4. Box-and-Whisker plot for the Advil brand. The x-axis here is
the mass of the ibuprofen tablets in grams.
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FOR THE GENERIC BRAND:
(

)

;

;

(

)

Since the minimum value in this data set is 0.3272 g, a low-value outlier does not
exist.

(

)

Again, all data points are less than this number, so a high-value outlier does not
exist. The Box-and-Whisker plot is shown below.

Figure 5. Box-and-Whisker plot for the generic brand. The x-axis here is
the mass of the ibuprofen tablets in grams.

QUESTIONS
1. During the statistical analysis section, you were asked to find the standard
deviation of the trademarked and the generic brand. Explain what this
value tells you, and why it is important. Compare the two standard
deviations you calculated, and determine what this means. Ans: As stated
in this lab, the standard deviation of the variation from the average. This
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shows the precision of each of the brands. If a brand has a lower
standard deviation, then it is more precise. From the statistical analysis
section, the generic brand had a smaller standard deviation. This means
that the process used to make the generic brand is more precise.
2. Now, you will determine whether or not these two brands are different
from each other. To do this, you will use a statistical analysis technique
known as an F-test. Ans: The answers for each piece are as follows:
a) The variance for the Advil® brand was found to be 9.72E-05, while the
generic brand was found to have a variance of 1.52E-05.
b) The F-value was found to be 40.63.
c) Since the F-value calculated was higher than the F-critical value given,
there is significant difference between the two brands at 95%
confidence.
3. Research suggests that one ibuprofen tablet should have a mass of 480
mg.2 Do you think there is significant difference between the values you
obtained and this literature value for a typical formulation? To answer this,
you will use another statistical test known as the t-test. Ans: The answer
for each piece are as follows:
a) For the Advil® brand, the experimental t-value was found to be 2.14.
b) Since the critical t-value is higher than the experimental t-value, there
is no significant difference between the literature value and the Advil®
brand.
c) For the generic brand, the experimental t-value was found to be
119.79. Since this value is considerably higher than the critical t-value,
there is significant difference between the value obtained from
literature and the generic brand value.
4. It has been estimated that the world production of ibuprofen is in the
vicinity of 15,000 tons per year.4 It has also been estimated that the
average price for one ibuprofen tablet containing 200 mg of ibuprofen is
roughly 0.12 USD.5 Using this information, calculate the total price of
ibuprofen production for a year. Ans: To determine the price of ibuprofen
production, this was done:
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5. Remember that you listed the inactive ingredients from each of the
brands. Research the first three ingredients from both brands and state
what type of excipient you believe them to be (i.e. filler, preservative,
lubricant, etc.).
Ans: The answer to each of the ingredients is as follows:
FOR THE ADVIL® BRAND:
1) The first listed inactive ingredient was acetylated monoglycerides.
According to Lipid Technologies and Applications, this ingredient is
often used as a coating ingredient.6
2) The second inactive ingredient, colloidal silicon dioxide, is also known
as silicon dioxide or silica. In nature, it is also known as sand or
quartz. According to Pharmaceutical Dosage Forms: Tablets, a
compendium of information on tablets, colloidal silicon dioxide is often
used as a glidant.7
3) The third inactive ingredient listed was corn starch. As described in
the excipients catalog on PharmaHUB.org, corn starch consists of the
starch granules separated from the mature grain of corn. This
excipient can fit into many categories, including binders, diluents, and
disintegrants.8
FOR THE GENERIC BRAND:
1) The first listed non-active ingredient listed on the CVS® brand was
carnauba wax. Carnauba wax is also known as palm wax or Brazil
wax, and comes from the leaves of a palm tree grown only in Brazil.
According to About.com, carnauba wax is often used as a coating
agent for candies and also for cars. Likewise, it is most likely used to
coat the tablet.9
2) The second listed non-active ingredient was corn starch. As stated in
number 3) of the Advil section of this answer, it is used as a
disintegrant, binder, or diluent.8
3) The third non-active ingredient listed was fumed silica gel. What
makes fumed silica gel unique is that it has a rather large surface area.
Fumed silica gel has many applications, but in this case, it is probably
used as a thickening agent, or a thickener.10
6. Do any pills in your sample fall outside of these bounds? Furthermore, did
you find any outliers in your sample? What does this say about the
consistency of the new pill press?
Ans: By taking the percent error of each data point from the average point of
0.4850 grams, we find that three tablets are out of the speculated range. The
equation used and the percent error for each point is shown below.
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Table 4. Percent error of each of the mass samples. The rows and columns correspond
to the same points as seen in the questions section.

0.000 12.062 3.381 0.268
7.175 8.289 7.443 21.546
4.082 3.753 0.268 7.773
0.144 7.938 13.052 3.876
1.320 0.309 7.608 5.175
Through outlier testing, one outlier was found. Through the use of the quartiles,
the following values were calculated:

Median
First Quartile
Third Quartile
OL
OH

0.4844
0.4665
0.5150
0.3938
0.5876

Through these values, we find one outlier. The data point 0.5895 is larger than
the OH value, and therefore an outlier to the series. A Box-and-Whisker plot was
developed, and shown below.
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Figure 6. Box-and-Whisker plot for Problem 6. The x-axis here is the
mass of the ibuprofen tablets in grams. One outlier is clearly visible in
this plot.

This tells us that this pill press is not consistent enough for the product
specifications and is not precise enough to produce no outliers.
7. For this exercise, read the following description on the creation of
ibuprofen tablets, and then create a process flow diagram of the process.
Ans: After reading the description, the following flow diagrams were made:
a.

Figure 7. Solution to part a) of Question 7.
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b.

Item 6

Figure 8. Solution to part b) of Question 7.
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B.2 Fluidization of Pharmaceutical Excipients Lab
Fluidization of Pharmaceutical Excipients – Instructor’s Guide
Developed by: Alex Jannini, David Krause, Heather Malino and Kevin Sweeney,
Rowan University, Department of Chemical Engineering
Edited by: C. Stewart Slater and Mariano Savelski, Rowan University,
Department of Chemical Engineering
Date of Experiment:
OBJECTIVES




Students will fluidize a pharmaceutical excipient, and learn about the
variables affecting fluid-particle transport
Students will construct and interpret fluidization graphs using experimental
data
Students will gain experience using the online literary search engines

INTRODUCTION
A fluidized bed occurs when solid
particulate matter is put under specific
conditions that allow it to behave as a
fluid. This is usually performed in some
sort of vessel and achieved through the
use of a pressurized fluid, such as air.
Some of the properties that the particulate
matter has in its fluidized state include the
ability to be transported in a manner that
is similar to other fluids. This
phenomenon is called fluidization.
Fluidization and fluidized beds are used in
several different industries for several
different purposes.

Solid
Particles

Gas

In fluidization, there are many different
variables that need to be considered. If one
Figure 1: Simple schematic of a
was to design a fluidized bed, equipment
fluidized bed
parameters such as the pressure of the
incoming fluid, the flow rate of the incoming
fluid, and the temperature of the system would need to be part of the design
process. In addition, the material that is to be fluidized will also need to be
investigated. Material properties such as particle size, density, and porosity (also
known as the void fraction, or the fraction of empty space in a packed vessel) are
important when designing a fluidized bed.
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As the solids are fluidized, they behave as common fluids. As such, flow
variables can be investigated with the moving particles. One such variable is
called pressure drop. Pressure drop is the difference in pressure between two
points along the path of fluid movement in the process. Pressure drop is caused
by frictional forces, resistances to the flow, as the fluid flows through the vessel.
In the pharmaceutical industry, fluidized beds have many different applications.
Initially, fluidized beds were mainly used for the drying and coating of solids 1.
Granulation, the act of forming or crystallizing substances into grains or granules
in fluidized beds, was later investigated for pharmaceutical purposes. 1
Fluidization can also be used for the transportation of solids, as the fluidized
solids can be transported via pipes rather than conveyer belts or in discrete
amounts1.
In this experiment, you will be investigating four different variables of a fluidized
bed; air flowrate, air pressure, pressure drop, and bed height. You will then use
the data you collected to perform some fluidized bed calculations. By the end of
this experiment, you should have a better understanding on how fluidization
occurs, and why it is an important aspect of pharmaceutical manufacturing.
MATERIALS NEEDED
PART I
 250 mL plastic graduated cylinder
 1000 mL plastic graduated cylinder
 Bench scale capable of reading at least 1 kg
 Avicel® PH 200
 Kaolin powder
 DI water
 Stirrer
PARTS II & III
 Fluidized bed filled with Avicel® PH 200
 Ruler
INSTRUCTOR’S NOTE
As part of a pre-lab assignment, have the students obtain a material safety data
sheet (MSDS) for both kaolin and Avicel® PH 200. Any Avicel® may be accepted,
but additional literature will be needed for future problems. This lab uses
fluidized beds that are described in the Hesketh et al. article, “Fluidized Bed
Polymer Coating Experiment.”2 This article describes how to create fluidized bed.
SAFETY CONSIDERATIONS
Laboratory goggles must be worn at all times when in the laboratory. Laboratory
gloves and a dust mask must be worn if handling pharmaceutical powders.
Obtain and read the MSDS on Avicel® PH 200 and kaolin.
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PROCEDURE
PART I – DETERMINING BULK AND PARTICLE DENSITIES
1. Begin by placing the empty 250 mL graduated cylinder on the bench
scale. Tare the instrument.
2. Place approximately 50 to 60 grams worth of one of the powders into the
graduated cylinder. If you are a little over or under, that is fine, as long as
the powder does not surpass a measureable level on the graduated
cylinder. You may have to use a scoop or a beaker to do this.
3. Record both the mass of the powder you added to the cylinder, and how
much volume it takes up. Use these values to calculate the bulk density
by dividing the mass added by the volume it takes up. Set aside this
graduated cylinder.
4. Now, fill the 1000 mL graduated cylinder with DI water to around the 700
to 800 mL mark. Again, this does not need to be precise. Record the
volume of water you added.
5. Place the graduated cylinder filled with water on the bench scale, and
once again tare the instrument.
6. Slowly, add the powder from the small graduated cylinder into the large
one. You may need to stir the solution at intervals of the pouring process
so that all the particles are suspended. Remember that you do not want
to surpass the readable levels of the graduated cylinder.
7. Once the particles have been poured in, stir the mixture thoroughly, but
carefully. You do not want to lose any of the water. Once stirred, place
back on the scale bench and record the mass of the powder you added to
the water. Also, record the new volume of the water and powder mixture.
8. Now, find the particle density. The particle density is the mass of the
powder added to the water and the volume taken up by the particles. You
can determine the volume taken up by the particles by subtracting the
volume of water from the volume of the mixture.
9. Do this for the other powder. Make sure that you clean and dry the
graduated cylinders thoroughly, and use new cylinders before starting to
work with the new powder. You may use the following table to record your
findings, but you should copy this table into your lab notebook.
Table1. Empty table for recording data during the fluidization lab.

Measurement
Mass of substance (g)
Volume of substance (mL)
Bulk density (g/cm3)
Volume of water (mL)
Volume of mixture (mL)
Volume of particles (mL)
Mass of substance (g)
Particle density (g/cm3)

Kaolin
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Avicel PH 200

PART II – THE FLUIDIZED BED
1. The first step in running these experiments is to become acquainted with
the equipment. First, briefly look over the equipment and the station in
front of you. Note where your pressurized air is coming from.
2. After investigating your system, measure the inner diameter of the
fluidized bed. You will need this for calculations later.

Figure 2. Laboratory scale fluidized bed.

PART III – SUBSTANCE INVESTIGATIONS
1. After becoming familiarized with your equipment,
you may begin testing. Begin by measuring the
height of the fixed
bed.
2. Set the incoming air
at a pressure of 60
pounds per square
inch (psi). Make
sure that the
flowmeter is closed,
but the air valve is
open (make sure you
Figures 3 and 4. From left to right; the inlet air valve
know which is
and the flow meter used in the fluidized bed setup.
which!).
3. With the inlet air
pressure at 60 psi, open the flowmeter and slowly raise the flow rate of the
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4.
5.

6.
7.

incoming air to 5 gallons per minute (gpm). At this reading, take a
pressure drop measurement and a bed height measurement.
Once the measurements have been recorded, increase the air flow rate by
5 gpm. Again, measure the pressure drop and the bed height.
Repeat this until you reach 30 gpm. Now, increase the intervals to 10
gpm. If you notice plug flow, bubbling, or channeling in the fluidized bed,
record the flow rate and pressure drop, but make a note of the
phenomenon that occurred. Also, it might be necessary to check on the
air pressure periodically during the experiment. You should make sure
this is done before taking any measurements.
Once you have taken the pressure drop and bed height at the maximum
flow rate of air, bring the flow rate back down to zero.
Complete the same steps as above, but now using an air pressure of 100
psi. You may use the tables below to record your data, but you should
also copy your data into your lab notebook.

Figure 5. Plug flow occurring in
the fluidized bed.
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Table 2. Empty data table for recording pressure drop at an air pressure of 60 psi and bed
expansion in the fluidization lab

Air Pressure of 60 psi
Flow Meter Reading (gpm) Pressure Drop (in H2O)

Bed Expansion
(inches)

0
5
10
15
20
25
30
40
50
60
70
80
90
100
Table 3. Empty data table for recording pressure drop at an air pressure of 60 psi and bed
expansion in the fluidization lab

Air Pressure of 100 psi
Flow Meter Reading (gpm) Pressure Drop (in H2O)
0
5
10
15
20
25
30
40
50
60
70
80
90
100

RESULTS
Record all results in your lab notebook.
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Bed Expansion
(inches)

QUESTIONS
1. Based on your results, what was the point of minimum fluidization (the
point where fluidization was first noticed) for both of the data sets? What
does this tell you about air pressure when it comes to minimum
fluidization? Does this mean that air pressure is a negligible variable
when it comes to fluidization? Why or why not?
2. You will make a graph of the air flow rate versus the bed height (this
means that the air flow rate is on the x-axis and the bed height is on the yaxis) for both of the air pressures. Using the graph, determine when the
bed goes from behaving as a packed bed to a fluidized bed.
3. Prepare a fluidization graph. A fluidization graph is obtained by plotting
the air flow rate versus the pressure drop. When you make these graphs,
there will be a change in the slope at a certain point. This point is known
as the point of minimum fluidization. At this point, the bed of solids
changes from behaving like a packed bed to behaving like a fluidized bed.
Label where you believe this point is on the graphs you made. Also label
what sections of the graph model the packed bed behavior and fluidized
bed behavior.
4. For this experiment, we have delved into some of the properties of fluid
mechanics, a branch of science that deals with the properties of fluids and
some of the phenomenon that occurs when they are placed under certain
conditions. One of the first variables you will learn in fluid mechanics is
known as the Reynolds Number, a dimensionless quantity that is used to
determine a flow regime. Today you will determine the Reynolds number
of the system at minimum fluidization. To do this, you will use the
following formula:
(1)
a. The Reynolds Number is considered a dimensionless quantity.
This means that there are no units attached. Prove this with the
following information:
= Average diameter of the particle (m)
= Velocity of minimum fluidization (m/s)
= Density of the gas (kg/m3)
= Dynamic viscosity of the gas (Pa*s)
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b. Find the Reynolds number for the minimum fluidization point for
both of your experimental runs. To help you in the calculation of this
number, use the following values3,4,5:
(

)
⁄
⁄

In addition, determine which of the fluidization regimes the fluidized
bed was in at minimum fluidization based on the figure below.

Figure 6. A few fluid regimes of fluidized beds.
Adapted from Perry’s Chemical Engineering
6
Handbook.

5. The following fluidization data was collected using kaolin powder with the
same apparatus (same dimensions) at an air pressure of 60 psi:
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Table 4. Fluidization data using kaolin powder at an air pressure of 60 psi

GPM Bed Height (in.) ΔP (psi)
0
5.00
0.0
5
5.00
0.5
10
5.00
1.8
15
5.50
1.8
20
5.75
2.4
25
5.75
2.4
30
6.00
2.5
40
6.00
2.8
50
6.50
3.2
60
6.50
3.6
70
6.50
3.8
80
6.75
4.1
90
6.75
4.2
100
6.50
4.6

a. Create a flow rate versus bed height graph and a flow rate versus
pressure drop graph.
b. Determine if there is a point of minimum fluidization using the
graphs.
c. If you could determine a point of minimum fluidization, determine
the Reynolds number at that point. If not, find the Reynolds
number at the same point you used for Question 4. Use an
average particle diameter of 1.4 µm for this problem.7
6. Now, we will go over another important tool for engineers; design
equations. Design equations are used by engineers to determine
information about a process without having to do extensive
experimentation. These equations are usually based on data obtained by
research. For example, the following equation can be used to determine
the Reynolds number at minimum fluidization8:
√(

)

Where Ar (Archimedes Number), C1, C2, are shown below:
(
)
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(2)

(3)

(

)

(4)
(5)

Where:
= Average diameter of the particle (m)
= Density of the gas (kg/m3)
= Particle density of the excipient (kg/m3)
= Acceleration due to gravity (9.81 m/s2)
= Dynamic viscosity of the gas (Pa*s)
In order to use the equations above, you will need to determine the
porosity at minimum fluidization (εmf). This can be a difficult characteristic
to determine, which is why many researchers have come up with different
constants to approximate the porosity.9 However, we have enough
information to determine εmf, so we will solve for C1 and C2.
To determine εmf, we first need to know the normal porosity, ε. This can
be determined by using the bulk density (ρb) and the particle density (ρs):
(6)
We also have to determine the total volume (Vtot). For this, use the bed
height at the 0 gpm air flowrate, and multiply by the cross-sectional area of
the bed. Now, we can determine the void volume (Vv) using the following
equation:
(7)
Now, to determine the volume occupied by the particles (Vp):
(8)
From here, we now need to use the point of minimum fluidization to
determine the volume (Vmf). This can be done by using the bed height at
the point of minimum fluidization and the cross-sectional area. Using Vmf,
you can determine the void volume at minimum fluidization (Vvmf):
(9)
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Finally, determine εmf:
(10)
e) Determine εmf for the Avicel® trial at the air pressure of 60 psi.
f) Determine the Remf using Equation (2) for the same conditions as part
a).
g) Calculate the percent difference between your answer for part b) and
the answer you obtained in Question 4.
|

|

(

)

(11)

h) You should notice a considerable (>10%) difference in part c). This is
because you are using superficial velocity, as opposed to interstitial
velocity. Superficial velocity is defined as the theoretical flow through
the bed based on the flow rate of the liquid divided by the cross
sectional area of the tube. Interstitial velocity takes into account how
the flow is affected by the volume occupied by particles. Interstitial
velocity is the flow velocity post a particle, and is the “correct” velocity
to use in the Remf equation. To determine the interstitial velocity (vi):
(12)
Where:
= volumetric flow rate at minimum fluidization (m3)
= cross sectional area (m2)
= porosity at minimum fluidization (dimensionless)

Determine vi, calculate a new Re as in Question 4, and then compare
as in part c).
7. It is important to learn how to use the online library tools that you have
available. These online tools have thousands of scientific papers and
articles in databases that you have free access to. Using one of the
scientific online resources (i.e. Science Direct, SciFinder, etc.) available,
you and your lab partners will find an article online about pharmaceutical
manufacturing practices. Try to find an article that also discusses either
fluidization or fluidized beds. Print out the article, and as a group, be
prepared to discuss the article in class. NOTE: It is all right if you do not
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understand all of the technical details of the paper, but you should have a
good understanding of the overall concept being discussed.
In addition, use the MSDS’s that you obtained as part of your pre-lab and
any other literature to compare the bulk densities that you found in part I of
the experiment.
ANSWER KEY
The data below was used in answering the questions.
Table 5. Sample data collected to carry out calculations for the questions below.

Measurement
Mass of substance (g)
Volume of substance (mL)
Bulk density (g/cm3)
Volume of water (mL)
Volume of mixture (mL)
Volume of particles (mL)
Mass of substance (g)
Particle density (g/cm3)

Kaolin
61.5
220
0.2795
850
875
25
61.25
2.450

Avicel PH 200
63.67
177
0.3597
700
740
40
63.40
1.585

Table 6: Sample fluidization data at 60 psi used for calculations.

Air Pressure of 60 psi
Flow Meter Reading (gpm) Pressure Drop (in H2O)
0
5
10
15
20
25
30
40
50
60
70
80
90
100

0.00
0.30
0.65
1.00
1.40
1.85
2.20
2.50
2.80
3.00
3.40
3.80
4.00
4.40
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Bed Expansion
(inches)
4.75
4.75
4.75
4.75
4.75
4.75
4.75
5.25
5.50
5.75
6.00
6.25
6.50
6.50

Table 7. Sample fluidization data at 100 psi used for calculations.

Air Pressure of 100 psi
Flow Meter Reading (gpm) Pressure Drop (in H2O)
0
5
10
15
20
25
30
40
50
60
70
80
90
100

0.00
0.20
0.60
0.90
1.20
1.60
2.00
2.40
2.80
3.10
3.40
3.80
4.00
4.40

Bed Expansion
(inches)
5.25
5.25
5.25
5.25
5.25
5.00
5.00
5.25
5.50
5.75
6.00
6.25
6.25
6.50

In both cases, channeling occurred after reaching 60 gpm, which could not be
stopped. Increasing agitation of the bed was seen in the 70-100 gpm data
points. The 60 air pressure could not move past the flow rate of 70 gpm.
1. Based on your data, what was the point of minimum fluidization (the point
where fluidization was first noticed) for both of the data sets? What does
this tell you about air pressure when it comes to minimum fluidization?
Does this mean that air pressure is a negligible variable when it comes to
fluidization? Why or why not? Ans: This may vary from group to group.
Using the data above, the point of fluidization was at approximately 40
gpm for both sets of data. From the data, it would appear that air pressure
doesn’t affect the minimum fluidization requirement of the particles. This
does not mean that the air pressure is a negligible variable when it comes
to fluidization, however. As shown in the data, the air pressure does limit
the flow rate of air through the system. The flow rate of air is known to
affect the fluidization of the particles. Therefore, the air pressure does
influence the fluidization of the particles.
2. The following graph was made. It is easy to see when fluidization occurs
because it is at that point that the bed height starts to increase. When the
air pressure was at 100 psi, the bed height was shown to decrease at 2
points, 25 and 30 gpm, before increasing. This could have been because
the powder was channeling, and the students shook the column to disrupt

193

the channeling. This shaking also settled the particles, decreasing the
bed height.
7.0

Bed Height (in)

6.5
6.0
5.5

Air Pressure
@ 60 psia

5.0

Air Pressure
@ 100 psia

4.5
4.0
0

20

40

60

80

100

120

Air Flow Rate (gpm)
Figure 7. Air flow rate versus the height of the bed. Here, we
can see that the bed fluidizes as the bed height increases.

3. You will need to make a fluidization graph. A fluidization graph is obtained
by plotting the air flow rate versus the pressure drop (this means that the
air flow rate is on the x-axis and the pressure drop is on the y-axis). Label
the parts of the graph. Ans: From the data above, the following graph
was made.
5.0
Pressure Drop (in. H2O)

4.5

Packed
Bed

4.0

Fluidized
Bed

3.5

Air Pressure
@ 60 psia

3.0
2.5
2.0

Air Pressure
@ 100 psia

1.5
1.0
0.5
0.0
0

20

40

60

80

100

120

Air Flow Rate (gpm)
Figure 8. Air flow rate versus the pressure drop. The black line was added
to show where the students thought that the packed bed starts to behave as
a fluidized bed.
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When we graph the data, it would appear that the two sets have the same
point of minimum fluidization (around 35 gpm).
4. One of the first variables you will learn in fluid mechanics is known as the
Reynolds Number, a dimensionless constant that is used to determine a
flow regime.
a. The Reynolds Number is considered a dimensionless quantity.
This means that there are no units attached. Prove this. Ans:
Using the table of information given, we plug in all the units for the
different variable that determine the Reynolds Number:
( ) (

)

(
(

(

)

(

)

)
)

(
(

)
)

As shown, the unit will cancel out, making the Reynolds Number a
dimensionless quantity.
b. Find the Reynolds number for the minimum fluidization point for
both of your experimental runs. Ans: Through the calculations, it
was found that the Reynolds number for the two experimental runs
was as follows.
Reynolds Number at 60 psi: 15
Reynolds Number at 100 psi: 27
The first, and not entirely correct, way to solve this is to use the
cross-sectional area of the cylindrical bed. Taking the minimum
fluidization flow rate and dividing that number by the cross-sectional
area to obtain the minimum fluidization velocity, as shown below. It
should be noted that this is based on superficial velocity, and is not
necessarily an accurate model for what is happening in the system.

(
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)

⁄

The density of air is converted from pounds per cubic feet to
kilograms per cubic meters, as shown below.
⁄
⁄
Now, to find the Reynolds number at 60 psi:
⁄

⁄

Based on the figure given, the minimum fluidization point is in the
particulate fluidization regime in both instances.
5. Using the data provided, do the following:
a. Create a flow rate versus bed height graph and a flow rate versus
pressure drop graph.
Ans: Using the data provided, the following graphs were created.
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Bed Height (in)

a)

7.0
6.5
6.0
5.5
5.0
4.5
4.0
0

20

40

60

80

100

Air Flow Rate (gpm)

5.0
Pressure Drop (psi)

b)

4.0
3.0
2.0
1.0
0.0
0

20

40

60

80

100

Air Flow Rate (gpm)

Figure 9. a) Air flow rate versus bed height for the
kaolin powder. b) Air flow rate versus pressure drop
for the kaolin powder.

b. Determine if there is a point of minimum fluidization using the
graphs.
Ans: From the graphs above, it is slightly difficult to determine
when the particle starts to behave like a fluidized bed. Using the
graph, it is estimated that the point of minimum fluidization occurs
at 20 gpm.
c. If you could determine a point of minimum fluidization, determine
the Reynolds number at that point. If not, find the Reynolds
number at the same point you used for Question 4.
Ans: Using the same equations as in Question 4, the Reynolds
number was found. Again, this is not entirely correct because we
are using a superficial velocity, so this may not be the most
accurate model.
⁄
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⁄

6. Now, we will go over another important tool for engineers; design
equations. Design equations are used by engineers to determine
information about a process when only limited information is given.
a) Determine εmf for the Avicel® trial at the air pressure of 60 psi.
Ans: First, use Equation (6):

Now, determine Vv using Equation (7):

To determine Vp, use Equation (8):

Solving for Vvmf using Equation (9):

Finally, determine εmf using Equation (10):

b) Determine the Remf using Equation (2) for the same conditions as part
a).
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Ans: We begin by finding Ar, C1, and C2 using Equations (3), (4), and
(5), respectively:
(
(

)
⁄

)

⁄

(

⁄

(

(

√(

)

)

)

(

)

)

)

√(

c) Calculate the percent difference between your answer for part b) and
the answer you obtained in Question 4.
Ans: Using Equation (11):
|

|

|

|

(

)

(

)

This large difference is mainly because the Remf equation should use
the interstitial velocity (vi).
d) Determine vi, calculate a new Re as in Question 4, and then compare
as in part c).
Ans: Using Equation (12):

Determining the new Re from Equation (1):
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⁄

⁄

⁄

Calculate the percent difference using Equation (11):
|

|

|

|

(

)

(

)

Using the correct velocity, the percent error decreases significantly.
7. Using one of the scientific online resources (i.e. Science Direct, SciFinder,
etc.) available, you and your lab partners will find an article online about
pharmaceutical manufacturing practices. Try to find an article that also
discusses either fluidization or fluidized beds. In addition, use the MSDS’s
that you obtained as part of your pre-lab and any other literature to
compare the bulk densities that you found in part I of the experiment.
Ans: On August 1, 2013, a Science Direct search was made with the
keywords pharmaceutical manufacturing and fluidization. A screenshot is
shown below.

Figure 10. A screenshot of the Science Direct search.

The articles found by the groups of students should be discussed on the
day that the laboratory report is turned in. Try to give each group of
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students roughly five minutes to discuss their paper. You might find it
helpful to have the students notify you in advance of their choice, so as to
limit the amount of repeating reports.
Using other literature sources, it was determined that the density of kaolin
was in the range of 1.8 to 2.6 grams per cubic centimeter (g/cc).10 For
Avicel® PH 200, the bulk density was found to be in the range of 0.29 to
0.36 g/cc.11 While the kaolin value found in experimentation was smaller
than specified by the literature, it could still be correct, as the density given
was not specified as either bulk or particle density. If considered particle
density, then the laboratory findings are still within range.
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B.3 Asthma Drug Delivery Lab
Asthma Drug Delivery Laboratory Experiment – Instructor’s Guide
Developed by: Alex Jannini, David Krause, Heather Malino and Kevin Sweeney,
Rowan University, Department of Chemical Engineering
Edited by: C. Stewart Slater and Mariano Savelski, Rowan University,
Department of Chemical Engineering
Date of Experiment:
OBJECTIVES
 Students will learn
about intrusive
laboratory experiments
 Students will gain
experience in reverse
engineering strategies
and project designs
 Students will conduct a
basic quality control
analysis operation
Figure 1: Diagram of the dry powder inhaler
INTRODUCTION
ADVAIR® is a dry powder
inhaler prescribed to patients with asthma and chronic obstructive pulmonary
disease that uses two active pharmaceutical ingredients. Fluticasone propionate,
one of the two, is a corticosteroid, which is used to reduce the inflammation of
the lungs. Salmeterol xinofoate, the second, is a bronchodilator, which relaxes
the muscles in the airways to help improve breathing.1

ADVAIR® is not only used as an option for people with asthma, but also can be
used as a maintenance treatment for chronic obstructive pulmonary disease.¹
Chronic obstructive pulmonary disease (COPD) is a disease that makes it difficult
to breathe. It also takes the form of chronic bronchitis, causing a long-term
cough with mucus, and emphysema, which destroys the lungs over time. Most
sufferers of COPD have a combination of the two symptoms.² Asthma occurs
when the airways of the lungs tighten and narrow, which leads to wheezing,
shortness of breath, coughing, and a tightening in the chest.³
ADVAIR® comes in three varieties: ADVAIR DISKUS® 100/50; ADVAIR DISKUS®
250/50; ADVAIR DISKUS® 500/50. The three varieties of ADVAIR® have
different amounts of fluticasone propionate in the powder. For example, in an
ADVAIR DISKUS® 100/50, there will be 100 μg (micrograms) of fluticasone
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propionate and 50 μg of salmeterol. The 250/50 prescription of ADVAIR® is used
for COPD treatment.¹
In this lab, the teams will be examining an ADVAIR DISKUS®, and conduct an
invasive reverse engineering experiment on the diskus. They will then compare
the dry powder inhaler to two other types of inhaled medication transport
systems; a nasal spray and a traditional metered dose inhaler. The goal is to see
the difference in the transport process that each system uses, and to also see if
there is any way to improve the design of the diskus. A quality control study on
the packaging of powder in the ADVAIR DISKUS® is also provided. This will
include an average and a standard deviation of the powder packages.
INSTRUCTOR’S NOTE
All of these forms of drug delivery can be
purchased online. It may also be possible to
obtain these through the companies that
make them. GlaxoSmithKline is the creator
of the ADVAIR DISKUS®, and may be
contacted for assistance. They may be
contacted through the following website:
https://www.contactus.gsk.com/callback.html.
Figure 2: Removal of outer shell

MATERIALS NEEDED
● ADVAIR DISKUS®
● Small flathead screwdriver
● Analytical scale (able to read
at least 1/10,000g)
● Albuterol metered dose
inhaler (or suitable substitute)
● Fluticasone propionate nasal
spray (or suitable substitute)
● Narrow-headed spatula
●
●

KimWipes
Weigh boats

Figure 3: Proper removal of mouthpiece

SAFETY CONSIDERATIONS
All students should know that laboratory gloves and eyewear must be worn at all
times to protect from sharp edges and medicines.
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PROCEDURE
PART I - REVERSE ENGINEERING
1. Open up the diskus box and remove the information packets. Make
general observations on the diagrams and information included.
2. Remove the inhaler from the tinfoil package. Based on its outside
appearance, how do you think it works? Sketch the diskus.
3. With the flathead screwdriver, proceed to remove the outer shell of
the inhaler. Be careful to not
break or shatter any plastic.
4. Insert the screwdriver
under the mouthpiece and use it
as a lever to dislodge the
mouthpiece.
5. Along the outside
circumference of the diskus you
will notice several slots and tabs
that hold each half of the inhaler
together. One by one, carefully
Figure 4: Proper depression of the tabs
depress each tab and pry the inhaler open.
6. This should expose the inside of the
inhaler. Make observations on its
appearance and the gears. Sketch the
inside of the diskus.
7. Pull the lever down and reset it a few
times. Discard the powder inside the
blisters. Note how the gears move. Based
on this, do you have any other ideas as to
how the inhaler works?
8. Remove the foil strip. It will be stuck
at one part after the foil has been split in half.
Cut this section away to fully remove the rest
of the foil strip.
9. The large white plastic mold that the
foil fits into can be removed. Look for white
tabs interlocking with the purple exterior shell
by the mouthpiece. Push these tabs in to
remove the white mold.
Figure 5: Inside the Diskus
10. At this point, the gears should be fully
exposed. Move the lever up and down. Was your hypothesis as to how
the diskus worked correct? If not, what is actually happening?
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11. Set the diskus aside and look at the aerosol inhaler and nasal

spray. Compare and contrast these methods of asthma drug delivery to
the diskus. (i.e. size, complexity, ergonomics, visual appeal, etc.)

Figure 6: Operating the open Diskus

Figure 7: Removal of the inner plastic layer

PART II - QUALITY CONTROL/MEASUREMENT
You may wish to place your findings in the table found in the RESULTS section
of this experiment, but you should also record them in your laboratory notebook.
ADVAIR® Quality Control
1. Take the foil strip that was previously removed over to a weighing
station that has a precise analytical scale.
2. Place a weigh boat on the scale and tare the instrument.
3. Remove the boat and pull back the foil strip exposing the powdered
drug in one blister. Carefully empty its contents into the weigh boat using
a spatula to scrape off any remaining powder.
4. Place the boat back on the scale and record the result. Tare the
scale once again so the powder does not have to constantly be thrown out
in between measurements. Repeat this nine more times so that the
weights of ten blister packs have been recorded.
5. After all measurements have been taken, dispose of the boat and
powder in the trash.
6. Reassemble the diskus and place it back in the box along with
included pamphlets.
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Figure 8: Proper removal of medicine from blister pack

Metered Dose Inhaler Quality Control (See Figure 9 for proper techniques for this
section)
1. First, take a weight boat, and place it on the analytical scale.
2. Now, take a KimWipe and fold it until you have a small rectangle that will
fit over the end of the metered dose inhaler. Place this folded KimWipe in
the weigh boat, and then zero the analytical scale.
3. Take the metered dose inhaler, and shake well. Remove the KimWipe
from the weigh boat, and place on the end of the inhaler where the
propellant will exit.
4. With the KimWipe on the end of the inhaler, press down on the canister
section of the inhaler, allowing the propellant to exit the inhaler and the
KimWipe to capture it.
5. Quickly place the Kimwipe back on the weigh boat and take a mass
measurement. (This may be difficult as the excipient, which acts as a
propellant, will evaporate.) Take the measurement once the scale stays
on the same value for at least a second.
6. Dispose of the KimWipe. Repeat steps 2 to 5 with fresh KimWipes until
you have ten mass measurements.
Nasal Spray Quality Control (See Figure 9 for proper techniques for this section)
1. Once again, take a weight boat, and place it on the analytical scale.
2. Now, take a KimWipe and fold it. Place this folded KimWipe in the weigh
boat so that it covers the bottom and most of the sides of the weigh boat.
Once this is done, place the weigh boat back on the scale, and then zero
the instrument.
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3. Take another KimWipe or a paper towel and fold several times. Take the
nasal spray and shake. Prime the device by spraying it a few times into
this second wipe.
4. With the spray primed, take the weigh boat off the scale, and place on a
slightly downward angle. Spray the propellant into the weigh boat once.
5. Place the weigh boat back on the scale and take a mass measurement.
6. Dispose of the KimWipe. Repeat steps 2 to 5 until you have ten mass
measurements. (Step 3 may not need to be repeated every time, but once
every 2 to 3 measurements.)

Figure 9: Different examples of the correct technique for metered dose inhaler (MDI) and
nasal spray quality control measurements. a) The folding of the KimWipe before taking a
mass sample of the MDI. b) The MDI cartridge being pushed down so that the medicine
will be ejected into the KimWipe, and a mass measurement taken. c) The lining of a
KimWipe on the bottom of a weigh boat far nasal spray mass measurements. d) Priming
the nasal spray apparatus before taking a mass measurement. e) Taking a mass
measurement using the nasal spray.

RESULTS
Make sure that the students record all results in a lab notebook, and that all
members of the teams receive the data. These results can be placed in the table
below and turned in along with solutions to the questions below. Questions were
also asked throughout the procedure, and should be answered as well.
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Table 1. Empty data table for collecting data in the Asthma Drug Delivery laboratory
experiment

Diskhaler Trial Mass (g) MDI Trial Mass (g) Nasal Spray Trial Mass (g)
1
1
1
2
2
2
3
3
3
4
4
4
5
5
5
6
6
6
7
7
7
8
8
8
9
9
9
10
10
10
Average
Std. Dev.
QUESTIONS
1. Compare and contrast the different styles of drug delivery that you
examined in part I. Which of these systems did you think had the most
appeal? Which do you think will work the best?
2. When comparing the MDI and the nasal spray, which of the two has a
higher standard deviation? Compare all three standard deviations.
Determine the highest and the lowest standard deviation. Explain what
these results imply about the quality control measures of the three
devices.
3. What were some sources of error in part II? How do you think you could
fix some of these problems?
4. Based on the average weight of the blisters, what percentage of the
powder are active pharmaceutical ingredients (API’s) and what
percentage is inactive? Assume that the amount of active ingredient from
each sample is equal to the amount stated in the prescription dosage.
The formula for finding the percentage of inactive ingredients is as
follows:
(2)
∑
(
)
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From this, find the percentage of active ingredients.
5. Do you think that the assumption made for problem 4 was a valid
assumption to make? Why or why not?
6. The Advair dry powder inhaler, as described in the introduction section,
contains two active ingredients, fluticasone propionate and salmeterol
powder. There is one other ingredient listed on the label, lactose.
a. What is lactose? Where else is lactose commonly found?
b. Why would lactose be used in the inhaler? What type of excipient
should it be considered?
c. What are some negatives of using lactose?
Be sure to site all references.

7. All metered dose inhalers (MDIs) need a propellant. A propellant makes
up almost 99% of the dose of an inhaler. The propellant must have
specific properties. Some of these include the boiling point, solubility of
the API, toxicity and others. The API is suspended in the propellant and
when the medication is dispensed the propellant creates an aerosol cloud,
that the medication can be inhaled by the patient.4
a. What is a CFC?
b. Why are CFCs no longer used as propellants in inhalers?
c. What type of propellant is used in the Ventolin inhaler? Which type
of propellant did it replace?
d. Compare the two propellants. Why do you think they replaced the
propellant?
Be sure to cite all references.

ANSWER KEY
PROCEDURE - PART I
8. Make general observations on the diagrams and data included.
Ans: The handouts included with the diskus contained very detailed
directions for the use of the diskus. Diagrams displaying how to use this
diskus were also included in the handouts. Several sections of the
handouts included legal issues, such as side effects, copyrights,
warranties, and other information that is assumed to be included by legal
regulation.
9. Based on its outside appearance, how do you think it works?
Ans: The lever needs to be pressed down to release the medicine,
and then the drug is inhaled from the mouthpiece.
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6. Make observations on its appearance and the gears.
Ans: The inside of the diskus is hollow, with several gears that
work to release the drug from the folder.
7. Based on this, do you have any other ideas as to how the inhaler
works?
Ans: There is no device that punctures the blisters that hold the
powder. Instead, the device rips the blister open using the lever.
10. Was your hypothesis as to how the diskus worked correct? If not,
what is actually happening?
Ans: If hypothesis is correct: Yes, the diskus works as
hypothesized earlier in the experiment. If hypothesis is
incorrect: No, the diskus works in a way that is different than
hypothesized. In fact, the lever helps tear the blister pack open,
which releases the powder so that it can be inhaled from the
mouthpiece.
11. Sketch both of these and take observations as to how they deliver
the drug.
Ans: Both the aerosol inhaler and the nasal spray work by
suspending the drug in fluid. This fluidized drug is then delivered to
the body by the use of a propellant.

PROCEDURE - PART II
The table in the results section was filled out. Below are the results.
Table 2. Sample data collected in the Asthma Drug Delivery laboratory experiment.

Diskhaler Trial Mass (g)
1
0.0130
2
0.0130
3
0.0127
4
0.0132
5
0.0126
6
0.0123
7
0.0130
8
0.0129
9
0.0124
10
0.0130
Average
Std. Dev.

0.0128
2.81E-04

MDI Trial Mass (g) Nasal Spray Trial Mass (g)
1
0.0130
1
0.0867
2
0.0128
2
0.0979
3
0.0088
3
0.0989
4
0.0107
4
0.0854
5
0.0130
5
0.1004
6
0.0140
6
0.0983
7
0.0140
7
0.1022
8
0.0148
8
0.1000
9
0.0120
9
0.0991
10
0.0121
10
0.0986
0.0125
1.66E-03
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0.0968
5.48E-03

QUESTIONS
1. Compare and contrast the different styles of drug delivery that you
examined in part I. Which of these systems did you think had the
most appeal? Which do you think will work the best?
Ans: The ADVAIR DISKUS® releases the drug in the most
controlled manner. However, some patients suffering from an
asthma attack or unable to inhale deeply may find it difficult to
generate enough force to inhale the entire dosage and therefore
would prefer a metered dose inhaler. Due to the aesthetics of the
ADVAIR DISKUS®, it is most likely the drug delivery system with
the highest appeal.
2. When comparing the MDI and the nasal spray, which of the two has
a higher standard deviation? Compare all three standard
deviations. Determine the highest and the lowest standard
deviation. Explain what these results imply about the quality control
measures of the three devices
Ans: When comparing the MDI and the nasal spray, the nasal
spray has the higher standard deviation. Of the three sets of data,
the one with the lowest standard deviation was the ADVAIR
Diskus® while the nasal spray had the largest standard deviation. If
we consider no error in the measurement taking process, it would
appear that the Diskus® is the most precise when it comes to the
delivery of medication, while the nasal spray is the least precise. It
would appear that the Diskus® has the highest quality control
measures in place for drug manufacturing and delivery.
3. What were some sources of error in part II? How do you think you could
fix some of these problems? Which of these systems do you think had the
smallest source of error? Why?
Ans: Inconsistency in weights for the ADVAIR Diskus® can be attributed
to powder remaining on the foil strip, the spatula, and not being caught in
the weigh boat. A more accurate method would be to not use a spatula
and tap each blister in with as little space between the weigh boat and foil
strip as possible. Residue remaining on the foil strip could be washed off
with water, collected in a separate beaker, and the water allowed to
evaporate. The small quantity of the measurements can be a problem, as
well. If there is a breeze and the wind guards are not shut on the scale
then this will affect the scale’s ability to make an accurate
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measurement. A more accurate scale could be used, if one could be
acquired (capable of reading 10-5 grams).
As far as the metered dose inhaler, error could be made in the
measurement process. Since the propellant will evaporate off, there is
difficulty in keeping an accurate measurement. With the nasal spray, error
could be included if the mechanism is not primed, causing a variable
amount of drug to be released each time. These problems with the
metered dose inhaler and the nasal spray are design flaws. It is difficult to
take an accurate mass measurement of the MDI because an excipient
used as a propellant evaporates off of the KimWipe. If you wait until after
the excipient evaporates, you will see little if any change in mass from
when the analytical scale was zeroed. There is little you can do to change
this, as it is part of the MDI design. To get more accurate results, a highend spectrophotometer could be used to obtain more accurate results.
The spectrophotometer could be set to the absorbance level of the API
and then sample could be taken in water to find the amount of API release
with each spray.5 For the nasal spray, it depends on how well you prime
the apparatus, and at what angle you place it while spraying. If the angle
is too small, the apparatus will not spray the same amount as it would at a
higher angle. However, you cannot spray at too high an angle, or else the
KimWipe will fall out of the weigh boat.
In other words, these errors are based on the design of the apparatus and
the inability to obtain quality measurements in a simple way, such as the
ADVAIR Diskus.® The Diskus is obviously the system with the smallest
source of error based on the design of the system. It is much easier to
determine the mass of the blister packets because they are in a solid form,
and do not require a gas propellant in order to be properly administered to
the lungs. The Diskus also does not require priming or a proper angle in
order to take mass measurements. With that being said, it can also be
determined that the Diskus will have the best results when it comes to
precisely administering a pharmaceutical substance.
4. Based on the average weight of the blisters, what percentage of the
powder are active pharmaceutical ingredients (API’s) and what
percentage is inactive? Assume that the amount of active ingredient from
each sample is equal to the amount stated in the prescription dosage.
Ans: This number will vary, but preliminary experimentation yields an
average weight of around 12.62 mg per blister. Using the 250/50 mcg
diskus, there should theoretically be 300 mcg of API, or 0.3 mg. Therefore
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the %inactive will be roughly (12.32/12.62 * 100) = 97.62%. To find
%active, subtract this number from 100%: 100-97.62 = 2.38%.
5. Do you think that the assumption made for problem 4 was a valid
assumption to make? Why or why not?
Ans: Technically, the assumption made to solve problem 4 cannot be
made, since there is no way to tell whether or not the mass of API is
exactly that which is prescribed for each dosage. Therefore, we cannot
say for certain that there is exactly the same amount of API in each of the
blister packs.

6. The Advair dry powder inhaler, as described in the introduction section,
contains two active ingredients, fluticasone propionate and salmeterol
powder. There is one other ingredient listed on the label, lactose.
a. What is lactose? Where else is lactose commonly found?
Ans: From the Elmhurst college website, Lactose is a disaccharide
sugar derived from galactose and glucose and it is found in cow
and human milk. It has a formula of C12H22O11.6
b. Why would lactose be used in the inhaler? What type of excipient
would it be considered?
Ans: Lactose is used as a powder excipient in the inhaler because
it is inexpensive, tasteless (except for a mild sweetness), and
harmless to humans, in most cases. In this type of product, lactose
would be used to enhance the API aerosolisation and delivery to
the lungs.7
c. What are some negatives of using lactose?
Ans: Lactose can cause some people to have an allergic reaction.
This could prohibit people with severe lactose allergies from using
this medication.1
7. All metered dose inhalers (MDIs) need a propellant. A propellant makes
up almost 99% of the dose of an inhaler. The propellant must have
specific properties. Some of these include the boiling point, solubility of
the API, toxicity and others. The API is suspended in the propellant and
when the medication is dispensed the propellant creates an aerosol cloud,
that the medication can be inhaled by the patient.4
a. What is a CFC?
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Ans: CFC is a chlorofluorocarbon, a molecule that contains
carbon, chlorine, and fluorine. They are often is in the
manufacturing of aerosol sprays and as refrigerants.8
b. Why are CFC’s no longer used as a propellant in inhalers?
Ans: CFC’s were found to be harmful to the Earth’s ozone layer,
and so the use of CFCs have been heavily regulated and
eventually eliminated by the Montreal Protocol to Reduce
Substances that Deplete the Ozone Layer (along with the London
Amendment).8
c. What type of propellant is used in the Ventolin inhaler? Which type
of propellant did it replace?
Ans: The Ventolin inhaler uses propellant HFA-134a. This
propellant is norflourane and it replaced the propellants CFC-11
and CFC 12, otherwise known as trichloromethane and
dichlorodifluoromethane.9
d. Compare the two propellants. Why do you think they replaced the
propellant?
Ans: The two compounds have similar properties and are both
non-toxic to humans when used as directed by a physician. HFA134a does not contain CFCs and is a much greener propellant than
the previous propellants used.9
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B.4 Degradation of Dissolvable Strips Lab
Degradation of Dissolvable Strips – Instructor’s Version
Developed by: Alex Jannini, David Krause, Heather Malino and Kevin Sweeney,
Rowan University, Department of Chemical Engineering
Edited by: C. Stewart Slater and Mariano Savelski, Rowan University,
Department of Chemical Engineering
Date of Experiment:
OBJECTIVES


Students will learn about mass transfer and degradation rates of drug
delivery films
 Students will learn how to properly operate a spectrophotometer
 Students will determine the effect of temperature on this process
INTRODUCTION
In 2000, the pharmaceutical company Pfizer
introduced a new over-the-counter product for
the treatment of bad breath. This product
came in a novel form that was not seen before;
a small, orally dissolvable strip. This product
revolutionized the industry, generating roughly
250 million dollars in sales. By 2002, many
other brands of dissolvable strips were also on
the shelves.1 In 2011, the energy supplement
industry also saw the potential profits of
sheets. One company, known as Sheets,
introduced a caffeine based strip which they
claim has zero calories, zero sugar, and has
Figure 1. The energy strips you
will be using in class.
the same caffeine as one cup of coffee, shown
in Figure 1. The brand also states that
negative side effects, such as a “crash,” are not common when taking the
product. Although the company has faced controversy, especially with the
endorsement of LeBron James, Sheets continues to make energy supplement
strips.2
While the use of dissolvable strips is a relatively new delivery method, it has
become a popular method of drug delivery. In fact, many other fields of over-thecounter pharmaceutical products have introduced dissolvable strip products.
Dissolvable strips that contain medicines for flu and sinus infection symptoms
can now be found in most pharmacies.3
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With dissolvable strips, the delivery vehicle is a thin, flexible sheet of polymer.
The active pharmaceutical ingredient (API) is incorporated into this polymer to
form the final product. Depending on the nature of the medicine, the API can be
incorporated in one of two ways; either through liquid dissolution or solid
suspension in the polymer. The size and thickness of these strips is dependent
on the dosage of API that needs to be delivered.3
In this experiment, you will investigate the dissolution and degradation rate of a
dissolvable strip that contains menthol. You will be using a spectrophotometer to
take absorbance readings. These absorbance readings will then be used to find
the amount of menthol that was released from the strips. You will also be
comparing these rates for two different temperatures; ambient, otherwise known
as room (roughly 20°C), and body (37°C).
MATERIALS NEEDED
 2 Sheets™ brand Mint Boost dissolvable strips
 2 petri dishes
 2 timers
 Incubator or oven capable of reaching and maintaining 37°C
 Pair of tweezers
 Deionized water
 500 µL to 5000 µL pipette
 Spectrophotometer capable of measuring absorbance at 630 nm
 Cuvettes
 Thermometer/thermocouple
INSTRUCTOR’S NOTE
This laboratory requires deionized (DI) water at a temperature of 37 °C (98.6 °F).
It may be necessary that you have a batch of DI water kept in an incubator/oven
at this temperature overnight or a few hours before the start of experimentation.
In addition, this lab models the release of blue food dye, not caffeine. To model
the release of caffeine, an advanced spectrophotometer that can take
absorbance readings at 273 nm must be used. While it may be possible to take
readings at the 273 nm wavelength, it is encouraged to use the 630 nm for this
experiment. A separate time versus absorbance chart is shown in the appendix,
along with separate answers based on using this other absorbance.
SAFETY CONDITIONS
Laboratory gloves and eyewear must be worn at all times inside the lab. Be sure
to keep water away from the spectrophotometer.

218

PROCEDURE
1. Start by turning on the spectrophotometer and setting it to take
absorbance readings at 630 nm.
2. While the spectrophotometer warms up, place 2.5 mL of deionized water
into each of the petri dishes.
3. Place one of the petri dishes into the oven/incubator that is set at 37°C.
4. Allow 20 minutes to pass so that the water may reach 37°C and the
spectrophotometer may warm up.
5. After the 20 minutes
have passed, fill a
cuvette with
deionized water and
zero the
spectrophotometer.
6. Now that the
spectrophotometer
has been zeroed, use
the tweezers to place
a strip into one of the
petri dishes. Once
Figures 2 and 3. From left to right, the proper (l) and
the strip has been
improper (r) way to take a sample.
placed in the petri
dish, cover and start
the timer.
7. Place the other strip in the other petri dish using the tweezers. Once
placed, close the petri dish and start a secondary timer. NOTE: It is a
good idea to stagger the starting times so that you do not find yourself
rushing to take two measurements. It may also be a good idea if you are
working in teams to split the team so that one section of the group is in
charge of one specific temperature study.
8. After five minutes have elapsed, take a sample of your water into a
cuvette. Make sure that this sample is relatively far from the dissolvable
strip so that you do not accidentally pick up any large portions of the
dissolvable strip, as in Figures 2 and 3.
9. Take an absorbance reading then return the sample to the corresponding
petri dish.
10. Take absorbance readings every five minutes for the first thirty minutes.
After that, take absorbance readings every ten minutes until you have
reached 90 minutes. You may use Table 1, but you should also record
your results in your laboratory notebook.
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Table 1. Empty data table to record absorbance at 630 nm data for the dissolvable strips
laboratory.

Time (min)
0
5
10
15
20
25
30
40
50
60
70
80
90

Absorbance readings at 630 nm
Room Temperature
Body Temperature
(20°C)
(37°C)
0
0

11. Once you have taken all the necessary measurements, make sure to turn
off the spectrophotometer and the incubator/oven.
12. Dispose of all equipment used in this lab, and make sure that any water
spills were cleaned up before exiting the laboratory.

RESULTS
Be sure to record all the data you collected in this experiment into your laboratory
notebook. If you split into two groups to complete this experiment, be sure that
you share the data sets.
DATA ANALYSIS
To analyze the data, the best method is to create a graph of the time versus
absorbance reading. In this case, the x-axis will be the time axis and the y-axis
will be the absorbance axis. Create one of these graphs using Excel or another
program and turn it in along with the rest of your laboratory report.
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QUESTIONS
7. Now, you will take your absorbance readings and figure out the
concentration of menthol in your solutions. You will do this using the
following graph, which correlates absorbance at 630 nm to concentration
in mg/mL. Once you have the concentrations, create another graph of
concentration versus time for both temperature sets. In addition, fill in
Table 2. Make a copy of this table and turn in along with the rest of the
deliverables for this experiment.

Absorbance at 630 nm

Blue 1 Standards Curve
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
0.0E+00

y = 1767.505155x

2.0E-04

4.0E-04

6.0E-04

8.0E-04

1.0E-03

1.2E-03

Concentration (mg/mL)

Table 2. Empty data table for recording concentrations in the dissolvable strips laboratory.

Time (min)
0
5
10
15
20
25
30
40
50
60
70
80
90

Concentration (mg/mL)
Room Temperature
Body Temperature
(20°C)
(37°C)
0
0
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8. Now that you have found the concentration of the solution over time, you
will need to use concentration and absorbance readings to determine the
molar absorptivity of the blue food dye. The molar absorptivity, or the
molar absorption coefficient, is defined as how strongly a substance
absorbs light at a particular wavelength4. This coefficient is seen in the
Beer-Lambert Law, an important law that governs the absorbance of light.
This law is shown below:
(3)

With:
(

)
(
( )

)

c) Use one of the higher time points (70 to 90 minutes) of both the
room temperature and body temperature experimental runs to
determine the molar absorption coefficients of both runs. Use the
following constants to help you in this calculation.

d) Based on the values, do you think that the temperature affects the
molar absorption coefficient?

9. Determine how well the molar absorption coefficients can determine the
concentration of the solution based on absorbance readings. Use the
molar coefficients you previously found and determine the concentration
that the solution should be at based on the Beer-Lambert Law. Use a time
point between 30 and 50 minutes in both cases. Determine how different
these two numbers are by using percent difference. The equation for
percent difference is shown below. In this case, the “E” terms are the
molar concentrations. It should be noted that percent difference is a
dimensionless number. Make sure you do all the necessary unit
conversions before calculating the percent difference.
|
|
(4)
(
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)

10. It is known that the molar absorptivity coefficient of the blue food dye used
in these sheets is 1.3x106 M-1cm-1.5
c) How different is the molar absorptivity coefficient that you found
using your experimental data from this known value? Use
experimental error to determine this difference. The equation for
percent error is shown below.

|

|

(3)

Here, the “E” term is the molar absorptivity coefficient obtained
through the experimental data, while the “A” term is the molar
absorptivity coefficient given to you above. It should be noted that
when using this equation, the two terms need to be in the same
units. It should be noted that percent error is also a dimensionless
number.
d) Now, use the same time point that you used in Question 6 and
determine the concentration based on the given molar absorptivity
coefficient. Again, compare using percent error. Do this for both
experimental runs. Here, the “E” term will be the concentration that
you obtained during experimentation, while the “A” term will be the
concentration that you obtained using the given molar absorptivity
coefficient.
11. The Beer-Lambert Law is one of the most important laws used in
spectroscopy (the interactions between light and matter). How could you
use this law in an engineering aspect?
12. Now, we will discuss a rate law. A rate law, or rate equation, is an
equation that governs the rate of a process as a function of a variable,
such as time. These laws are used by engineers to determine the design
of a chemical process. Rate laws applied to this experiment relate
absorbance with time. For example, an important variable of a rate law,
the rate coefficient/constant (k), can be determined using absorbance
data. This can be done using the following equation:
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(
(

)
)

(4)

Where:
t
Time
A Absorbance at time t
A0 Absorbance at t=0
A∞ Absorbance at t=∞
k
Rate coefficient
c) Determine the rate coefficient from your absorbance data. To do this,
you will need to determine A∞ based on your data. Use a point earlier
in your experiment, and determine a rate coefficient for both sets of
data.
d) Based on these results, does temperature affect the dissolution rate?
Use the rate constant values you obtained to verify your answer.
ANSWER KEY
The following data shown in Table 3 will be used when answering the questions
section of this report:
Table 3. Sample absorbance readings at 630 nm for the dissolvable strips laboratory

Time (min)
0
5
10
15
20
25
30
40
50
60
70
80
90

Absorbance readings at 630 nm
Room Temperature (20°C) Body Temperature (37°C)
0
0
0.049
0.107
0.133
0.268
0.182
0.421
0.245
0.424
0.29
0.457
0.299
0.485
0.356
0.459
0.371
0.476
0.387
0.453
0.417
0.451
0.425
0.458
0.43
0.464
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Absorbance at 630 nm

0.6
0.5
0.4
0.3

Room Temperature

0.2

Body Temperature

0.1
0
0

20

40

60

80

100

Time (min)

1. Once you have the concentrations, create another graph of concentration
versus time for both temperature sets. Fill in the table and turn in along
with the graphs generated and the rest of the report.
Ans: The unit conversions were made and the table was filled in with the
following data points, yielding the graph shown below.
Table 4. Sample data for the concentrations in the dissolvable strips laboratory

Time
0
5
10
15
20
25
30
40
50
60
70
80
90

Concentration (mg/mL)
Room Temp
Body Temp
(20°C)
(37 °C)
0.00E+00
0.00E+00
2.77E-05
6.05E-05
7.52E-05
1.52E-04
1.03E-04
2.38E-04
1.39E-04
2.40E-04
1.64E-04
2.59E-04
1.69E-04
2.74E-04
2.01E-04
2.60E-04
2.10E-04
2.69E-04
2.19E-04
2.56E-04
2.36E-04
2.55E-04
2.40E-04
2.59E-04
2.43E-04
2.63E-04
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Concentration (lmg/mL)

3.00E-04
2.50E-04
2.00E-04
1.50E-04

Room Temperature

1.00E-04

Body Temperature

5.00E-05
0.00E+00
0

20

40

60

80

100

Time (min)

2. a) Use one of the higher time points (70 to 90 minutes) of both the room
temperature and body temperature experimental runs to determine the
molar absorption coefficients of both runs. Ans. For this answer, the time
point of 80 minutes was used. The molar absorption constants were
found to be:
ε at room temperature = 1.401* 106 M-1 cm-1
ε at body temperature = 1.401* 106 M-1 cm-1

This was found by first calculating the molar concentration:

Now, using the Beer-Lambert Law:

b) Based on the values, do you think that the temperature affects the
molar absorption coefficient? Ans. Since the molar absorptivity
coefficient is identical between the two sets of data, the temperature of the
system does not affect the molar absorption coefficient. This is
interesting, considering that it is mentioned in several articles that the
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molar absorptivity coefficient does depend on the temperature of the
system.6,7 Then again, it might be different since we are working in the
visible spectrum range, and not the ultra violet region or the infrared
region. It should also be noted that we are only working in a temperature
range of 17 °C. This might not be enough of a difference to thoroughly
conclude that temperature has no effect on the molar absorption
coefficient.
3. Determine how well the molar absorption coefficients can determine the
concentration of the solution based on absorbance readings. Use the
molar coefficients you found previously and determine the concentration
that the solution should be at based on the Beer-Lambert Law. Use a time
point between 30 and 50 minutes in both cases. Determine how different
these two numbers are by using percent difference. Ans. Using the time
of 40 min, the Beer-Lambert Law was completed:
⁄
⁄
Then, find the percent difference:
|

|

(

)

The percent difference should be very small, as the molar absorption
coefficient was found using these readings.
4. a) How different is the molar absorptivity coefficient that you found using
your experimental data from this known value? Use experimental error to
determine this difference. Ans. Using the percent error equation, the
percent error was found to be:
|
|

b) Now, use the same time point that you used in Question 6 and
determine the concentration based on the given molar absorptivity
coefficient. Again, compare using percent error. Do this for both
experimental runs. Ans. The sample calculations were done with the
room temperature experimental run. Using the Beer-Lambert Equation:
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Now, find the percent difference:
⁄

|

⁄

|

⁄

The same was done for the body temperature experimental run. The
concentration was found to be 2.27 *10-4 and a percent error of 14.5%.
5. How could you use this law in an engineering aspect? Ans. This law is
one of the governing laws of spectrophotometry. This is used in several
areas for determining concentrations based on absorbance data. Some of
these areas are analytical chemistry, algal studies, and organic chemistry.
In the case of engineering aspects, this can be useful to chemical and
civil/environmental engineers. For example, civil/environmental engineers
would use this to determine the growth of algae or the concentration of a
contaminant in water. Chemical engineers can use this to determine
contaminants in a system, determine the dissolution rate of a drug, and
determine the concentration of product in a chemical reaction.
6. a) Determine the rate coefficient from your absorbance data. To do this,
you will need to determine A∞ based on your data. Use a point earlier in
your experiment, and determine a rate coefficient for both sets of data.
Ans. Using the time of 15 minutes, the calculations were followed, and k
was determined for both of the data sets. These values are shown below:
k @ room temperature 0.0374 min-1
k @ body temperature 0.1683 min-1
This is obtained through the following calculation:
(
(

)
)
)

(
(

)

(

)

A∞ was determined taking the average of the last three points of the
absorbance data.
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b) Based on these results, does temperature affect the dissolution rate?
Use the rate constant values you obtained to back up your answer. Ans.
Based on the rate constants, the temperature of the system does affect
the dissolution rate. From the values obtained, we can see that the rate
constant increases as the temperature increases. This means that the
dissolution rate also increases with temperature. This makes sense,
especially when you look at the graph made of the absorbance data.
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B.5 Effervescence Reaction Lab
Effervescence Reaction – Instructor’s Version
Developed by: Alex Jannini, David Krause, Heather Malino and Kevin Sweeney,
Rowan University, Department of Chemical Engineering
Edited by: C. Stewart Slater and Mariano Savelski, Rowan University,
Department of Chemical Engineering
Date of Experiment:
OBJECTIVES




Students will perform a basic mass balance on an effervescence reaction
in pharmacology
Students will conduct theoretical stoichiometric calculations and compare
to experimental results
Students will learn about the equilibrium constants and other fundamental
aspects of reactions

INTRODUCTION
Alka-Seltzer® is an effervescent
antacid (NaCO3, KCO3 plus
anhydrous citric acid) containing
acetylsalicylic acid (aspirin), which is
an analgesic, antipyretic, and antiinflammatory drug. Simply put, AlkaSeltzer® relieves upset stomach,
provides pain relief, breaks fevers,
and reduces inflammation.
Figure 1. Standard original strength packet
The effervescence allows for a faster
rate of drug dissolution into a liquid medium
(water in this case) by increasing the surface
area of the drug exposed to solution and by
“bubbling” the mixture, causing a stirring effect.
The effervescence reaction is:
C6H8O7(aq) + NaHCO3(aq)
→ H2O(l) + CO2(g) +
Na3C6H5O7(aq)

(1)

Figure 2. Weighing the tablets
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In this lab you will determine how much CO2 is generated and released to the
atmosphere by taking the initial and final weights of an Alka-Seltzer® solution.
This is an introduction to mass balances, an important concept for engineers.
This experimental value will then be compared to the theoretical amount of CO2
mass generated, found through stoichiometry.
MATERIALS NEEDED







2 Alka-Seltzer® tablets (1 packet)
Analytical scale (+/- 0.0001 g)
Weigh boat
Graduated cylinder
200 mL plastic beaker
Timer

PROCEDURE
1. Make sure safety glasses and examination
gloves are on before entering the lab.
2. Remove both Alka-Seltzer® tablets from the
packet. If the tablets are broken, be careful to
not lose any pieces. How do you think a
broken tablet will affect the rate of the tablets
dissolving?
3. Place a weigh boat on the scale. Tare the
instrument so it calibrates to zero with the
Figure 3. Creating the
added weight of the boat.
®
4. Weigh the Alka-Seltzer tablets and record in solution
your notebook.
5. Alka-Seltzer® is supposed to be dissolved in 4 oz. (118.3 mL) of water
according to the manufacturer’s directions. Using deionized water,
measure out this volume of water with a graduated cylinder and add it to
the beaker.
6. Weigh the beaker plus the added water and record it in your notebook.
This weight plus the weight of the Alka-Seltzer® tablets is your initial
weight.
7. Drop both tablets into the beaker.
8. For the first five minutes, take a weight every 60 seconds. After five
minutes have passed, measure the weight every five minutes until an hour
has elapsed. Tap the bubbles off of the sides of the beaker as they form.
9. Dispose of the solution down the sink.
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PART II
10. Fill the beaker back up with the same amount of deionized water and
weigh the water and the beaker.
11. On a weigh boat, measure out 2.0 g citric acid and 3.832 g sodium
bicarbonate.
12. Drop the powder into the beaker and record weights at the same time
intervals as Part I.
13. Dispose of the solution down the sink and clean up the lab area.
QUESTIONS
1. Fill in the tables:

2. You should notice that the initial weights of the two solutions are different.
a. What may cause this?
b. To fix this, take the difference between the two sets, find the
difference between the two initial points. This difference will need

232

to be subtracted from the solution with the higher weights. Find the
new weights and record them in the table below.

Adjusted

Weight Time

Initial:

0m
1m
2m
3m
4m
5m
10 m
15 m
20 m
25 m
30 m
35 m
40 m
45 m
50 m
55 m

Final:

60 m

c. Please graph the revised data set along with the other set that was
not changed.
3. Determine the experimental amount of CO2 generated and released to the
atmosphere by subtracting the initial weight from the final weight.
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4. Balance the reaction given in the beginning of the laboratory.
5. According to the manufacturer’s website, each tablet contains 1000 mg of
citric acid and 1916 mg of sodium bicarbonate. Determine the moles of
each reactant.
6. Determine which reactant is the limiting reactant. What is the percent
excess? Why do you think there is extra added?
7. Using the effervescence reaction given in the beginning of the lab,
determine the moles produced of CO2 gas.
8. How many milligrams of CO2 were made in both reactions?
9. What is the theoretical final weight of each solution? Use the weight of the
beaker and water measured in the lab.
10. Determine your percent error at each point with the given equation:
(
(

(

))

)

(3)

11. What were some sources of error in this lab?
12. Was there if a difference in the way the pure components dissolved versus
the tablets? Why do you think they behaved the same/differently? Do you
think that the use of milling the powders when forming the tablets adds
into the difference in behavior?
13. What is a different way that this experiment can be designed so that the
gas released could be directly measured?
14. In reaction engineering, it is important to understand the mathematics
behind chemical reactions. One of the important concepts is the reaction
rate of a chemical reaction. This reaction rate determines how many
moles of a reactant are being converted to a product over a period of time.
The rate of reaction is commonly symbolized by rA. The basic equation of
the rA is:
[ ]
(4)
Where k is the rate constant and CA is the concentration of the limiting
reactant in a chemical reaction. This is also known as a rate law. A rate
law can be linear or nonlinear in regards to the concentration. In most
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cases, rate laws are zero-order (x=0), first-order (x=1), or second-order
(x=2). Now, you will determine the rate constant and order of the rate law
for a sub-reaction that takes place in the effervescent reaction.
This sub-reaction is the formation of bicarbonate to carbon dioxide:
(5)
In this reaction, the limiting reactant is the bicarbonate ion. To determine
the concentration of the bicarbonate ion (
), we can use the following
equation.
(6)
We can assume that there is 0.029 moles of bicarbonate ions in solutions.
a. Using the data you collected, determine the moles of CO2
generated at each time point, and use that to determine the
concentration of bicarbonate ions at each time point. Once this is
done, make graphs of the following:
vs. time, ln(
) vs.
time, and 1/
vs. time. Print out all three graphs. Do this for
just the tablet set of data.
b. Now, determine the order of both sets of data. As a reminder; a
zero-order reaction will be linear for concentration vs. time; a firstorder reaction will be linear for ln(concentration vs. time; a secondorder reaction will be linear for 1/concentration vs. time.
c. The rate constant can be found by determining the slope of the
linear relationship. Find the k for the tablet.
ANSWER KEY
1. Fill in the table:
Ans: Data will vary depending on the team. However, the table should
have data similar to the set shown below:
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2. You should notice that the initial weights of the two solutions are
different.
a. What may cause this?
Ans: This may be due to the aspirin in the Alka-Seltzer® tablets.
However, this would only account for roughly 0.6 g of difference.
The other difference in mass could be due differences in the
volume of water. Human error could have led to the difference
in water volume between the two trials.
b. To fix this, take the difference between the two sets, find the
difference between the two initial points. This difference will
need to be subtracted from the solution with the higher weights.
Find the new weights and record them in the table below.
Ans: The difference found between the two starting points was
3.163 g. The first trial (Alka-Seltzer® tablets) had to have this
difference subtracted from all points taken during
experimentation. Below is the corrected data set.
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Adjusted

Weight

Time

Initial:

119.9593

0m

119.2441

1m

119.1068

2m

119.0503

3m

119.0183

4m

118.9997

5m

118.9390

10 m

118.9056

15 m

118.8749

20 m

118.8506

25 m

118.8290

30 m

118.8067

35 m

118.7835

40 m

118.7601

45 m

118.7356

50 m

118.7115

55 m

118.6858

60 m

Final:

c. Please graph the revised data set along with the other set that
was not changed.
Ans: The following graph was made using the fixed AlkaSeltzer® data and the pure components.
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Alka-Selzter Adjusted

Mass (g)

119.5
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Figure 4. Mass lost over time during the effervescence reactions.

3. Determine the experimental amount of CO2 generated and released to
the atmosphere by subtracting the initial weight from the final weight.
Ans: With the data obtained above for part I, it was determined that
the mass lost was 1.36 grams.

The amount of mass lost in Part II was 0.338 grams.

4. Balance the reaction given in the beginning of the laboratory.
Ans:
C6H8O7(aq) + 3NaHCO3(aq) → 3H2O(l) + 3CO2(g) + Na3C6H5O7(aq)
5. According to the manufacturer’s website, each tablet contains 1000 mg
of citric acid and 1916 mg of sodium bicarbonate. Determine the
moles of each reactant by converting each mass.
Ans:
(
(

)(

)
)(

)

6. Determine which reactant is the limiting reactant. How much of the
other reactant is left over? Why do you think there is extra added?
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Ans:
(

)(

)

Therefore, citric acid is the limiting reactant

There is extra sodium bicarbonate added. In addition to driving the
reaction, it also acts as an antacid when it enters the stomach.
7. Using the effervescence reaction given in the beginning of the lab,
determine the moles produced of CO2 gas.
Ans:
(

)(

)

8. How many milligrams of CO2 are made in this reaction?
Ans:
(

)(

)

9. What is the theoretical final weight of the solution? Use the weight of
the beaker, water, and tablets measured in the lab.
Ans:
Part I
(

)

[

)(

((

))]

Part II
(

)

[

((

)(

))]

10. Determine your percent error at each point with the given equation:
Ans: A sample calculation for this is shown. Using this, the table was
filled out:
(
(

(

(

(

(

))

)

))
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)

Time
(min)

Alka-Seltzer difference from
theoretical

Pure difference from
theoretical

0

100

100

1

48.014

81.247

2

38.034

62.435

3

33.927

54.105

4

31.601

49.562

5

30.249

46.502

10

25.837

39.161

15

23.410

35.650

20

21.178

33.448

25

19.412

31.958

30

17.842

30.751

35

16.221

29.639

40

14.535

28.672

45

12.834

27.756

50

11.053

26.862

55

9.3010

25.997

60

7.4330

25.140
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Percent Difference from Stoichiometry

A graph of this was made:
100
80

Tablets
Pure Components

60
40
20
0
0

20

40

60

Time (min)
Figure 5. The percent difference from stoichiometry seen in the effervescence
reaction.

11. What were some sources of error in this lab?
Ans. Some sources of error in this lab include (most obviously) not all
of the CO2 leaving solution. In addition, a portion of CO2 could have
been absorbed by the water, as described by Henry’s Law. The
addition of aspirin (an acid) could have had some effect on the pH of
the system, which could affect the rate and extent of the reaction. The
pure powder may have not been well-mixed, which may have caused
the reaction to not occur in optimal conditions.
12. Was there if a difference in the way the pure components dissolved
versus the tablets? Why do you think they behaved the
same/differently? It is known that Alka-Seltzer tablets use a milling
process to reduce the size of their powder.1 Do you think that the use
of milling the powders when forming the tablets adds into the
difference in behavior?
Ans: The pure components will dissolve at a much slower rate if not
properly mixed. It is not specified in the procedure to thoroughly mix
the components together, so it is expected of students to realize why
this case dissolves slower. The milling of the powder, the first step
listed in the Handbook of Pharmaceutical Manufacturing Formulations2
for the creation of effervescent tablets, will of course affect the
behavior of the reaction. Milling the powder creates particles of smaller
size, and the smaller the particle, the greater the surface area for the
reaction to take place. Since the powder is finer in the tablets, the
powder will dissolve quicker, which is shown above in Question 10.
13. What is a different way that this experiment can be designed so that
the gas released could be directly measured?
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Ans: If the reaction is carried out in a container that has a flow meter
attached to it than the amount of CO2 released can be directly
measured. A similar, but more crude method, would be to attach a
balloon to the top of a flask then estimate the volume occupied by the
gas and density of CO2 at experimental conditions to find a mass
released.
14. Now, you will determine the rate constant and order of the rate law for
a sub-reaction that takes place in the effervescent reaction.
a. Using the data you collected, determine the moles of CO2
generated at each time point, and use that to determine the
concentration of bicarbonate ions at each time point. Once this
is done, make graphs of the following:
vs. time, ln(
)
vs. time, and 1/
vs. time. Print out all three graphs. Do
this for just the tablet set of data.
Ans: First, we need to find the mass of CO2 that is being
generated in the reaction. This can be found by taking the total
weight and subtracting the weight at the different time points.
Then we can find the moles by dividing the grams of CO2 by the
molar mass (44 g/mol).

Then, we use Equation 6 to find the concentration HCO3 in
mol/L. A sample of this calculation is shown for the time of 10
minutes:

This was done for each point, and the following table of data
was made:
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Time
(min)

CO2 (g)

CO2(mol)

HCO3
(mol/L)

0

0.0000

0.0000

0.2451

-1.4059

4.0793

1

0.2580

0.0059

0.1956

-1.6318

5.1129

2

0.5168

0.0117

0.1459

-1.9250

6.8551

3

0.6314

0.0143

0.1239

-2.0886

8.0733

4

0.6939

0.0158

0.1119

-2.1905

8.9397

5

0.7360

0.0167

0.1038

-2.2655

9.6363

10

0.8370

0.0190

0.0844

-2.4725

11.8518

15

0.8853

0.0201

0.0751

-2.5890

13.3159

20

0.9156

0.0208

0.0693

-2.6696

14.4345

25

0.9361

0.0213

0.0653

-2.7281

15.3043

30

0.9527

0.0216

0.0622

-2.7782

16.0894

35

0.9680

0.0220

0.0592

-2.8266

16.8879

40

0.9813

0.0223

0.0567

-2.8707

17.6494

45

0.9939

0.0226

0.0542

-2.9144

18.4369

50

1.0062

0.0229

0.0519

-2.9589

19.2765

55

1.0181

0.0231

0.0496

-3.0039

20.1649

60

1.0299

0.0234

0.0473

-3.0507

21.1307

Now, we make the three graphs:
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ln(HCO3) 1/HCO3
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Figure 6. The bicarbonate concentration versus time.
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Figure 7. The natural log of the bicarbonate concentration
versus time.
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Figure 8. The inverse of the bicarbonate concentration
versus time.
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b. Now, determine the order of both sets of data. As a reminder; a
zero-order reaction will be linear for concentration vs. time; a
first-order reaction will be linear for ln(concentration vs. time; a
second-order reaction will be linear for 1/concentration vs. time.
Ans: Of the three graphs, the inverse of the bicarbonate
concentration versus time is the closest to being linear. With
this in mind, it is determined that the tablet effervescence
reaction is a second-order reaction. A trendline was put through
the figure, which had an R2 value of 0.91. This is shown below.

Figure 9. Trendlines added to a) the bicarbonate concentration, b) the natural log
of the bicarbonate concentration, and c) the inverse of the bicarbonate
2
concentration versus time graphs. From the R values, it would appear that the
reaction is second order in nature.

c. The rate constant can be found by determining the slope of the
linear relationship. Find the k for the tablet.
Ans: The equation that fits through the trendline was found to
be:
The k would then be 0.2504.
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B.6 Dextromethorphan Crystallization Lab
Dextromethorphan Crystallization Laboratory – Instructor’s Version
Developed by: Alex Jannini, David Krause, Heather Malino and Matthew Van
der Wielen
Edited by: C. Stewart Slater and Mariano J. Savelski, Rowan University,
Department of Chemical Engineering
Date of Experiment:

OBJECTIVES




Students will develop a solubility curve for dextromethorphan.
Students will gain an understanding of the techniques of crystallization
and how it is used in the pharmaceutical industry.
Students will learn the fundamentals of energy balances and heat transfer.

INTRODUCTION
A crystal is defined as a solid material whose atoms, molecules, or ions are
arranged in an ordered pattern in three dimensions. Crystallization is the
process by which solid crystals precipitate out of a solution. After the
precipitation occurs, there will be a solid phase and a liquid phase in the solution.
Then, the solution will be filtered to separate the two phases. Sometimes the
solid phase is the desirable phase while other times the liquid phase is desired.
Crystallization is a commonly used method of separating solid-liquid solutions in
industry. Crystallization has been utilized in many different processes for
decades. For example, many commodity chemicals like xylene and inorganic
salts such as sodium chloride are formed using crystallization1.
In more recent years, crystallization is used in the pharmaceutical industry. The
most common reason for using crystallization in the pharmaceutical industry is to
obtain a high purity active pharmaceutical ingredient (API). In the case of vitamin
C purification, crystals are formed in either an aqueous or alcohol based media
and then filtered out of solution2.
One of the tools used in designing crystallization processes is the solubility
curve. A solubility curve can be used to determine the saturated concentration of
a solution of solids in a liquid. An example solubility curve is shown on the next
page. The solubility curve is usually based on the concentration of solid in the
solution and the temperature of the solution. In most cases, solubility curves are
made with a solute in a solvent. In this lab, you will be making a solubility curve
for the salt form of dextromethorphan in water.
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Solubility (g/100mL water)
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Figure 1. A sample solubility curve for several different salts. Adapted from the Halifax
3
Regional School Board.

Dextromethorphan (DXM) is the active pharmaceutical ingredient (API) in several
cough syrups. Dextromethorphan is a strong antitussive agent. 4 It is often found
as a monohydrated hydrobromated salt. This means that one molecule of HBr is
attached to the dextromethorphan crystal. It belongs to the morphine group of
alkaloids. A typical amount of dextromethorphan in one dose of cough medicine
is approximately 15 mg.
INSTRUCTOR’S NOTE
Each group will need roughly 5 grams of DXM. Dextromethorphan HBr is a
controlled substance. In order to obtain the API, you may need to send in a
formal request letter stating the purpose of the experiment to your preferred
vendor (Dextromethorphan HBr was obtained through Spectrum Chemical®). It
should be noted that dextromethorphan can be illicitly used as a recreational
drug. For this reason, we suggest that you provide a lecture on the dangers of
working with pure API’s and the discussion of specific MSDS information
(LC50/LD50, toxicological effects, etc.). It is also suggested that you have the
students look up a dextromethorphan MSDS and bring it in for the experiment.
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SAFETY AND CONSIDERATIONS
Safety googles must be worn at all times in the lab. Gloves should also be worn
during this experiment. When working with the powder, a dust mask should be
worn. The chemical is of USP grade.
MATERIALS NEEDED
















Dextromethorphan HBr (one lab that contains 6 groups of students will
need approximately 30 grams)
Citric Acid, Anhydrous (one lab that contain 6 groups of students will need
approximately 180 grams)
Analytical scale (capable of reading 10-3 grams)
Weigh boats
14 test tubes
Test tube rack
1 large (approximately 800 mL or higher) beaker
Heat/stir plate
Stir bar
2 thermocouples with rod attachments
Large graduated cylinder (1000 mL)
5mL micropipette
Sharpie® or marking pencil
Ring stand with test tube clamp

PROCEDURE
PART 1: DXM
For time limitations, divide the lab up so that half the team completes steps 1-2
while the other half of the group completes step 3-6.
1. Using the marking pencil or Sharpie®, number 7 test tubes and place them
into a test tube rack.
2. Using the analytical scale, measure the dextromethorphan and prepare
the test tubes as indicated below:
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Test tube # Milligrams (mg) of DXM
1
200
2
400
3
600
4
800
5
1000
6
1200
7
450-750
Tube #7 is a choice. You may choose
any value (other than 600 mg) to place in
this vial. Make sure to record this
number.
3. Note the maximum volume of the large
beaker. You will need to fill the beaker
¾ of the way full. Use the large
graduated cylinder in order to precisely
measure the amount of water you add to
the beaker. Record the volume of water
that you added to the beaker.
4. The beaker that you filled with water will
be used as a hot water bath. Place the
water bath on the hot/stir plate, and
place a stir bar in the beaker. Place the
heat control setting somewhere in the
middle, and set the stir setting to the
Figure 2. Proper setup of a test
lowest possible setting.
tube in the hot water bath.
5. Place one of the thermocouple rods in
the water. The water bath needs to
stay within 80 to 90 °C, which is the temperature suitable for dissolving all
the DXM. This will require supervision and maintenance.
6. Now, setup the test tube clamp on the ring stand so that the clamp is just
above the beaker.
7. Once you have measured out the masses of DXM necessary, use the
micropipette and place 5 mL of water in each of the test tubes.
8. Now, secure test tube #1 in the tube clamp, and place the second
thermocouple rod in the tube. Lower the clamp so that the test tube is as
submerged as possible in the water bath.
9. Stir the test tube with the rod of the thermocouple. Keep stirring the
solution until you see the DXM completely dissolve in the water. Loosen
the clamp and remove the tube. Use a test tube holder if the tube is too
hot.
10. Now hold the thermocouple in the solution. You may also need to wipe off
the tube if there is excess condensation on the tube. Hold the test tube up
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to the light and examine the solution for the first signs of crystallization.
Record the temperature immediately as crystallization begins in the data
table.
11. Repeat steps 8 through 10 for the other test tubes. Record all data. You
may use the table below, but you should also record all results in your lab
notebook.

Figure 4. The
DXM and water
solution once
crystallization has
begun. Notice the
white substance
at the bottom of
the tube.

Figure 3. The
DXM and water
solution once
completely
dissolved.

RESULTS
You may use the table below to record your data. However, it is encouraged to
also write your results down in your lab notebook.
Test Tube
Number
1
2
3
4
5
6
7

Temperature of
Recrystallization (°C)
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DATA ANALYSIS
For this section, you will be using Microsoft
Excel. Once you have completed the lab and
collected all the data, open up a new Excel file
and place the data in a spreadsheet. Now, the
concentration that we have right now is in
mg/5mL. Change this to g/L. Remember that
there are 1000 mg per g and 1000 mL per L.
Figure 5. A screenshot of
the graph you will need in
Excel.

Once this is done, we need to create a
solubility curve. To do this, we will be using
the chart wizard. In excel, go to the insert tab and chose to insert a scatter
graph. Look specifically for the “scatter with smooth lines and markers” option.
Create a scatterplot that has temperature on the X-axis and concentration on the
Y-axis for the first six points of the data collected. In addition, please use the
following data points when creating your graph of the DXM data:
Table 1. Additional points for the solubility curve for DXM. Obtained from DrugBank and INCHEM.

Concentration (g/L) Temperature (°C)
0.00851
0
0.0747
20
15.0
25
Once this is done, change the chart layout so that you have titles for the x- and yaxis. This should be the first option in the chart layout section. Once you have
titles for the axes, label them accordingly. Label the chart with your group
number or the last names of your group members, and then delete the “Series 1”
label.
Once you have a chart, you will need to edit the x-axis. To do this, click on the
values on the x-axis. You should see these values boxed. Once done, right
click, and click on the “Format Axis” option. You should now see the Axis Option
menu. In this menu, look for “Major tick mark type.” In the dropdown menu,
select the inside option. Once this is done, print out your graph. Do the same
thing for the citric acid data. Make sure to print out that graph as well. You will
need these later.
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5,6

Figure 6. A screenshot of the “Major tick mark” option.

QUESTIONS
1. Now that we have a graph, we can check the accuracy of it. We will do
this by using the random point that you collected during the procedure.
a. We will check the accuracy of the graph through a process known
as interpolation. In interpolation, you determine a new data point
that lies within data that has already been collected. To do this,
you will need a ruler. First, determine the concentration of your
unknown in grams/L. Once you know that value, locate it on your
chart. If your concentration lies within two tick marks, you will need
to use the ruler. First, determine the length between the two tick
marks. Next, solve the following equation:
(

)
(

(1)
)

Once you have found the length between the concentration and the
lower tick, mark that on your graph. Once that is done, draw a
straight line from this point to the line generated. Then, draw a
straight line down to the x-axis. Now, you will have to determine
the temperature this corresponds to. Here, you will have to do the
same thing that you did previously. Determine the length between
the tick marks on the x-axis, and then determine the length
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between the lower tick mark and the line you drew down. Using the
equation below, determine the temperature:

(

)

(

)

(2)

b. Now that we have the temperature obtained from interpolation, we
will determine the percent error between the temperature obtained
through part a. and the temperature obtained experimentally. Use
the following equation:
|
|
(3)

What does this tell you about the possible shape of the solubility
curve?

2. Energy is required to heat the water bath to 90°C. The most basic
equation that models the energy required to heat the water from room
temperature to 90°C is:
(4)

Where “Q” is the energy required in J/g, “m” is the mass of water and “Cp”
is the specific heat capacity of water.
a. Using the specific heat as 4.18 J/(g * °C) and the density of water
as 1.00 g/mL, determine the amount of energy required to heat the
water to 90°C. You may assume that the water was at room
temperature (20 °C) before heating.
b. If a tank in an industrial process needs to heat 200 gallons of water
to 90°C, how much energy would be needed?
3. Whenever there is a flow of heat from one source to another, there is an
exchange of energy. This flow of energy is studied in the field of heat
transfer. We will now discuss one of the basic conventions of heat
transfer; conduction. Conduction can be defined as the transfer of energy
from more energetic particles to less energetic particles due to their
interactions.7 One important term in conduction is the thermal diffusivity of
a substance. The thermal diffusivity (represented from now on by the
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variable, α) measures the ability of a material to conduct thermal energy in
relation to its ability to store thermal energy.7 To find α, we can use the
following equation:
(5)
With:
[
[

]

]
[

]

a. The term α is considered a dimensionless constant. With the units
provided, prove that this is so.
b. Determine the thermal diffusivity of water at 25 °C and aluminum at
25 °C. Which is higher? What does this tell you about the two
substances in regards to the conduction and storage of thermal
energy? To do this, you will need to use the following table:
Table 2. Thermophysical properties for water and aluminum at varying temperatures. Adapted
7,8
from Incropera et al and Thermal Fluids Central.

Temperature
(K)
290
300

Water
[
0.598
0.613

]

[

]

0.999
0.997

Aluminum
[
4.184
4.179

]

[
235
237

]

[
2708
2702

]

[

]

0.868
0.903

Obviously, you will need to use interpolation in order to obtain the
correct data points. Use a similar method as used in Question 1.
c. Now, determine the thermal diffusivity for aluminum at 200 and 400
K. Use the following data below. What does this tell you about the
thermal diffusivity of aluminum in regards to temperature? Do you
think this is true for all temperature ranges? Try with 400 and 800.
Does this provide more insight into the thermal diffusivity of
aluminum with respect to temperature?
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Table 3. Thermophysical data for aluminum at varying temperatures. Adapted from
7,8
Incropera et al and Thermal Fluids Central.

Temperature (K)

[

⁄

]
[

200
400
800

2719
2681
2591

⁄

]

237
240
218

4. In simple heat transfer, we can model the flow of heat using onedimensional, steady-state conduction. What this means is that we model
the flow of energy as though it were in one direction at an unvarying rate.
This allows us to model the flow of heat over a certain distance. We will
do this for the case of the test tubes we used in this experiment.
First, we must show how to properly model this flow of heat. Picture the
test tubes used in this. We will say that in the direct middle of the water
will be the starting point. Then, we will say that top of the water level
(where water meets air) is the ending point. So with these start and end
points, we will be modeling the flow of heat from the middle of the test
tube water level to the top of the test tube water level.

Figure 7. A representation of the one-dimensional, steady-state conduction model
for the test tube.
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In order to model this, we need to make two assumptions: 1) that the heat
flows at a steady-state (does not fluctuate over time) and 2) that all the
sides except for the end point are perfectly insulated. (NOTE: The other
assumption that is made in order to use this model is that the surface
temperature of the water is the same as the air temperature. If this
assumption is not made, the flow of heat from the surface via natural
convection, or the natural flow of air on the surface of the water, needs to
be taken into account. This makes the model much more difficult; and as
such, is eliminated from the model.)
With these assumptions made, we can use the following equation to
model the flow of heat from the starting point to the end point. To do this,
we can use the following equation to solve for the heat flow7:
(6)
With:

[ ]
[ ]
[ ]
[

]

[ ]
Now, we will also say that half the volume of the water added to the test
tube is in this specific space used for the model (2.5 mL). Assuming that
the water is a perfect cylinder, and that the test tube has an inner diameter
of 0.55 in, you find all the information necessary to model this flow of heat.
a. First, we will model this as though it were pure water. Take the
temperature of recrystallization you found for test tube #1 in your
DXM experiments, and state that this is To. T1 will be the
temperature of the air (20 °C). Determine the heat transfer rate if
the thermal conductivity of water is at a weighted average of 0.58
W/m*K.
b. Now, we are going to find the thermal conductivity (k) for a mixture
of the salts used in this experiment. To do this, we will use a
thermal conductivity approximation for salt solutions. This is shown
below9:

Where:
(
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(

)

)

⁄

⁄

⁄

Make sure to use these units when using the calculation. Again,
use data obtained from test tube #1 for this. For the temperature,
determine the average between the air and the temperature of
crystallization. Determine the k value for DXM using this equation,
then find qx using the equation from part a.
c. Determine the percent difference between parts a and b. Is there a
considerable difference? Which do you think is more accurate?
Keep in mind that the thermal conductivity approximation you were
given was developed using sea salt.
d. In order to calculate this, we made two assumptions about the heat
flow. Can these assumptions be made for our experiment? Why or
why not?
5. Citric acid is often used as a flavoring agent in pharmaceuticals. The
saturation point for citric acid in water is provided. This is another way of
showing the solubility of a substance, but with different units. Instead of
concentration in mass solute per volume solution, we give the
concentration in mass solute per mass solution.
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Weight % Citric Acid
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Figure 8. The saturated weight percent of citric acid in water with
10
respect to temperature. Adapted from Dalman.

a. Now, we have discussed solubility curves in great detail. In the
introduction of this experiment, we discussed how a solubility curve
tells you the point where a solution of solid crystals will completely
dissolve into a solvent. Using the graph above, describe what
would happen if you picked a point above the solubility curve
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(example, 60 wt% and 10 °C) and what would happen if you picked
below the solubility curve (example, 50 wt% and 60°C).
b. During the production of the new pharmaceutical tablet, 75 kg of
citric acid is placed in a mixer with 100 kg water at 40 °C. The
operators on duty notice that not all of the powder is dissolving into
the water. Using the solubility curve, explain why this occurs. If we
needed to fully dissolve the citric acid in the water, what would you
recommend doing?
c. In another operation that uses citric acid, 78 pounds of citric acid is
dissolved in 60 pounds of water and is heated to 80 °C. The
solution needs to be cooled so that 18 pounds of crystals can be
collected. To what temperature should this solution be cooled to?
6.

In the previous question, you were given a scenario in which a solution of
crystals and solvent were cooled past the solubility point. Indeed, this is
what is commonly done in industry in order to separate crystals from
liquids. Usually, the solution is sent to a cooler, a type of machine that
drops the temperature of the solution. This allows crystals and saturated
solution to form. This mixture is sent to a filter, which physically separates
the liquid from the solid. Then, the solid (known as “cake”) is sent to a
dryer, so that more liquid can be removed from the crystals. An example
of this can be seen below:

Figure 9. A simplified version of the setup used to separate crystals from
11
solution. Adapted from Felder and Rousseau.
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a. 100 kg of a solution with a concentration of 150 grams of DXM per
liter of water is sent through this process. The temperature of the
solution is initially 75 °C, and is cooled down to 45 °C. Using your
DXM data, determine the mass of crystals that would precipitate
out. Assume that the solution has the same density as water.
b. Now, say this cooled solution is sent to a filter. The filter is
considered 100% effective at removing the crystals. If the
composition of the cake is 80% crystal by mass, calculate the mass
of saturated solution that has been separated with the crystals.
c. If the dryer only allows the water to evaporate, what is the overall
mass of crystals that was collected? If compared to the original
amount of crystals in solution, what is the overall yield of this
process?
ANSWER KEY

DATA ANALYSIS
The following data was collected and used for the data analysis section:

Test tube #
1
2
3
4
5
6
7

Milligrams (mg) of DXM
/5 mL water
200
400
600
800
1000
1200
750

Temperature of
Recrystallization (°C)
32.2
43.4
52.4
53.0
56.1
58.2
52.5

Since the concentrations are in mg/5mL water, the concentration was changed to
g/L. An example of the conversion is shown below using the 200 mg/5mL
concentration:
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Using this conversion, the data is now:
Test tube #

Concentration (g/L)

1
2
3
4
5
6
7

40
80
120
160
200
240
150

Temperature of
Recrystallization (°C)
32.2
43.4
52.4
53.0
56.1
58.2
52.5

Using this data, and the extra data provided, the following chart was made:

Concentration of DXM (g/L)

250
200
150
100
50
0
0

10

20

30

40

50

60

Temperature (°C)

Figure 10. Example data for the Dextromethorphan
Crystallization Lab.

The solubility curve generated has similar features to other solubility curves
shown previously. In fact, this appears to be similar to the solubility curve of
KNO3, where it grows in a large, nonlinear way with increasing temperature. 2
Some of the limitations to this data is that it can only be used for concentrations
and temperatures that were used in this experiment. This isn’t a severe
limitation, though, as the boiling point of water is 100 °C. Going beyond the
boiling point of a solvent is never done when making a solubility curve.
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QUESTIONS
1. Now that we have a graph, we will be checking the accuracy of it. We will
do this by using the random point that you collected during the procedure.
a. First, we will check the accuracy of the graph through a process
known as interpolation…
ANS. Using point 7, we found that the concentration in g/L was 150.
This was already marked on the y-axis, so interpolation was not
needed. If needed, however, Equation (1) would be:

From there, a horizontal line would be drawn until it intersected the
trendline at that concentration. Again, since this was already marked,
the developers simple marked where the intersection occurred. From
there, a vertical line was drawn until it intersected the x-axis. Equation
(2) was used to determine the temperature:
(

)

(

)

b. Now that we have the temperature obtained from interpolation, we
will determine the percent error between the temperature obtained
through part a. and the temperature obtained experimentally. What
does this tell you about the possible shape of the solubility curve?
ANS. Using Equation 3, the percent error was found to be 0.95% for
part a. An example calculation for part a) is shown below:
|

|

This shows us that the solubility curve seems to be an accurate model
of the effects of temperature on concentration.
2.

Energy is required to heat the water bath to 90°C…
a. Using the specific heat as 4.18 J/g and the density of water as 1.00
g/mL, determine the amount of energy required to heat the water to
90°C. You may assume that the water was at room temperature (20
°C) before heating.
ANS. First, the mass of water was found using the volume of water for
the bath (650 mL) and the density of water:
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Then, using Equation (4), and assuming water was at room
temperature prior to heating:
(

)

b. If a tank in an industrial process needs to heat 200 gallons of water
to 90°C, how much energy would be needed?
ANS. First, to obtain the mass, we use the same density:

Then, we use Equation (4) and again assume room temperature at the
starting point:
(

)

3. The thermal diffusivity (represented from now on by the variable, α)
measures the ability of a material to conduct thermal energy in relation to
its ability to store thermal energy.7
a. The term α has specific units. With the terms provided, find the
units of α.
ANS. If we plug in the units of the equation:
⁄

⁄
⁄

⁄

⁄

After cancelling out all like terms, α can be found to have the following
units:

b. Determine the thermal diffusivity of water at 25 °C and aluminum at
25 °C. Which is higher? What does this tell you about the two
substances in regards to the conduction and storage of thermal
energy?
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ANS. To do this, interpolation is needed. Using the table of data
available, interpolation can be carried out to find the k, Cp, and ρ
values. An example of this is shown for the k value of water:

(

)
(

(

)

)

(

)

Using this technique, the following values were calculated:

Substance

[

]

Water
Aluminum

0.6100
236.6

[

]

0.9974
2703

[

]

4.18
0.896

Using these values, α was determined. The following is a sample
calculation for water:
⁄
⁄

⁄

The α value for aluminum was found to be 9.77 * 10-5 m2/s. It appears
that water has a higher thermal diffusivity than aluminum at 25 °C. It
appears that a higher thermal diffusivity means that it has more of an
ability to conduct thermal energy than to store it.

c. Now, determine the thermal diffusivity for aluminum at 200 and 400
K. What does this tell you about the thermal diffusivity of aluminum
in regards to temperature? Do you think this is true for all
temperature ranges? Try with 400 and 800. Does this provide
more insight into the thermal diffusivity of aluminum with respect to
temperature?
ANS. Again, we will go through the thermal diffusivity calculation. A
sample calculation is shown for the 200 K:
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⁄
⁄

⁄

Using this calculation, the thermal diffusivity was found to be:
Temperature (K) α (m2/s)
200
1.09*10-4
400
9.43*10-5
800
7.34*10-5
From the first range in temperatures, it would appear that the thermal
diffusivity will decrease with temperature. By looking at the list of
terms that are used to determine the thermal diffusivity, it might be
thought that the thermal diffusivity will increase at the 800 K
temperature point. However, when the thermal diffusivity is calculated
at 800 K, it was found to decrease from the value at 400 K. This
reinforces the idea that the thermal diffusivity will decrease with
temperature.
4. Now, we will also say that half the volume of the water added to the test
tube is in this specific space used for the model (2.5 mL). Assuming that
the water is a perfect cylinder, and that the test tube has an inner diameter
of 0.045 in, you can find all the information necessary to model this flow of
heat.
a. First, we will model this as though it were pure water. Take the
temperature of recrystallization you found for test tube #1 in your
DXM experiments, and state that this is To. T1 will be the
temperature of the air (20 °C). Determine the heat transfer rate if
the thermal conductivity of water is at a weighted average of 0.58
W/m*K.
ANS. First, using the information, we determine the surface area using
the inner diameter.
(

)

Now, we determine the height of the cylinder with the area and the
volume:
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Now, we can find qx:
(
(

)

)

(

)

(

)

b. Now, we are going to find the thermal conductivity (k) for a mixture
of the salts used in this experiment. To do this, we will use a
thermal conductivity approximation for salt solutions. Make sure to
use these units when using the calculation. Determine the k value
for DXM using this equation, then find qx using the equation from
part a.
ANS. First, we determine the temperature:
(

)

And, we use the approximation equation:

(
(
(

)

)
⁄

)

⁄

And then, we use this k for the qx equation.
(

)

(
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)

c. Determine the percent difference between parts a and b. Is there a
considerable difference? Which do you think is more accurate?
Keep in mind that the thermal conductivity approximation you were
given was developed using sea salt.
ANS. The percent difference was found to be:
|

|

(

)

It is hard to determine which is more accurate. Since the concentration
is quite dilute, the thermal diffusivities probably wouldn’t vary too much.
The fact that the thermal conductivity approximation was gathered with
sea salt solutions is probably not the most accurate approximation
method for DXM, but again, the fact that the sample was a small
concentration accounted for minimal difference between the two.
d. In order to calculate this, we made two assumptions about the heat
flow. Can these assumptions be made for our experiment? Why or
why not?
ANS. Technically, we cannot assume that all but one side is perfectly
insulated. These sides are not perfectly insulated, and therefore, heat
is being lost from all sides.
5. Citric acid is often used as a flavoring agent in pharmaceuticals
a. Using the graph above, describe what would happen if you picked a
point above the solubility curve (example, 60 wt% and 10 °C) and
what would happen if you picked below the solubility curve
(example, 50 wt% and 60°C).
ANS. If you were to pick a point above the solubility curve, such as the
one provided, the concentration is passed the saturation point.
Therefore, crystals will not be dissolved in the solvent. Any point
below the solubility curve is below the saturation point, so the crystals
will fully dissolve in the solvent.
b. During the production of the new pharmaceutical tablet, 75 kg of
citric acid is placed in a mixer with 100 kg water at 40 °C. The
operators on duty notice that not all of the powder is dissolving into
the water. Using the solubility curve, explain why this occurs. If we
needed to fully dissolve the citric acid in the water, what would you
recommend doing?
ANS. Upon reviewing the graph, it is clear that the concentration of this
mixture is beyond the saturation point for that specific temperature.
This would explain the powder will not dissolve fully in the water. For a
temperature of 40 °C, the saturation concentration is roughly 65 kg of
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citric acid per 100 kg of water. In order to get the citric acid to fully
dissolve into the citric acid into the solution, it would be suggested to
be somewhere between 65 and 70 °C. It would be safe to be on the
higher end of this temperature range, just to make sure that the
concentration is below the saturation point, and that crystals will not
start forming in the solution.

Weight % Citric Acid

c. In another operation that uses citric acid, 78 pounds of citric acid is
dissolved in 60 pounds of water and is heated to 80 °C. The
solution needs to be cooled so that 18 pounds of crystals can be
collected. To what temperature should this solution be cooled to?
ANS. First, we find that the weight percent of citric acid in the initial
solution is roughly 56%. If we needed to crystallize out 18 pounds, the
weight percent of citric acid would change to 50%. Therefore, we need
to cool the solution down to the temperature where the saturation point
of the solution would be 50% citric acid. Using the graph, we can
determine that to be around 7°C. A graph of this is shown below.
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Here, the gray line is how to answer the problem. Interpolation is used
to determine the initial weight percent and the final temperature.

6. In the previous question, you were given a scenario in which a solution of
crystals and solvent were cooled past the solubility point. Indeed, this is
what is commonly done in industry in order to separate crystals from
liquids.
a. 100 kg of a solution with a concentration of 150 grams of DXM per
liter of water is sent through this process. The temperature of the
solution is initially 75 °C, and is cooled down to 45 °C. Using your
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DXM data, determine the mass of crystals that would precipitate
out. Assume that the solution has the same density as water.
ANS. We know that 75°C is beyond the point of saturation for a 150
g/L solution of DXM and water. So, we first go to the point of 150 g/L
and 45°C. This is above the saturation point, so we should first
determine the saturation concentration at 45°C. First, a vertical line is
made to intersect the point of this example and the solubility curve.
Then, a horizontal line is drawn to connect the y-axis to the point of the
solubility curve. This is shown below:
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Once again, the gray squares represent the solution to this problem.
Then, using interpolation:

(

) ⁄

(

) ⁄

Now, assuming that the density of this solution is the same as water,
the volume of solution is:
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So on a 1 liter basis, 40 grams of crystals are precipitated out. Using
the volume of 100 L, we get 4000 grams, or 4 kg, precipitated out.
b. Now, say this cooled solution is sent to a filter. The filter is
considered 100% effective at removing the crystals. If the
composition of the cake is 80% crystal by mass, calculate the mass
of saturated solution that has been separated from the crystals.
ANS. If the filter is 100% effective at removing the crystals, then we
know 40 grams of crystals makes up the cake, then, using the
definition of mass percent:

c. If the dryer only allows the water to evaporate, what is the overall
mass of crystals that was collected? If compared to the original
amount of crystals in solution, what is the overall yield of this
process?
ANS. If 1 kg of solution is with the crystals, there is 1 L of saturated
solution. If the dryer only evaporates water, and the solution had a
concentration of 90 grams of DXM per liter, then 90 grams, or 0.09 kg,
of crystals is left after drying. This gives:

The original amount of crystals is:

The yield is:

270

REFERENCES
1. C. Wibowo, "Solid-Liquid Equilibruim: The Foundation of Crystallization
Process Design," Chemical Engineering Progress, pp. 38-45, March 2014.
2. I. Le Fur, J.-P. Richard and G. Wolff, "Process for preparing ascorbic
acid". United States of America Patent 5391770, 21 February 1995.
3. Halifax Regional School Board. “Solubility Curves (ANSWERS).” Halifax
Regional School Board Staff. Accessed 19 May 2014. Available:
http://hrsbstaff.ednet.ns.ca/benoitn/chem12/solutions/exercises/ans_solubi
lity_curves.htm
4. G. Y. S. K. Swamy, K. Ravikumar and A. Bhujanga Rao,
"Dextromethorphan, an antitussive agent." Acta Crystallographica Online,
Sanathnagar, India, 2003.
5. J. Magarey. International Program on Chemical Safety.
“Dextromethorphan.” INCHEM. Available:
http://www.inchem.org/documents/pims/pharm/pim179.htm. August 1997.
Accessed: 21 May 2014.
6. The Metabolomics Innovation Center. “Dextromethorphan.” Available:
http://www.drugbank.ca/drugs/DB00514. 22 November 2014. Accessed:
21 May 2014.
7. F.P. Incoprera, D.P. Dewitt, T.L. Bergman, and A.S. Lavine. “Introduction
to Heat Transfer.” 5th ed. John Wiley and Sons. Hoboken. 2007.
8. Thermal-Fluids Central. “Thermophysical Properties: Aluminum and
Aluminum Alloy.” Available:
https://www.thermalfluidscentral.org/encyclopedia/index.php/Thermophysi
cal_Properties:_Aluminum_and_Aluminum_Alloy. 14 July 2010.
Accessed: 22 May 2014.
9. J.V. Wilson. Approximations for Physical Properties of Sea Salt Solutions.
Office of Saline Water. March 1973.
10. L.H. Dalman, “The Solubility of Citric and Tartaric Acids in Water.” Journal
of the American Chemical Society, vol. 59, no. 12, pp. 2547-2549.
December 1937.
11. R.M. Felder and R.W. Rousseau. Elementary Principles of Chemical
Processes. 2nd Edition. New York. John Wiley and Sons. 1986.

271

B.7 Creation of Dissolvable Strips Lab
Creation of Dissolvable Strips – Instructor’s Version
Developed by: Alex Jannini, David Krause, Heather Malino, and Matthew van
der Wielen, Rowan University, Department of Chemical Engineering
Edited by: C. Stewart Slater and Mariano J. Savelski, Rowan University,
Department of Chemical Engineering
Date of Experiment:
OBJECTIVES




Students will learn about the commonly used processes for industrial thin
film production
Students will learn and use basic quality control testing methods
Students will gain insight into energy requirements for drying thin films

INTRODUCTION
Dissolvable strips have become an important mechanism for drug delivery.
Orginially created as candy, dissolvable strips fill a niche role, providing rapidrelease drug delivery. Due to the drug being dissolved directly into the blood
stream through the tounge, it bypasses the metabolism of the body, which can
cause drugs to lose some of their bioavaliability (the amount of drug that will
circulate through the body). Other advantages of using thin films include not
having to take the drug with water, no risk of choking, and reduced dose size
because the drug is more bioavailable sublingually (tissues under the tounge). 1
The ingredients of a dissolvable strip will vary, depending on the desired drug
release rate, the sensitivity of the drug, and several other factors. However, all
strips will contain the following ingredients; an active pharmaceutical ingredient
(API), polymers, placticzers, and sweetners/flavoring.2 A polymer is often
determined based on its reactions with water. The more hydrophilic (attraction to
water) the polymer is, the faster the film will dissolve and release the API. The
plasticzer helps improve flexibilty and prevent brittleness in the strip, while the
sweetners and flavorings help to improve palatability and increases patient
compliance.
On an industrial level, dissolvable strips are primarily made with either a solventcasting film system or a film extrustion system. Solvent-casting systems are the
most common process, as they do not require heat, which could damage an API,
and are relatively inexpensive to construct. A typical setup for a solvent-casting
system can be seen on the next page.3 The drawbacks to solvent-casting
techniques can include variances in film thickness and non-uniform drying.
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Figure 1. A diagram of a solvent-casting system as adapted from Particle Sciences.

Alternatively, hot melt extrusion
is also used to create strips.
The advantages to extrusion
are a simpler design and the
lack of water needed to run the
process, but the materials used
in the dissolvable strip must be
heat resistant and be able to
flow as a dry powder. A sample
of both of these systems can be
seen in Figures 1 and 2.

3

Figure 2. Screw-forced extrusion of dry feedstock
3
as adapted from Particle Sciences.

In this lab, you will be creating your own dissolvable strips. This procedure is
based on the solvent casting method described above. Through this lab, you will
have a better understanding of the way that dissolvable strips are created, and
some of the engineering principles behind the process.
INSTRUCTOR’S NOTE
In this experiment, no API is added to the dissolvable strips, as no drug modeling
is being analyzed. If you wish to use an API, that is acceptable, and caffeine is
recommended as an inexpensive API. In addition, it is possible to obtain foodgrade versions of each of these chemicals. If possible, you may wish to do this
in a food-safe area, and allow the students to try their strips once they are done
the experiment. Lastly, the apparatus used in this experiment is a Teflon sheet
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that has metal thickness guides adhered to the surface. A model is shown
below:

Figure 3. The sheet used to make
dissolvable strips.

These thickness guides have dimensions as follows: Length of 31 cm, a height
of 2.7 cm, and a thickness of 0.06 cm. The thickness guides were made from
aluminum metal sheets. Note that the thickness guides are adhered to the
surface. This was done through silicone adhesive caulk. The adhesive caulk
takes time to dry (48-72 hours), so it is suggested to have these sheets prepared
ahead of time for the experiment.
SAFETY CONSIDERATIONS
Make sure to wear safety goggles at all time. Laboratory safety gloves should
also be worn.
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MATERIALS NEEDED

PROCEDURE
Table 6: Recipe for CMC preparation

Species*
Weight (g) Weight %
CMC
7.7
1.6
Glycerol
2.6
0.6
Peppermint oil
0.5
0.1
Citric acid
1.0
0.2
Sodium lauryl
1.0
0.2
sulfate
Sucrose
1.5
0.3
Water
500
97
TOTAL
514.3
100
* Instructor’s Note: All chemicals can be
obtained from Fisher Scientific. Peppermint
oil can be found in specialty food stores or
online.
1. Weigh out the appropriate amounts of all powdered ingredients.
2. Add the required amount of deionized water to the large beaker.
Reminder: density of water = 1 g/mL.
3. Place the beaker on the hot plate and add the stir bar. Set the heat to the
lowest setting and set the stir to a low-medium rate (4 out of 10).
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4. Add the CMC to the water at a very slow
rate, dusting the powder over the surface
of the water and waiting for it to be
absorbed. Once most of it is mixed in, the
solution will become very viscous and trap
air bubbles. Once the viscosity increases,
you will need to increase the stirring
intensity. Do this slowly.
5. Add the glycerol to the solution with the 3
mL syringe. You will need approximately 2
mL of glycerol to correspond to the weight
shown in Table 1.
6. Add the remaining components to the
solution similarly to how the CMC was
Figure 4. Funnel and screen
setup for pouring into flask.
added. At this point, the solution should
be extremely viscous and appear opaque
white.
7. Add three drops of peppermint oil
to the solution.
8. Add one drop of blue food dye.
The mixture should now be a light
blue color.
9. Transfer the solution into the
vacuum flask with the mesh and
funnel, pouring through the mesh,
to catch any large clumps of
solidified product and the stir bar.
Discard the solidified product.
Figure 5. The setup that should
10. We will now make a vacuum
be used when using the
filtration system. The purpose of
vacuum.
this is to de-aerate the mixture.
This minimizes the bubbles in the solution. Hook the vacuum flask up to a
tube and place a rubber stopper in the top of the flask. Then, connect the
tube to the other vacuum flask. Next, place a stopper with an attachment
into the top of the other flask and connect this to the vacuum source. See
Figure 5 for the appropriate setup. This second beaker will stop any foam
from entering the vacuum.
11. Turn on the vacuum and wait approximately 30 minutes for the gas to
leave the solution. The solution should slowly turn clear and may get
frothy. The froth will subside.
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12. Turn off the vacuum and disconnect the
tubing from the vacuum source. Then,
remove the beaker with solution from the
setup.
13. Carefully pour some of the solution into a
500 mL graduated cylinder. This will make
it easier to transfer the solution to the
Teflon sheet or petri dish.
14. Take a petri dish and weigh it. Record this
Figure 6. Strips being cut
weight.
15. Prepare a sample of the film in the petri dish
by adding 10 mL to the dish. Do this by
using a small graduated cylinder (10 to 25 mL). If any bubbles remain on
top of the solution, be sure to draw solution from under the surface.
16. Weigh the wet petri dish and record this weight.
17. Pour out 400 mL of the remaining solution onto the sheet using the 500
mL graduated cylinder.
18. Allow 1-2 days for the samples to dry. The batch should appear much
thinner and have a glossy finish on its surface. Take a final weight of the
petri dish sample and record its weight.
QUALITY ANALYSIS
How uniform is your batch? In industry, this is done
by sampling a batch and testing it in several ways to
ensure that specifications are met. Several samples
are taken and their results are averaged. Quality
analysis is critical to the success of a company, so
that deviations can be caught and fixed before they
become a costly problem.
Sample Creation
1. Carefully peel the strip out of the mold with a
Figure 7. How to use the
calipers to determine
spatula.
thickness
2. Take a ruler and measure 4 samples with
dimensions of 1” x 1.5”. Try to find room for samples from each of the four
corners so that the samples are representative of the entire batch.
3. Using a scalpel carefully cut out the four samples.
Thickness Measurements
1. Using a caliper, take each sample and place it in the jaws of the caliper.
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2. Adjust the jaws so that the sample fits snugly between them. Do not over
tighten the caliper so that the sample tears. The sample should be
pinched, but also be able to slide out from between the jaws when a small
force is applied to it.
3. Record your results and repeat for all samples.
Folding endurance
1. Take a sample and fold it in half along the 1.5”
face (At the 0.75” mark). Pinch the folding point
with your fingers so that a distinct crease is
formed.
2. Unfold the strip and flip it over. Carefully fold the
strip in the opposite direction, along the same
crease and pinch. This has now been 2 folds.
Figure 8. Ensure a good
3. Repeat steps 1 and 2, counting the number of
fold by pinching the
folds that you perform.
strip
4. Record the final number of folds, and repeat for
the rest of the samples.
Surface pH
1. Using one of the halves from each sample, use a pipette to drop a small
quantity of DI water on the strip.
2. Place a broad-range litmus paper strip in the drop.
3. Compare the color of the strip to the package to determine the pH of the
sample.
4. Record your results and repeat for the rest of the samples. Again, you
only need to measure the pH from one half of each sample.
Analysis
1. Average the results from each test.
2. Find the range of results for all tests. Was there significant variance in the
data you collected?
3. Do you think that the average pH of the samples would be dangerous to
ingest? What about the highest/lowest pH sample?
4. The average number of folds it takes to break a Sheets® brand strip was
found to be in the range of 15-20 folds. Does your average fall in this
range? If not, why do you think it didn’t?
5. What could be a dangerous consequence from a lot of variance in the
thickness of each sample? Would you sell the strips you made to
pharmacies?
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Moisture Content Analysis
In this section, you will use the initial and final weights of the petri dish sample,
as well as an introductory energy balance, to find the energy required to dry the
sample and the amount of water remaining in the sample.
1. Find the change in mass of the sample. Assume that the mass that
evaporated was 100% water.
2. Find the moisture content with the following equation:
[

(

)]

Where,
= final weight of the sample
= initial weight of the sample
3. You will now calculate the amount of energy required to evaporate all of
the water that was lost. This energy was transferred into the sample from
its surroundings, so the balance of energy transferred appears as such:

Where,
= energy required to dry the sample
= mass of water vaporized, (
)
= Latent heat of vaporization for water, 2260 kJ/kg
Make sure to watch your units!
4. Where do you think this energy came from?
INSTRUCTOR’S NOTE: For an in-class exercise, the averages from each group
can be compiled on the board, and then used to create a control chart. Was the
“process” of the student’s lab activity in control or out of control? This can be
used as an introduction to control charts, Western Electric rules, and Six-Sigma
manufacturing.4
QUESTIONS
1. For the following APIs, research the drug’s therapeutic use and determine
if a hydrophilic or hydrophobic polymer matrix would be best suited for
drug delivery:
a) Salbutamol
b) Zolpidem tartrate
c) Ondansetron
d) Fentanyl citrate
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2. Your boss approaches you with a new design project. The
pharmaceutical company you work for has recently signed a contract with
a client, requiring that you produce 800,000 dissolvable strips/year of a
new API designed to treat the common cold. The API, referred to as DK12, is potent in very small doses, but degrades rapidly when it hits
stomach acid. Therefore, a dissolvable strip is the perfect method for
introducing the drug into the body. The film must be fast-dissolving.
a) Before any equipment can be decided upon, you must create the
formulation. The required ingredients are:
 DK-12 (10% w/w)
 Water soluble polymer (40-50% w/w)
 Plasticizers (0-20% w/w)
 Sweetening agent (3-6% w/w)
 Saliva stimulating agent (2-6% w/w)
 Colors and flavors (1-10% w/w)
Find a suitable chemical for each of these components and compile
a list for your boss.
b) Now that you’ve selected the ingredients for the strip film, you have
to select whether you are going to use a hot-melt extruder or a
solvent casting system. The material dissolves easily in water and
polar solvents, and is not friable (does not degrade from heat). It
must be noted that since DK-12 is new, it is very expensive, and
therefore it is important to minimize wasted API. Explain your
reasoning.
ANSWER KEY
The following data was used for the answer key:
Sample
1
2
3
4
Average

Thickness
(mm)
0.08
0.10
0.12
0.07
0.09

280

Folds
endured
32
28
39
23
30.5

Surface
pH
5.0
5.5
5.5
6.0
5.5

The following data was for the petri dish portion of the experiment:
Initial weight of sample (g) Final weight of sample (g)
20.65
0.335
Analysis
1. Average the results from each test.
ANS: See the above table.
2. Find the range of results for all tests. Was there significant variance in the
data you collected?
ANS: “Significant” is used loosely here. This does not mean statistical
significance, but the student should be able to relatively compare the
ranges of the three tests against each other. For example, the ranges
above are 0.05 mm, 16 folds, and 1 pH. A student should realize that
the folding test generated inconsistent results.
3. Do you think that the average pH of the samples would be dangerous to
ingest? What about the highest/lowest pH sample?
ANS: For this set of data, the strips would be safe to ingest. Humans
can ingest foods such as lemon juice, which has a pH of 2. However,
stomach discomfort or heartburn may result from ingesting something
this acidic. A student thinking critically will realize the potential side
effects.
4. The average number of folds it takes to break a Sheets® brand strip was
found to be in the range of 15-20 folds. Does your average fall in this
range? If not, why do you think it didn’t?
ANS: The strips in this mock scenario do not. The folding endurance
study was found to be highly dependent on the humidity of the room.
In very dry air, the strips will become brittle and shatter after 1 or 2
folds. In humid air, the strips can be folded a near-indefinite amount of
times with little fatigue. Commercial strips are packaged in controlled
climates so they always have ideal properties. Opening a commercial
strip package and leaving the strip out to reach equilibrium with the
surroundings should yield similar fold endurance to the experimental
strips.
5. What could be a dangerous consequence from a lot of variance in the
thickness of each sample? Would you sell the strips you made to
pharmacies?
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ANS: Large variance means concentrated areas of API, and areas
with little API. The highly-dosed strips could lead to an overdose, and
the under-dosed strips could lead to diminished therapeutic value.
Obviously, these strips would not be sold commercially. This question
segues nicely into the importance of process control.
Moisture Content Analysis
1. Find the change in mass of the sample. Assume that the mass that
evaporated was 100% water.
ANS: The Δm = 20.315 g.
2. Find the moisture content with the following equation:
[

(

)]

Where,
= final weight of the sample
= initial weight of the sample
ANS:
[

(

)]

3. You will now calculate the amount of energy required to evaporate all of
the water that was lost. This energy was transferred into the sample from
its surroundings, so the balance of energy transferred appears as such:

Where,
= energy required to dry the sample
= mass of water vaporized, (

)

= Latent heat of vaporization for water, 2260 kJ/kg
Make sure to watch your units!
ANS:
(

)

4. Where do you think this energy came from?
ANS: This energy was transferred into the liquid from the natural
convection of the air.
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Questions
1. For the following APIs, research the drug’s therapeutic value and
determine if a hydrophilic or hydrophobic polymer matrix would be best
suited for drug delivery:
a) Salbutamol
ANS: Because salbutamol is used for immediate relief of an
asthma attack5, a fast dissolving hydrophilic polymer would be
best suited for this application.
b) Zolpidem tartrate
ANS: Zolpidem tartrate has only been shown to induce sleep,
but not maintain it, unless it is in a controlled release form.6
Therefore, a hydrophobic polymer would be best suited for this
application. The strip would most likely be applied sublingually
or to the cheek.
c) Ondansetron
ANS: Again, ondansetron is used primarily for immediate relief
of nausea in chemotherapy patients.7 Therefore, a hydrophilic
polymer would be best in this application.
d) Fentanyl citrate
ANS: Being a highly potent opioid analgesic that is used for
moderate to severe pain relief,8 it can be found in both
hydrophilic and hydrophobic polymer matrices. It may even be
found in a layered strip that uses both types of polymer.
2. Your boss approaches you with a new design project. The
pharmaceutical company you work for has recently signed a contract with
a client, requiring that you produce 800,000 dissolvable strips/year of a
new API designed to treat the common cold. The API, referred to as DK12, is potent in very small doses, but degrades rapidly when it hits
stomach acid. Therefore, a dissolvable strip is the perfect method for
introducing the drug into the body. The film must be fast-dissolving.
a) Before any equipment can be decided upon, you must create the
formulation. The required ingredients are:
 DK-12 (10% w/w)
 Water soluble polymer (40-50% w/w)
 Plasticizers (0-20% w/w)
 Sweetening agent (3-6% w/w)
 Saliva stimulating agent (2-6% w/w)
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 Colors and flavors (1-10% w/w)
Find a suitable chemical for each of these components and compile
a list for your boss.
ANS: Make sure the ingredient is safe for consumption!







DK-12 (10%)
Pectin, HPMC, hypromellose, etc. (40-50%)
Glycerol, etc. (0-20%)
Sucrose, dextrose, aspartame, etc. (3-6%)
Ascorbic acid, malic acid, citric acid (2-6%)
Peppermint oil, various esters, Red No.40, etc. (110%)

b) Now that you’ve selected the ingredients for the strip film, you have
to select whether you are going to use a hot-melt extruder or a
solvent casting system. The material dissolves easily in water and
polar solvents, and is not friable (does not degrade from heat). It
must be noted that since DK-12 is new, it is very expensive, and
therefore it is important to minimize wasted API. Explain your
reasoning.
ANS: Hot melt extrusion would be the best operation for
creating the strips. They do not degrade from heat, and
extrusion minimizes product lost. While a more expensive
process, it is worth it if a contract has been made with a
client.
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Appendix C
Test and Survey for the Advil Statistical Analysis Lab

Rowan University – Freshman Clinic
Fall/Spring Semester
Please answer the following questions as best you can:
1. What does API stand for?
o Active Pharmaceutical Ingredient
o Appropriate Pharmaceutical Ingredient
o Abridged Pharmaceutical Inspection
o Altered Pharmaceutical Ingredient
2. What is the purpose of an API?
o To test the production process
o To make sure that you are meeting safety regulations
o To perform the treatment of the patient
o To keep the pill intact until swallowed
3. What are the non-active ingredients in a pharmaceutical product called?
o Glue
o Binders
o By-products
o Excipients
4. A binder is:
o A substance to ensure the drug is fully dissolved in the body
o A substance that makes components in the drug stick together
o A piece of equipment that makes tablets stick to each other
o A device that keeps two pieces of equipment attached to each other
5. The substance used in a tablet to take up space in a pharmaceutical product is:
o A filler
o A settler
o A spacer
o A glidant
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6. The purpose of an F-test is to:
o To compare a sample to a known value
o To compare a sample to an unknown value
o To compare a set of data to a known value
o To compare two sets of data with one another
7. The purpose of a t-test is to:
o To compare two sets of data to one another
o To compare a sample to a known value
o To compare averages of two sets of data
o To compare a known value to an unknown value
8. What is the purpose of a flow diagram?
o To model the flow of material for a process
o To determine the curvature in a model
o To compare a material balance to an energy balance
o To determine the costs of utilities
9. What is the definition of variance?
o The dispersion of data from the mean
o The probability of a number being the mean
o The average of the squared difference of the mean
o The mean of the data
10. What is the purpose of a box-and-whisker plot?
o To determine the cost of utilities
o To determine if any outliers exist in a set of data
o To determine the variance of a set of data
o To find critical values for an F-test and t-test

287

This survey is in regards to the laboratory experiment: Tablet Statistical Analysis Lab.
Please fill in the column that most closely resembles your opinion with the statement to
the left. This survey in no way affects your grade for this class. Please be honest with
your answers. If you fell a specific statement does not pertain to the lab, please fill in the
N/A column for that question. If you were absent from lab, please fill in the N/A column
for all questions relating to the experiment.

1

2

3

4

5

6

7

8
9
10

Statement
The experiment introduced
a concept of
pharmaceutical
engineering
I have been, or am now,
interested in
pharmaceutical
engineering
I wish to pursue more
studies in the field of
pharmaceutical
engineering
The experiment helped me
understand the application
of statistics to
pharmaceutical product
quality control
I can apply the statistical
principles I learned in this
lab to other engineering
problems
I had to appropriately use
laboratory equipment
(scales, etc.) for
measurements
I felt I could complete the
experiment in the time
given
I knew exactly what was
expected of me from the
write-up given
I felt challenged by the
experiment
I felt safe in the laboratory
while under the
supervision of faculty

Strongly
Disagree

Disagree

1

2

Neither
Agree
nor
Disagree
3

Major: _____________________________________
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Agree

Strongly
Agree

N/A

4

5

6

Appendix D
Tablet Statistical Analysis Test and Survey Data

For this raw data, the questions were the same as those presented in Appendix C.
Students remain anonymous for this, but their major is stated. For the “Test” portion of
this data, a “C” represents a correct response, while an “I” represents an incorrect one.
Pre-Lab Test Results
Student NO.

Major

Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10

1

Mechanical Engineering

I

I

I

C

C

I

I

C

I

C

2

Chemical Engineering

C

I

C

C

C

I

I

C

I

I

3

Chemical Engineering

I

C

C

C

C

I

I

C

C

C

4

Chemical Engineering

C

C

I

I

C

C

C

C

I

C

5

Chemical Engineering

C

I

I

C

I

I

I

I

C

C

6

Chemical Engineering

I

C

I

C

C

I

I

C

C

I

7

Chemical Engineering

C

C

I

C

C

C

C

C

I

C

Number of Incorrect

3

3

5

1

1

5

5

1

4

2

Percent Correct

57

57

29

86

86

29

29

86

43

71
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Student NO.
1
2
3
4
5
6
7

Major
Mechanical
Engineering
Chemical
Engineering
Chemical
Engineering
Chemical
Engineering
Chemical
Engineering
Chemical
Engineering
Chemical
Engineering
Number of
Incorrect
Percent Correct

Q1

Q2

Q3

Q4

Q5

Q6

Q7

Q8

Q9

Q10

C

C

C

C

C

C

C

C

I

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

I

C

0

0

0

0

0

0

0

0

2

0

100

100

100

100

100

100

100

100

71

100
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Post-Lab Test Results

The results of the survey are shown below. Again, student names are kept confidential,
and only the student’s majors will be shown. Responses are numbered 1 to 6, 1 being “I
strongly disagree with the statement” and 6 being “I strongly agree to the statement.”
The statement numbers coincide with those shown in Appendix C.

Post-Lab Survey Responses
Student
NO.
1
2
3
4
5
6
7

Major
Mechanical
Engineering
Chemical
Engineering
Chemical
Engineering
Chemical
Engineering
Chemical
Engineering
Chemical
Engineering
Chemical
Engineering
Average
Response

S1

S2

S3

S4

S5

S6

S7

S8

S9

S10

5

1

1

4

5

5

5

4

3

4

4

5

4

5

5

5

4

5

3

4

4

5

4

4

4

5

5

3

3

5

5

5

5

3

4

5

5

5

2

5

4

4

3

4

4

4

4

3

3

4

4

4

5

5

5

1

1

4

2

1

3

4

4

5

5

4

4

4

1

1

4

4

4

4

5

5

5

4

2

4
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